• SHOP
  • COMBOS
  • TESTIMONIALS
  • CART
  • INGREDIENTS
    • 2-DEOXY-D-GLUCOSE (2DG)
    • ACACIA CYANOPHYLLA FLOWER
    • ACORI GRAMINEI RHIZOMA
    • AEGLE MARMELOS CORREA
    • AGARICUS BLAZEI
    • AGED GARLIC EXTRACT
    • AFRAMOMUM MELEGUETA
    • ALOE ARBORESCENS
    • ALBIZIA
    • ALPINIA OFFICINARUM
    • ALTERNANTHERA SESSILIS
    • AMERICAN GINSENG
    • AMYGDALIN
    • ANACYCLUS PYRETHRUM
    • ANGELICA ARCHANGELICA
    • ANGELICA SINENSIS
    • ANTRODIA
    • ARTICHOKE LEAF
    • ARTOCARPIN
    • AJUGA TURKESTANICA
    • ASHWAGANDHA
    • ASPALATHIN
    • ASTRAGALUS COMPLANATUS
    • AVENA SATIVA
    • BACOPA MONNIERI
    • BAVACHIN
    • BEE POLLEN
    • BETULINIC ACID
    • BOSWELLIC ACID
    • BREVILIN A
    • CAMPESTEROL
    • CAPSAICIN
    • CARCININE
    • CASTICIN
    • CHRYSIN
    • CIANIDANOL
    • CINNAMOMUM ZEYLANICUM
    • CITRULLUS COLOCYNTHIS
    • CITRUS RETICULATA PEEL
    • CODONOPSIS
    • CONJUGATED LINOLEIC ACID
    • COSTUNOLIDE
    • CYANIDIN
    • CUCURBITACIN D
    • DAIDZEIN
    • DECURSIN
    • DELPHINIDIN
    • DIGITALIS PURPREA (DIGOXIN)
    • DIOSMIN
    • Ecklonia Cava
    • Ellagic Acid
    • EMBELIN
    • ERIODICTYOL
    • GALLIC ACID
    • GLYCITEIN
    • GLYCYRRHIZIN
    • HYPERFORIN
    • ICARIIN
    • ISORHAMNETIN
    • ISOORIENTIN
    • ISOVITEXIN
    • JACEOSIDIN
    • KAEMPFEROL
    • KIGELIA AFRICANA
    • KURARINONE
    • LEMON BALM
    • LICORICIDIN
    • LIPOIC ACID
    • LUPEOL
    • MAGNOLOL
    • MENAQUINONE 4
    • MULBERRY LEAF
    • NARINGENIN
    • NOBILETIN
    • OLEACEIN
    • OLEANOLIC ACID
    • OLIVE OIL
    • ORIDONIN
    • PARTHENOLIDE
    • PHLOROGLUCINOL
    • PHLORIZIN
    • PICEATANNOL
    • PRISTIMERIN
    • PROANTHOCYANIDINS
    • PROCYANIDIN B3
    • PSEUDOLARIC ACID B
    • PTEROSTILBENE
    • RUTIN
    • SOLIDAGO VIRGAUREA
    • TANGERETIN
    • TARAXASTEROL
    • TRICHOSTATIN A
    • WEDELOLACTONE
    • WOGONIN
    • YERBA MATE
  • ABOUT
  • SCIENTIFIC STUDIES
    • ADAPTOGENS
    • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
    • ADDICTION & THE BRAIN
    • ADDICTION & STRESS
    • ADDICTION WITHDRAWAL
    • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
    • ADIPOCYTE DIFFERENTIATION
    • ADROPIN
    • ALLERGIES & CYTOKINES
    • ALDOSTERONE & OBESITY/HYPERTENSION
    • ALZHEIMER’S, DEMENTIA, PARKINSON’S
    • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
    • ADVANCED GLYCATION END PRODUCTS (AGES)
    • ADDICTION TREATMENT
    • ADDICTION & DOPAMINE
    • AMPK
    • ANTI AGING
    • ANTIAGING EFFECTS OF COFFEE
    • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
    • ANTI-APOPTOTIC PATHWAYS
    • ANTI ATHEROGENIC
    • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
    • ANTI CARIOGENIC (Protecting From Tooth Decay)
    • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
    • ANTI GLYCATIVE
    • ANTI GLYCATION AGENTS
    • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
    • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
    • ANTI WRINKLE AGENTS
    • ANXIOGENIC
    • ANXIOLYTIC
    • APOPTOSIS
    • APOPTOSIS IN 3T3-L1
    • AUTOPHAGY
    • BCL-2
    • BCL-W
    • BCL-XL
    • BDNF
    • BECLIN-1 & AUTOPHAGY
    • BH3 MIMETICS
    • BIM aka BCL2L11
    • BIOMIMETIC HYDROXYAPATITE
    • BMI-1
    • BPA & OBESITY
    • BRASSINOSTEROIDS
    • CALORIE RESTRICTION
    • CALORIE RESTRICTION & LIFESPAN EXTENSION
    • CARBAMYLATION
    • CARBONYL SCAVENGER
    • CARBONYL STRESS
    • CARDIOPROTECTIVE AGENTS
    • CARDIAC GLYCOSIDES
    • CATALASE
    • CELL CYCLE ARREST
    • CENTENARIANS
    • CDK5
    • CHOLESTEROL EFFLUX
    • COGNITIVE ENHANCEMENT
    • COLD SHOCK PROTEINS
    • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
    • CONDITIONED PLACE PREFERENCE
    • CORTICOTROPIN RELEASING FACTOR
    • COSMECEUTICAL
    • CRYOTHERAPY
    • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
    • CYP2E1
    • CYTOKINES IN PAIN, INFLAMMATION & AGING
    • DAF-16
    • DEPERSONALIZATION
    • DIABETES & CANCER
    • DIHYDROTESTOSTERONE (DHT)
    • DNA METHYLATION & AGING
    • DNA REPAIR
    • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
    • DRY FASTING AND FLUID RESTRICTION FASTING
    • DYNORPHIN
    • ELLAGITANNINS
    • ENDOCRINE DISRUPTING CHEMICALS
    • ENLARGED HEART AND CARDIOMEGALY
    • EPIGENETIC ALTERATIONS
    • EPIGENETIC MODIFIERS
    • EPINEPHRINE
    • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
    • EXCITOXICITY & THE BRAIN
    • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
    • EXTRACELLULAR MICROVESICLES
    • EXTENDS LIFESPAN
    • EXTINCTION TRAINING
    • FASTING & THE BRAIN
    • FASTING & CANCER
    • FASTING MIMICKING DIET
    • FEAR EXTINCTION
    • FGF21
    • FLAVONES
    • GABA (γ-AMINOBUTYRIC ACID)
    • GALLOTANNINS
    • GLUCONEOGENESIS
    • GLUCOCORTICOID RECEPTOR ACTIVATION
    • GLUTAMATE & BRAIN
    • GLYCATION
    • GUT BRAIN AXIS
    • GYPENOSIDE
    • KLOTHO
    • K OPIOD RECEPTOR & ADDICTION
    • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
    • FGF21
    • FOXO3
    • FOXO4
    • HALLMARKS OF AGING
    • HAIR GROWTH
    • HAIR REGENERATION
    • HAIR REPIGMENTATION
    • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
    • HMGB1
    • HORMESIS
    • HPA AXIS
    • HSP70, THE ANTI-AGING PROTEIN
    • HSP90 INHIBITORS
    • HYPERGLYCEMIA
    • HYPERALGESIA
    • HYPERINSULINEMIA
    • HYPOTHALAMIC PITUITARY ADRENAL HPA AXIS
    • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
    • HYPOCRETIN OREXIN
    • IKK
    • IL-6/STAT3
    • IRISIN
    • ISOFLAVONES
    • IMMUNOSENESCENCE
    • INHIBITION OF ADVANCED GLYCATION END PRODUCTS
    • INCREASE PROTEIN SYNTHESIS
    • INCREASES SPERMATOGENESIS
    • INFECTOBESITY
    • INFLAMMATION & ANXIETY
    • INFLAMMATION & CANCER
    • INFLAMMATION & DEPRESSION
    • INFLAMMATION & OBESITY
    • INFLAMMAGING
    • INHIBITION OF RENAL GLUCOSE REABSORPTION
    • INSULIN & AGING
    • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
    • INSULIN & MTOR
    • INSULIN & OBESITY
    • INSULIN OXIDATIVE STRESS
    • INTERMITTENT FASTING
    • JAK INHIBITION ALLEVIATES SASP
    • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
    • KETONE BODIES
    • KETOGENIC DIET
    • LACTOBACILLUS REUTERI
    • LACTOFERRIN
    • LEYDIG CELL STEROIDOGENESIS
    • LIFESPAN EXTENSION
    • LIVER REGENERATION
    • LIPOLYTIC AGENTS
    • LIPID DROPLETS
    • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
    • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
    • MATRIX METALLOPROTEINASES (MMPs)
    • MCL-1
    • MDM2 INHIBITION AS SASP INHIBITOR
    • MEDICINAL MUSHROOMS
    • MEDITERRANEAN DIET
    • METABOLIC REPROGRAMMING
    • METABOLIC SYNDROME
    • METHIONINE RESTRICTION
    • MITOCHONDRIAL UNCOUPLING
    • MONKEYPOX
    • MSG (MONOSOSODIUM GLUTAMATE)
    • MUSCLE FORCE PRODUCTION
    • MUSCLE ATROPHY (PREVENTING)
    • MYOGENESIS
    • MYOSTATIN INHIBITION
    • MYOSTATIN INHIBITION PRESERVES MUSCLE
    • mTORC2
    • mTOR: THE RAPID AGING PATHWAY
    • NATURAL ANTICOAGULANTS
    • NATURAL AROMATASE INHIBITORS
    • NEUROGENESIS (GROWING NEW BRAIN CELLS)
    • NEUROCHEMISTRY OF ADDICTION
    • NEUROPLASTICITY
    • NEUROINFLAMMATION
    • NEUROPROTECTIVE AGENTS
    • NEUTRALIZING OXIDATIVE STRESS WITH MEDICINAL PLANTS
    • NMDA & ANXIETY & DEPRESSION
    • NMDA RECEPTOR & FEAR
    • NON OPIOD ANALGESICS
    • NOOTROPICS
    • NORADRENERGIC
    • NOREPINEPHRINE
    • NRF2: MASTER REGULATOR OF THE AGING PROCESS
    • NF-KB
    • NUTRACEUTICAL
    • OBESOGENS
    • ONCOGENE ACTIVATION INDUCED SENESCENCE
    • ORGANOTINS
    • OVERNUTRITION
    • OXIDATIVE STRESS & AGING
    • P16INK4A
    • P38MAPK
    • P53: TUMOR SUPRESSOR
    • PERIODONTITIS
    • PHOSPHATIDYLINOSITOL 3 KINASE
    • PHYTOCHEMICALS
    • PHYTOSTEROLS
    • PHYTOSTANOLS
    • PHYTOECDYSTEROIDS
    • PROANTHOCYANIDINS
    • PROTEIN CARBONYLATION
    • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
    • POLYPHENOLS AS COVID-19 TREATMENT & PREVENTION
    • PPARY2
    • PREMATURE SENESCENCE
    • PREVENTING SKIN AGING
    • PUFAS
    • PURGATIVES
    • RADIATION EXTRACT
    • RAPAMYCIN (MTOR INHIBITION)
    • RED WINE
    • RENAL (KIDNEY) PROTECTIVE AGENTS
    • REMINERALIZATION OF TEETH
    • REMYELINATION
    • REPAIR OF DNA BREAKS “DOUBLE STRAND”
    • RESTORE INSULIN SENSITIVITY
    • REVERSAL OF OBESITY
    • SASP & ADIPOSE TISSUE
    • SEX HORMONE BINDING GLOBULIN
    • SENESCENT CELLS, SASP & SENOLYTICS
    • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
    • SGLT2 INHIBITORS
    • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
    • SHBG
    • SIRT1
    • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
    • SKIN ELASTICITY
    • SKIN PHOTOAGING (Preventing & Repairing)
    • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
    • SIRT1 & LONGEVITY
    • SMALLPOX
    • SUGAR & AGING
    • STAR PROTEIN
    • STAT3
    • STEM CELL EXHAUSTION
    • STEM CELL REGENERATION
    • STEM CELL THERAPY
    • STIMULATED LIPOLYSYS
    • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
    • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
    • STRESS & AGING
    • STRESS & THE BRAIN
    • TELOMERE SHORTENING & PREMATURE AGING
    • TIME RESTRICTED FEEDING
    • THROMBOLYTICS (PLANT BASED)
    • TRAUMATIC BRAIN INJURY (HEALING)
    • TRYPTOPHAN HYDROXYLASE 2
    • VISCERAL ADIPOSITY
    • XENOBIOTICS
    • XENOESTROGEN
  • HOME
  • CONTACT
  • TELEGRAM PORTAL
  • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
  • The Ultimate Dry Fasting Resource
  • MY ACCOUNT
  • RESET PASSWORD
0
blank
IMMUNOSENESCENCE
March 8, 2021
blank
FEAR EXTINCTION
March 11, 2021
  1. Aldosterone in obesity
  2. Resistant hypertension, obesity, sleep apnea, and Aldosterone: theory and therapy
  3. The role of Aldosterone in obesity-related hypertension
  4. Visceral obesity and insulin resistance are associated with plasma Aldosterone levels in women
  5. obesity, hypertension and Aldosterone: is leptin the link?
  6. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration
  7. Aldosterone production and signaling dysregulation in obesity
  8. Fibrosis and cardiac function in obesity: a randomised controlled trial of Aldosterone blockade
  9. Plasma Aldosterone, plasma lipoproteins, obesity and insulin resistance in humans
  10. The role of the renin-angiotensin-Aldosterone system in obesity-related renal diseases
  11. Adipocytes produce Aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus–associated obesity and vascular dysfunction
  12. Adipocytes, Aldosterone and obesity-related hypertension
  13. The link between the renin-angiotensin-Aldosterone system and renal injury in obesity and the metabolic syndrome
  14. Leptin-Aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity
  15. The renin–angiotensin–Aldosterone system as a link between obesity and coronavirus disease 2019 severity
  16. obesity, sleep apnea, Aldosterone, and hypertension
  17. Morbid obesity, hypertensive disease and the renin-angiotensin-Aldosterone axis
  18. Vasculometabolic and Inflammatory Effects of Aldosterone in obesity
  19. A critical review of the evidence supporting Aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension
  20. The regulation of Aldosterone secretion by leptin: implications in obesity-related cardiovascular disease
  21. The renin angiotensin Aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome
  22. obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of Aldosterone, neprilysin, and sodium-glucose …
  23. The association of Aldosterone with obesity-related hypertension and the metabolic syndrome
  24. The link between adipose tissue renin-angiotensin-Aldosterone system signaling and obesity-associated hypertension
  25. The involvement of Aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes
  26. Interaction of Aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review
  27. Fat cells may be the obesity–hypertension link: human adipogenic factors stimulate Aldosterone secretion from adrenocortical cells
  28. obesity and cardiovascular disease: role of adipose tissue, inflammation, and the renin-angiotensin-Aldosterone system
  29. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and Aldosterone levels in morbid obesity
  30. Role of mineralocorticoid receptor and renin–angiotensin–Aldosterone system in adipocyte dysfunction and obesity
  31. Aldosterone deficiency in mice burdens respiration and accentuates diet-induced hyperinsulinemia and obesity
  32. obesity-induced hypertension develops in young rats independently of the renin-angiotensin-Aldosterone system
  33. Differential effects of renin–angiotensin–Aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity …
  34. Role of renin-angiotensin-Aldosterone system in metabolic syndrome and obesity-related hypertension
  35. Relationship between obesity, hypertension, and Aldosterone production in postmenopausal African American women: a pilot study
  36. Response to ‘renal injury in extreme obesity: the important role of Aldosterone‘
  37. Increased Aldosterone: mechanism of hypertension in obesity
  38. Changes in serum Aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults
  39. Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt/β-catenin signaling in podocytes
  40. Impact of obesity on the association of active renin and plasma Aldosterone concentrations, and Aldosterone-to-renin ratio with preeclampsia
  41. Reviving the use of Aldosterone inhibitors in treating hypertension in obesity
  42. Race, obesity, and the renin-angiotensin-Aldosterone system: treatment response in children with primary hypertension
  43. obesity and the renin–angiotensin–Aldosterone system
  44. PS 08-85 ASSOCIATION OF Aldosterone SYNTHASE (CYP11B2) GENE POLYMORPHISMS WITH obesity IN ESSENTIAL HYPERTENSIVE CHILDREN AND …
  45. Beneficial long-term effect of Aldosterone antagonist added to a traditional blockade of the renin–angiotensin–Aldosterone system among patients with obesity …
  46. Changes in Aldosterone and obesity-related cardiometabolic risk factors with a 1-year weight loss intervention in normotensive overweight and obese young …
  47. Insulin resistance and the renin-angiotensin-Aldosterone system in metabolic syndrome and obesity-related hypertension
  48. The renin, angiotensin, Aldosterone, and obesity connection
  49. The renin-angiotensin-Aldosterone system (RAAS) and its relation with calcium homeostasis in male obesity
  50. The Relationship between obesity, insulin resistance and Aldosterone levels
  51. Emerging role of Aldosterone in mediating the vicious cycle of obesity, insulin resistance and metabolic syndrome
  52. Distribution of genotypes and alleles of the Aldosterone-synthase gene in patients with abdominal obesity
  53. Targeting the Renin-Angiotensin-Aldosterone System in obesity
  54. Altered circadian plasma cortisol and Aldosterone group rhythms in Cushing’s syndrome versus obesity and health.
  55. Characteristics of the Renin-Angiotensin-Aldosterone System in Carriers of Polymorphic Variants of the VDR Gene With Arterial hypertension and obesity
  56. obesity-stimulated Aldosterone release is not related to an S1P-dependent mechanism
  57. ARTERIAL STIFFNESS, Aldosterone, CRP AND DIASTOLIC DYSFUNCTION IN PATIENTS WITH hypertension, obesity AND ATRIAL FIBRILLATION
  58. RENIN-ANGIOTENSIN-Aldosterone SYSTEM IN PATIENTS WITH ABDOMINAL obesity AND ARTERIAL hypertension
  59. Changes in excretion of Aldosterone in urine during absolute starvation in essential obesity.
  60. The Renin-Angiotensin-Aldosterone System as a Link Between obesity and Coronavirus Disease 2019 Severity
  61. Effect of Aldosterone receptor antagonist on obesity-related glomerulonephropathy
  62. Aldosterone Production and Signaling Dysregulation in obesity
  63. Adipocyte-derived Aldosterone And Cortisol Are Nox1/4 Dependent: Implications In obesity-associated Vascular Dysfunction.
  64. … efficacy and safety of dual blockage of the renin-angiotensin-Aldosterone system in patients with type 2 diabetes, hypertension and obesity without renal dysfunction
  65. Role of Aldosterone in obesity-induced endothelial dysfunction
  66. Aldosterone synthase gene polymorphism in alimentary obesity, metabolic syndrome components, some secondary forms of arterial hypertension, pathology of the …
  67. RELATIONSHIP BETWEEN obesity AND PLASMA Aldosterone IN ESSENTIAL hypertension: INFLUENCE OF GENDER: PP. 34.372
  68. Possible Interactions Among Fatty Acids, Other Lipids, and Aldosterone in the hypertension of obesity
  69. Influence of Race and obesity on the Renin-Angiotensin-Aldosterone System in Adolescents Born Preterm
  70. Does Renin‐Angiotensin‐Aldosterone System Inhibition Impact obesity as a Co–Risk Factor?
  71. P658Left ventricular function improvement by Aldosterone blockade in obesity: contribution of beneficial changes in collagen turnover
  72. BAS/BSCR35 Effects of Aldosterone and obesity on the anticontractile properties of perivascular adipose tissue in rat aortic rings
  73. Abstract MP009: Changes in Aldosterone are Associated With Changes in obesity-Related Factors in Normotensive Overweight/Obese Young Adults Undergoing …
  74. RENIN-ANGIOTENSIN-Aldosterone-SYSTEM IN PATIENTS WITH ABDOMINAL obesity AND hypertension: PP. 26.334
  75. The relationship between renin-Aldosterone system and obesity in non-insulin dependent diabetes mellitus (NIDDM).
  76. Role of the adipose-tissue renin-angiotensin-Aldosterone system in obesity and obesity-associated hypertension.
  77. obesity, adipocytes, and the renin-angiotensin-Aldosterone axis.
  78. … of Aldosterone, Plasma Renin Activity (PRA) and Superoxide Dismutase (SOD) with Inflammation and Insulin Resistance in Adult Men with Central obesity
  79. Effect of obesity on Activation of the Renin Angiotensin-Aldosterone system in Patients with Moderate to Advanced Heart Failure
  80. Differential aspects of the dynamics of the renin-angiotensin-Aldosterone system in obesity with and without hypertension and in essential arterial hypertension
  81. … receptor agonists and antagonists of Aldosterone on the performance of daily blood pressure monitoring in patients with hypertension and concomitant obesity
  82. Hyperinsulinemia Leads the Elevation of Plasma Aldosterone Concentration Independently with obesity, Dyslipidemia, and Insulin Resistance in Patients with Type 2 …
  83. Function of the adrenal cortex in obesity. 6. Aldosterone secretion and excretion of its metabolites during some dynamic tests.
  84. Abstract A39: Gene-environment interactions between SNPs in the renin-angiotensin-Aldosterone system and hypertension, obesity, and blood pressure-related …
  85. Function of the adrenal cortex in obesity. 5. Daily secretion of Aldosterone.
  86. … : C-344T Aldosterone-SYNTHASE GENE POLYMORPHISM AND RENIN-ANGIOTENSIN-Aldosterone SYSTEM IN PATIENTS WITH ABDOMINAL obesity
  87. … growth factor-23—klotho—vitamin D 3 axis and the renin—angiotensin—Aldosterone axis in the development and progression of obesity-related kidney disease
  88. PS 04-15 MICE LACKING Aldosterone SYNTHASE OR TREATED WITH EPLERENONE ARE RESISTANT TO DIET-INDUCED obesity
  89. Role of NADPH oxidase (Nox) 1/4 in adipocyte-derived Aldosterone production and in inflammation and fibrosis in obesity
  90. 6.1 hypertension Associated with obesity or Overweight: a Role for Aldosterone?
  91. The renin–angiotensin–Aldosterone system, glucose metabolism and diabetes
  92. Plasma Aldosterone concentration in the patient with diabetes mellitus Rapid Communication
  93. Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases
  94. Local renal Aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor
  95. Aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease
  96. Renin‐angiotensin‐Aldosterone system in diabetes and hypertension
  97. Diabetes mellitus, the renin-angiotensin-Aldosterone system, and the heart
  98. The role of the renin-angiotensin-Aldosterone system in diabetes and its vascular complications
  99. Selective Aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
  100. Renin‐angiotensin‐Aldosterone system, glucose metabolism and incident type 2 diabetes mellitus: MESA
  101. … role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, Aldosterone and catecholamines in type 1 (insulin-dependent) diabetes …
  102. Blockade of the renin–angiotensin–Aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes
  103. Sodium, renin, Aldosterone, catecholamines, and blood pressure in diabetes mellitus
  104. Diabetes and reninangiotensin-Aldosterone system: implications for COVID-19 patients with diabetes treatment management
  105. Evidence for renoprotection by blockade of the renin–angiotensin–Aldosterone system in hypertension and diabetes
  106. Aldosterone and myocardial extracellular matrix expansion in type 2 diabetes mellitus
  107. The crosstalk between insulin and renin-angiotensin-Aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention
  108. Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–Aldosterone system in type 2 diabetes: a prospective study using …
  109. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus
  110. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic …
  111. Aldosterone, renin, and diabetes mellitus in African Americans: the Jackson Heart Study
  112. A systematic review of the role of renin angiotensin Aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy
  113. Increased Aldosterone levels in a model of type 2 diabetes mellitus
  114. Aldosterone increases urine production and decreases apical AQP2 expression in rats with diabetes insipidus
  115. Renin-angiotensin-Aldosterone system activation in long-standing type 1 diabetes
  116. Impact of the renin-angiotensin-Aldosterone-system on cardiovascular and renal complications in diabetes mellitus
  117. The renin-angiotensin-Aldosterone system and the eye in diabetes
  118. Big renin and biosynthetic defect of Aldosterone in diabetes mellitus
  119. The state and responsiveness of the renin-angiotensin-Aldosterone system in patients with type II diabetes mellitus
  120. Aldosterone and type 2 diabetes mellitus
  121. Renin-angiotensin-Aldosterone system blockade is associated with higher risk of contrast-induced acute kidney injury in patients with diabetes
  122. Renin angiotensin Aldosterone system blockade and renal disease in patients with type 2 diabetes: an Asian perspective from the RENAAL study
  123. Blocking the renin-angiotensin-Aldosterone system to prevent diabetes mellitus
  124. Aldosterone responsiveness in patients with diabetes mellitus
  125. miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated Aldosterone-induced renal fibrosis in mice with diabetes
  126. Renin-angiotensin-Aldosterone system in diabetes mellitus.
  127. Effect of renin–angiotensin–Aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review …
  128. Diabetes impairs the vascular effects of Aldosterone mediated by G protein-coupled estrogen receptor activation
  129. The renin-angiotensin-Aldosterone system is suppressed in adults with type 1 diabetes
  130. Determinants and changes associated with Aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy
  131. Cardiac Aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density
  132. The role of renin–angiotensin–Aldosterone system‐based therapy in diabetes prevention and cardiovascular and renal protection
  133. The role of Aldosterone in cardiovascular disease in people with diabetes and hypertension: an update
  134. Aldosterone induces Vasoconstriction in Individuals with Type 2 Diabetes: Effect of Acute Antioxidant administration
  135. Renin–angiotensin–Aldosterone system genotypes and haplotypes affect the susceptibility to nephropathy in type 2 diabetes patients
  136. Higher screening Aldosterone to renin ratio in primary aldosteronism patients with diabetes mellitus
  137. Eplerenone reduces proteinuria in type II diabetes mellitus: implications for Aldosterone involvement in the pathogenesis of renal dysfunction
  138. The tissue renin-angiotensin-Aldosterone system in diabetes mellitus
  139. Impact of aliskiren treatment on urinary Aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy
  140. Genetic variant of the renin-angiotensin system and prevalence of type 2 diabetes mellitus: a modest but significant effect of Aldosterone synthase
  141. The study of renin–angiotensin–Aldosterone in experimental diabetes mellitus
  142. Renin-angiotensin-Aldosterone system, electrolyte homeostasis and blood pressure in alloxan diabetes.
  143. The role of the tissue renin-angiotensin-Aldosterone system in the development of metabolic syndrome, diabetes mellitus and itsvascular complications
  144. Serum potassium is a predictor of incident diabetes in African Americans with normal Aldosterone: the Jackson Heart Study
  145. Renin angiotensin Aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes
  146. Effect of renin-angiotensin-Aldosterone system inhibitors on all-cause mortality and major cardiovascular events in patients with diabetes: A meta-analysis focusing on …
  147. Renin angiotensin Aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study
  148. Responsiveness of plasma renin and Aldosterone in diabetes mellitus
  149. Glucose-induced hyperkalemia with normal Aldosterone levels: Studies in a patient with diabetes mellitus
  150. … between urinary sodium excretion and serum Aldosterone in patients with diabetes in the presence and absence of modifiers of the renin–angiotensin–Aldosterone …
  151. Low plasma Aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: effects of RAAS stimulation
  152. Ongoing treatment with renin-angiotensin-Aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population
  153. Associations between glycaemic control and activation of the renin-angiotensin-Aldosterone system in participants with type 2 diabetes mellitus and hypertension
  154. Individual variability in response to renin angiotensin Aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care …
  155. Endocrinological aspects of proteinuria and podocytopathy in diabetes: role of the Aldosterone/mineralocorticoid receptor system
  156. Decreases in renin and Aldosterone secretion in alloxan diabetes: an effect of insulin deficiency
  157. The renin‐Aldosterone axis in patients with diabetes insipidus
  158. Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems
  159. Aldosterone-mediated apical targeting of ENaC subunits is blunted in rats with streptozotocin-induced diabetes mellitus
  160. The potential benefits of Aldosterone antagonism in Type 2 diabetes mellitus
  161. Renin-angiotensin-Aldosterone system blockade in diabetes: role of direct renin inhibitors
  162. Mechanistic and clinical aspects of renin-angiotensin-Aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease
  163. Reduced plasma Aldosterone concentrations in randomly selected patients with insulin‐dependent diabetes mellitus
  164. Increased integrated concentration of norepinephrine, epinephrine, Aldosterone, and growth hormone in patients with uncontrolled juvenile diabetes mellitus
  165. Effect of sodium glucose co-transporter-2 inhibition on the Aldosterone/renin ratio in type 2 diabetes mellitus
  166. Changes of Aldosterone levels in patients with type 2 diabetes complicated by moderate to severe obstructive sleep apnea–hypopnea syndrome before and after …
  167. Effects of SGLT2 Inhibitors on Renin-Aldosterone System for One Month and Six Months in Type 2 Diabetes
  168. Renin–angiotensin–Aldosterone–blockade is associated with decreased use of antidepressant therapy in patients with type 1 diabetes and diabetic nephropathy
  169. … of the antihypertensive and antialbuminuric response to higher doses of renin–angiotensin–Aldosterone system blockade in albuminuric hypertensive type 2 diabetes …
  170. Effect of acute hyperglycaemia on plasma potassium and Aldosterone levels in type 2 (non-insulin-dependent) diabetes
  171. Atrial natriuretic peptide and renin-angiotensin-Aldosterone system in non-insulin-dependent diabetes mellitus.
  172. Dissociation of renin and Aldosterone during dehydration: studies in a case of diabetes insipidus and adipsia
  173. Responsiveness of plasma Aldosterone to angiotensin II in patients with diabetes mellitus
  174. Aldosterone responses to angiotensin II, adrenocorticotropin, and potassium in chronic experimental diabetes mellitus in rats
  175. RU28318, an Aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes
  176. Renin angiotensin-Aldosterone system (RAAS) blockers usage among type II diabetes mellitus patients—A Retrospective Study
  177. Add-on antihypertensive medications to angiotensin-Aldosterone system blockers in diabetes: a comparative effectiveness study
  178. Renin-Aldosterone responsiveness in uncomplicated juvenile-type diabetes mellitus
  179. Renin-Aldosterone axis in normoalbuminuric insulin-dependent diabetes mellitus patients with glomerular hyperfiltration
  180. … Renal Association clinical guidelines: hypertension management and renin-angiotensin-Aldosterone system blockade in patients with diabetes, nephropathy and/or …
  181. … of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: association with BNP and Aldosterone …
  182. Blockade of the renin-angiotensin-Aldosterone system and renal protection in diabetes mellitus
  183. Renin‐Angiotensin‐Aldosterone System Blockers in Elderly Adults with Chronic Kidney Disease without Diabetes Mellitus or Proteinuria
  184. Altered relation of the renin-Aldosterone system and vasoactive peptides in type 2 diabetes: the KORA F4 study
  185. Renin-angiotensin-Aldosterone system antagonists and the prevention of type 2 diabetes mellitus
  186. Advanced glycation of high-density lipoprotein and the functionality of Aldosterone release in type 2 diabetes
  187. Renin angiotensin Aldosterone system altered in resistant hypertension in Sub-Saharan African diabetes patients without evidence of primary hyperaldosteronism
  188. Responsiveness of plasma 18-hydroxycorticosterone and Aldosterone to angiotensin II or corticotropin in nonazotemic diabetes mellitus
  189. Production of Aldosterone in male rats with inherited diabetes insipidus (Brattleboro strain)
  190. … –Aldosterone system before and during submaximal bicycle exercise in relation to circulatory catecholamines in patients with Type 1 (insulin-dependent) diabetes …
  191. THE RENIN‐Aldosterone SYSTEM IN NEPHROGENIC DIABETES INSIPIDUS AND THE INFLUENCE OF HYDROCHLOROTHIAZIDE AND INDOMETHACIN
  192. Recurrent hyperkalemic renal tubular acidosis and hyponatremia in diabetes mellitus due to Aldosterone resistance
  193. Renin-Angiotensin-Aldosterone system inhibition in prevention of diabetes mellitus.
  194. P153 Modulation of renin-angiotensin-Aldosterone system reverses adverse left atrial remodelling in type 2 diabetes
  195. Renoprotective effects of renin–angiotensin–Aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis
  196. Relationships between renin, Aldosterone, blood pressure and renal function in hypertensive insulin-dependent diabetes mellitus
  197. Aldosterone responsiveness to an acute potassium load in diabetes mellitus and chronic renal insufficiency
  198. Diabetes Mellitus and Risks of Dual Blockade of the Renin-angiotensin-Aldosterone System
  199. Effects of amiloride on oral glucose loading, serum potassium, renin, and Aldosterone in diet‐controlled diabetes
  200. Glomerular hyperfiltration in insulin-dependent diabetes mellitus: no evidence for enhanced activity of the renin-angiotensin-Aldosterone system
  201. Renin–angiotensin–Aldosterone system blockade and urinary albumin excretion in community‐based patients with Type 2 diabetes: The Fremantle Diabetes Study
  202. Genetic polymorphism of renin-angiotensin-Aldosterone system in type 2 diabetes and in combination with arterial hypertension among Dagestan inhabitants
  203. The function of Aldosterone in patients with diabetes
  204. Renin-angiotensin-Aldosterone system in diabetes insipidus
  205. Diabetes insipidus after surgery of intracranial arterial aneurysms–with special reference to the human ADH and Aldosterone secretion (author’s transl)
  206. … angiotensin converting enzyme (ACE) insertion/deletion and Aldosterone synthase (CYP11B2)-344C/T polymorphisms in relation to type 2 diabetes mellitus risk in …
  207. The Role of Aldosterone in Diabetes-Related Vascular Disease: A New Therapeutic Target?
  208. Plasma renin and Aldosterone in youngsters with insulin-dependent diabetes mellitus
  209. The efficacy and safety of dual blockage of the renin-angiotensin-Aldosterone system in patients with type 2 diabetes, hypertension and obesity without renal …
  210. Azelnidipine Decreased Plasma Aldosterone andPlasminogen Activator Inhibitor Type 1 Levelsin the Hypertensive Patients with Type 2 Diabetes Mellitus―the Jikei …
  211. Relationship between Aldosterone and diabetes mellitus and its chronic complications
  212. Correlation Between Aldosterone and Gestational Diabetes Mellitus.
  213. Effects of Aldosterone, methylprednisolone and triiodothyronine on the response to water loading in the conscious hypothyroid rat with diabetes insipidus.
  214. Aldosterone excess: a rare non-nephrophathic cause of hypertension in type I diabetes.
  215. 538-P: Copeptin and Renin Angiotensin Aldosterone System (RAAS) Activation in Long-Standing Type 1 Diabetes (T1D)
  216. The potential benefits of Aldosterone antagonism in Type 2 diabetes mellitus
  217. Mineralocorticoid receptor and diabetes: in favour of other corticosteroids than Aldosterone
  218. Aldosterone prevents deleterious effects of diabetes in mouse hearts
  219. The effect of rosiglitazone combined with insulin on plasma Aldosterone in diabetes patients
  220. Aldosterone and Protein Disulfide Isomerase Activity in Diabetes
  221. Aldosterone Prevents Deleterious Effects of Diabetes in Mouse Hearts by a Proangiogenic Effect
  222. hypertension management and renin-angiotensin-Aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease
  223. … , May 15, 10: 00 AM-12.00 PM: Rationale for Aldosterone receptor blockade in the treatment of cardiovascular diseases*: Aldosterone receptor antagonists in diabetes …
  224. Pancreatic Renin‐Angiotensin‐Aldosterone System in the Cardiometabolic Syndrome and Type 2 Diabetes Mellitus
  225. … of acid-releasing renal function of rats in the dynamics of experimental diabetes mellitus with underlying pharmacological blockade of renin-angiotensin-Aldosterone …
  226. Cardiovascular Complications in Diabetes: Role of Aldosterone and Mineralocorticoid Receptors
  227. Acute Aldosterone Administration Increases Vascular Resistance in Patients with Type 2 Diabetes
  228. The Increase of Plasma Aldosterone Concentrations Were Correlated with Insulin Resistance in Patients with Type 2 Diabetes Mellitus.
  229. Aldosterone antagonism in type 2 diabetes mellitus—a new therapeutic approach to diabetic macrovascular disease?
  230. N‐Acetylcysteine Attenuates Aldosterone induced Vasoconstriction in Individuals with Type 2 Diabetes
  231. Relationship Between Circulating Aldosterone and Adipocytokines or Oxidative Stress in Patients With Type 2 Diabetes
  232. Renin Angiotensin Aldosterone System (RAAS) Activation and Diabetic Nephropathy (DN) Resistor Status in Longstanding Type 1 Diabetes
  233. … Usage of Renin-Angiotensin-Aldosterone System Blocking Agents on Incidence of Contrast-Induced Nephropathy in Patients with Diabetes Mellitus and Renal …
  234. Comparison of the morphological changes in the capillaries and the state of the renin-angiotensin-Aldosterone system in diabetes mellitus
  235. RENIN-ANGIOTENSIN-Aldosterone SYSTEM IN DIABETES MELLITUS
  236. H003 Cardiac Aldosterone overexpression prevents harmful effects of diabetes in mouse heart by preserving capillary density
  237. Correlation between insulin resistance and renin-angiotensin-Aldosterone system in newly diagnosed type 2 diabetes mellitus
  238. Plasma and Urinary Aldosterone Levels in Rats with Non-Insulin Dependent Diabetes Mellitus-Association with Myocardial Fibrosis
  239. The role of the renin-angiotensin-Aldosterone system blockade in preventing type 2 diabetes
  240. G Protein-coupled Estrogen Receptor Contributes To The Vascular Effects Of Aldosterone And Type Two Diabetes-associated Vascular Dysfunction
  241. Ednit effects on activity of renin-angiotensin-Aldosterone system and renal function in hypertensive subjects with diabetes mellitus
  242. Effects of atenolol add-on treatment on plasma renin activity (PRA) and Aldosterone escape in hypertensive patients with diabetes receiving valsartan
  243. Are renin angiotensin Aldosterone system gene polymorphisms risk factors for hypertension and diabetes? A literature review report from Malaysia
  244. … ADHERENCE TO RENIN-ANGIOTENSIN-Aldosterone-SYSTEM (RAAS) INHIBITORS AND RENAL FUNCTION AMONG PATIENTS WITH TYPE 2 DIABETES: A …
  245. Orthostatic hypotension in complicated diabetes mellitus: study of the renin-angiotensin-Aldosterone system (author’s transl)
  246. Diabetes mellitus type-II related hypertension and cardiovascular diseases: involvement of impaired regulatory renin-angiotensin-Aldosterone system
  247. Abstract P632: Nlrp3/inflammasome Activation Contributes To Aldosterone-induced Vascular Dysfunction In Type 2 Diabetes.
  248. … autonomous Aldosterone secretion in patients with type 2 Diabetes Mellitus and arterial hypertension. The effect of SGLT2 inhibitors on renin-angiotensin-Aldosterone …
  249. Effect of sodium depletion on the renin-angiotensin-Aldosterone system and prostaglandins in patients with insulin-dependent diabetes mellitus
  250. Impaired Sodium Excretion during Water Immersion in Diabetes Mellitus: Observations on the Renin-Aldosterone System
  251. Renin‐angiotensin‐Aldosterone system blockade ameliorates myocardial and ventricular function of rats with diabetes mellitus
  252. … Leads the Elevation of Plasma Aldosterone Concentration Independently with obesity, Dyslipidemia, and Insulin Resistance in Patients with Type 2 Diabetes Mellitus
  253. Renin-Angiotensin-Aldosterone System of Local Organizations and Chronic Complications of Type 2 Diabetes
  254. Aldosterone, Not Leptin, is Correlated With High Sympathetic Activity in Resistant hypertension With or Without Type 2 Diabetes
  255. … with angiotensin converting enzyme inhibitor and Aldosterone antagonist on insulin sensitivity and serum leptin concentration in patients with type 2 diabetes …
  256. … NITRIC OXIDE SYNTHASE, ANGIOTENSINOGEN AND Aldosterone SYNTHASE GENE POLYMORPHISMS IN TYPE 2 DIABETES MELLITUS AND THEIR …
  257. The kidney in diabetes mellitus: urinary transfer in excretion, hypertension, the Renin-Angiotensin-Aldosterone system, and the role of angiotensin converting enzyme …
  258. PP. 09.11: ASSOCIATION OF PLASMA Aldosterone CONCENTRATION WITH PREVALENCE OF DIABETES MELLITUS IN SUSPECTED PRIMARY …
  259. CMS and Type 2 Diabetes Mellitus: Bound Together by the Renin Angiotensin Aldosterone System
  260. … irbesartan, and perindopril plus irbesartan on blood pressure, renal hemodynamics, proteinuria, renin angiotesin-Aldosterone system, and TGF-B1, in type 2 diabetes …
  261. A Nox4 Inhibitor, GKT 137831, Decreases Aldosterone Synthesis, Adiposity and Vascular Contractility in a Murine Model of Diabetes.
  262. Effect of 5-month guanfacine treatment on the renin-angiotensin-Aldosterone system and some metabolic factors in patients with diabetes mellitus type II and …
  263. S-423 Plasma Aldosterone level and its metabolic implications in patients with type 2 diabetes
  264. … CILNIDIPINE ON SYMPATHETIC NERVOUS SYSTEM AND PLASMA Aldosterone CONCENTRATION IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES …
  265. … OF THE RENIN-ANGIOTENSIN SYSTEM AND PREVALENCE OF TYPE 2 DIABETES MELLITUS. A MODEST BUT SIGNIFICANT EFFECT OF Aldosterone …
  266. Aldosterone and arterial hypertension
  267. Mechanisms of hypertension: the expanding role of Aldosterone
  268. Serum Aldosterone and the incidence of hypertension in nonhypertensive persons
  269. Structural analysis and evaluation of the Aldosterone synthase gene in hypertension
  270. Genetic determination of plasma Aldosterone levels in essential hypertension
  271. Essential hypertension: renin and Aldosterone, heart attack and stroke
  272. Role of Aldosterone in left ventricular hypertrophy in hypertension
  273. hypertension: renin–angiotensin–Aldosterone system alterations
  274. Narrative review: the emerging clinical implications of the role of Aldosterone in the metabolic syndrome and resistant hypertension
  275. Aldosterone-receptor antagonism in hypertension
  276. Global-and renal-specific sympathoinhibition in Aldosterone hypertension
  277. Aldosterone, hypertension, and cardiovascular disease: an endless story
  278. Saline suppression of plasma Aldosterone in hypertension
  279. Plasma Aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension
  280. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension
  281. The renin-angiotensin-Aldosterone system: a specific target for hypertension management
  282. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and Aldosterone profiles
  283. ICV infusion of corticosterone antagonizes ICV-Aldosterone hypertension
  284. hypertension, increased Aldosterone secretion and low plasma renin activity relieved by dexamethasone
  285. Aldosterone Excretion Rate and Blood Pressure in Essential hypertension Are Related to Polymorphic Differences in the Aldosterone Synthase Gene CYP11B2
  286. Resistant hypertension, obstructive sleep apnoea and Aldosterone
  287. Aldosterone and the risk of hypertension
  288. Somatic mutations in ATP1A1 and ATP2B3 lead to Aldosterone-producing adenomas and secondary hypertension
  289. Aldosterone-to-renin ratio, arterial stiffness, and the response to Aldosterone antagonism in essential hypertension
  290. Intracerebroventricular infusion of Aldosterone induces hypertension in rats
  291. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome
  292. Aldosterone and the vasculature: mechanisms mediating resistant hypertension
  293. Association between increased plasma levels of Aldosterone and decreased systemic arterial compliance in subjects with essential hypertension
  294. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea
  295. Aldosterone, inflammation, immune system, and hypertension
  296. Characterization of resistant hypertension: association between resistant hypertension, Aldosterone, and persistent intravascular volume expansion
  297. Severity of obstructive sleep apnea is related to Aldosterone status in subjects with resistant hypertension
  298. Central interactions of Aldosterone and angiotensin II in Aldosterone-and angiotensin II-induced hypertension
  299. Eplerenone, a selective Aldosterone blocker, in mild-to-moderate hypertension
  300. A chimaeric llβ-hydroxylase/Aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension
  301. Influence of arterial blood pressure and Aldosterone on left ventricular hypertrophy in moderate essential hypertension
  302. Association of the C− 344T Aldosterone synthase gene variant with essential hypertension: a meta-analysis
  303. Increased cardiac types I and III collagen mRNAs in Aldosterone-salt hypertension.
  304. A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-Aldosterone hypertension
  305. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of Aldosterone synthase
  306. Arterial pressure, left ventricular mass, and Aldosterone in essential hypertension
  307. Vascular complications in patients with Aldosterone producing adenoma in Japan: comparative study with essential hypertension
  308. Effects of the selective Aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension
  309. Aldosterone is produced from ventricles in patients with essential hypertension
  310. Aldosterone antagonists in hypertension and heart failure.
  311. Aldosterone antagonist improves diastolic function in essential hypertension
  312. Molecular basis of salt sensitivity in human hypertension: evaluation of renin-angiotensin-Aldosterone system gene polymorphisms
  313. Aldosterone secretion and primary and malignant hypertension
  314. Experimental Aldosterone hypertension in the dog.
  315. Intracerebroventricular infusion of RU28318 blocks Aldosterone-salt hypertension
  316. Influence of antihypertensive medication on Aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism
  317. Variation at the Aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised Aldosterone-to-renin ratio
  318. Renin-Aldosterone Relationships in Pregnancy-Induced hypertension: An Alternative Viewpoint
  319. Molecular genetics of the renin-angiotensin-Aldosterone system in human hypertension.
  320. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, Aldosterone excess, and low plasma renin
  321. hypertension and severe hyperkalaemia associated with suppression of renin and Aldosterone and completely reversed by dietary sodium restriction
  322. Genetic variants in the epithelial sodium channel in relation to Aldosterone and potassium excretion and risk for hypertension
  323. Plasma renin activity and angiotensin I and Aldosterone concentrations in cats with hypertension associated with chronic renal disease.
  324. hypertension and primary hyperparathyroidism: the role of adrenergic and renin-angiotensin-Aldosterone systems.
  325. Myocardial ultrasonic backscatter in hypertension: relation to Aldosterone and endothelin
  326. Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, Aldosterone and blood pressure levels.
  327. Brain sodium channels and ouabainlike compounds mediate central Aldosterone-induced hypertension
  328. … of congestive heart failure: vasopressin, Aldosterone, and angiotensin II: further evidence for renal-adrenal interaction from studies in hypertension and in cirrhosis
  329. … -responsive Aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension.
  330. Investigation of the role of Aldosterone in hypertension associated with spontaneous pituitary‐dependent hyperadrenocorticism in dogs
  331. Ratio of serum Aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism
  332. Assessment of the novel selective Aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension
  333. Genetic polymorphism of the renin–angiotensin–Aldosterone system and arterial hypertension in the Italian population: the GENIPER Project
  334. Long-term safety and efficacy of the selective Aldosterone blocker eplerenone in patients with essential hypertension
  335. Haplotype analysis of Aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension
  336. Can the genetic factors influence the treatment of systemic hypertension? The case of the renin-angiotensin-Aldosterone system
  337. Incidence of primary aldosteronism uncomplicated essential hypertension: a prospective study with elevated Aldosterone secretion and suppressed plasma renin …
  338. Non-genomic actions of Aldosterone: role in hypertension
  339. Aldosterone-producing adenoma without hypertension: a report of two cases
  340. The control of Aldosterone secretion in normal and hypertensive man: abnormal renin-Aldosterone patterns in low renin hypertension
  341. Relation of renin, angiotensin II, and experimental renal hypertension to Aldosterone secretion
  342. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension
  343. An abnormal sodium metabolism in Japanese patients with essential hypertension, judged by serum sodium distribution, renal function and the renin-Aldosterone …
  344. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, Aldosterone-producing adenoma, and pheochromocytoma
  345. Age versus urinary sodium for judging renin, Aldosterone, and catecholamine levels: studies in normal subjects and patients with essential hypertension
  346. Systemic hypertension after cardiac transplantation: effect of cyclosporine on the renin-angiotensin-Aldosterone system
  347. Angiotensin, Aldosterone and human arterial hypertension
  348. Is Aldosterone the missing link in refractory hypertension?: Aldosterone-to-renin ratio as a marker of inappropriate Aldosterone activity
  349. Effect of chronic diuretic treatment on the plasma renin‐angiotensin‐Aldosterone system in essential hypertension.
  350. > VI. RENIN, Aldosterone, AND hypertension: The Intercurrent hypertension of Primary Aldosteronism
  351. Contrasting associations between Aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites
  352. Renin and Aldosterone levels and hypertension following envenomation in humans by the yellow scorpion Leiurus quinquestriatus
  353. Importance of the renin-angiotensin-Aldosterone system (RAS) in the physiology and pathology of hypertension
  354. Plasma Aldosterone response to ACTH in primary aldosteronism and in patients with low renin hypertension
  355. Plasma Aldosterone-renin interrelationships in various forms of essential hypertension: studies using a rapid assay of plasma Aldosterone
  356. Production of experimental hypertension by Aldosterone
  357. hypertension and hypersalimentation. 1. Aldosterone hypertension.
  358. Renin, Aldosterone, body fluid volumes, and the baroreceptor reflex in the development and reversal of Goldblatt hypertension in conscious dogs
  359. Familial hyperpotassemia and hypertension accompanied by normal plasma Aldosterone levels: possible hereditary cell membrane defect
  360. Renin-angiotensin-Aldosterone system gene polymorphisms and hypertension in Hong Kong Chinese
  361. Abnormally sustained Aldosterone secretion during salt loading in patients with various forms of benign hypertension; relation to plasma renin activity
  362. Essential hypertension and Aldosterone
  363. … of Aldosterone in man: Evidence for regulation of electrolyte balance and arterial pressure by a renal-adrenal system which may be involved in malignant hypertension
  364. Serum Aldosterone level in patients with hypertension during treatment by acupuncture
  365. VI. RENIN, Aldosterone, AND hypertension: The Relationship Between Plasma Renin and Aldosterone in Normal Man
  366. Aldosterone metabolites and possible Aldosterone precursors in hypertension
  367. Aldosterone synthase (CYP11B2)− 344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension
  368. Influence of plasma Aldosterone on left ventricular geometry and diastolic function in treated essential hypertension
  369. Effect of fructose-induced hypertension on the renin-angiotensin-Aldosterone system and atrial natriuretic factor
  370. Further studies on urinary Aldosterone in human arterial hypertension.
  371. The cardiac structure-function relationship and the renin-angiotensin-Aldosterone system in hypertension and heart failure
  372. Impact of renin-angiotensin-Aldosterone system gene variants on the severity of hypertension in patients with newly diagnosed hypertension
  373. Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of Aldosterone in hypertension
  374. Familial hyperkalemia, hypertension, and hyporeninemia with normal Aldosterone levels: A tubular defect in potassium handling
  375. Effects of amlodipine on urinary sodium excretion, renin-angiotensin-Aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension.
  376. Eplerenone: a selective Aldosterone receptor antagonist for hypertension and heart failure.
  377. Disparate patterns of Aldosterone response during diuretic treatment of hypertension
  378. Effect of atrial natriuretic factor on blood pressure, renin, and Aldosterone in Goldblatt hypertension.
  379. Results of adrenal surgery in patients with hypertension, Aldosterone excess, and low plasma renin concentration.
  380. Alterations in Aldosterone secretion and metabolism in low renin hypertension
  381. Regulation of cardiac output during Aldosterone-induced hypertension.
  382. Renin-Aldosterone profiling in hypertension
  383. Aldosterone studies in obese patients with hypertension
  384. Left ventricular hypertrophy in asymptomatic essential hypertension: its relationship with Aldosterone and the increase in sodium-proton exchanger activity.
  385. Reversal of cardiovascular structural changes when treating essential hypertension: the importance of the renin-angiotensin-Aldosterone system
  386. Combining renin-angiotensin-Aldosterone system blockade with diuretic therapy for treatment of hypertension
  387. Functional derangements in the regulation of Aldosterone secretion in hypertension.
  388. Role of renin-angiotensin-Aldosterone system in salt-sensitive hypertension induced by sensory denervation
  389. Endothelin receptor blockade lowers plasma Aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension
  390. Aldosterone and specific Aldosterone receptor antagonists in hypertension and cardiovascular disease
  391. Possible mechanism of action for Aldosterone-induced hypertension
  392. Aldosterone antagonists in the treatment of hypertension and target organ damage
  393. Effect of nifedipine on plasma renin, Aldosterone and catecholamines in arterial hypertension
  394. Enhanced Aldosterone response to angiotensin II in human hypertension.
  395. Aldosterone and renin in essential hypertension.
  396. Role of the Aldosterone system in the salt-sensitivity of patients with benign essential hypertension
  397. Symptoms and the distress they cause: comparison of an Aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension
  398. Renin-angiotensin-Aldosterone and hypertension
  399. Electrolyte metabolism and Aldosterone secretion in benign and malignant hypertension
  400. Alterations of calcium, magnesium, and zinc in essential hypertension: their relation to the renin-angiotensin-Aldosterone system
  401. Aldosterone excretion in essential hypertension
  402. Calcium metabolism and the renin-Aldosterone system in essential hypertension.
  403. Does the renin-angiotensin-Aldosterone system modify cardiac structure and function in essential hypertension?
  404. The steroid content of adrenal adenomas and measurements of Aldosterone production in patients with essential hypertension and primary aldosteronism
  405. The role of Aldosterone in the development of hypertension in spontaneously hypertensive rats
  406. Malignant hypertension due to an Aldosterone producing adrenal adenoma
  407. Effect of corticotropin on Aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism
  408. Role of renin and Aldosterone in hypertension due to a renin-secreting tumor
  409. Studies on Aldosterone: II. hypertension as a cumulative effect of Aldosterone administration
  410. Unexpected pressor responses to propranolol in essential hypertension: an interaction between renin, Aldosterone and sympathetic activity
  411. Low-renin, low-Aldosterone hypertension and abnormal cortisol metabolism in a 19-month-old child
  412. The role of the renin-angiotensin-Aldosterone system in circulatory control and hypertension.
  413. Regression of left ventricular hypertrophy in patients with hypertension: blockade of the renin-angiotensin-Aldosterone system
  414. Influence of sodium intake on hydrochlorothiazide‐induced changes in blood pressure, serum electrolytes, renin and Aldosterone in essential hypertension
  415. Malignant hypertension: effect of therapy on renin and Aldosterone
  416. Role of Aldosterone in angiotensin II-induced hypertension in rats
  417. Effects of losartan on the renin-angiotensin-Aldosterone axis in essential hypertension.
  418. The influence of a heparin-like compound on hypertension, electrolytes and Aldosterone in man
  419. hypertension with Aldosterone excess and low plasma-renin: preoperative distinction between patients with and without adrenocortical tumour
  420. Renin-angiotensin-Aldosterone system and G-protein beta-3 subunit gene polymorphisms in salt-sensitive essential hypertension
  421. Aldosterone diagnosis in hypertension: comparative evaluation of radioimmunoassays for urinary Aldosterone and 18-OH-corticosterone
  422. Renin–Angiotensin–Aldosterone System Loci and Multilocus Interactions in Young‐Onset Essential hypertension
  423. Effects of glucocorticoid administration on Aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism
  424. hypertension corrected and Aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressible …
  425. Serum Aldosterone changes during hyperinsulinemia are correlated to body mass index and insulin sensitivity in patients with essential hypertension
  426. Renin, Aldosterone, sodium and hypertension
  427. Molecular variants in the P450c11AS gene as determinants of Aldosterone synthase activity in the Dahl rat model of hypertension
  428. Gene polymorphisms of the renin-angiotensin-Aldosterone system and essential arterial hypertension in childhood.
  429. Abnormal responsiveness of the renin Aldosterone system to acute stimulation in patients with essential hypertension
  430. hypertension induced by oral contraceptives containing estrogen and gestagen: effects on plasma renin activity and Aldosterone excretion
  431. Aldosterone secretion in hypertension
  432. Effects of biobehaviorally-assisted relaxation training on blood pressure, plasma renin, cortisol, and Aldosterone levels in borderline essential hypertension.
  433. Renin-angiotensin-Aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in …
  434. A decreased metabolic clearance rate of Aldosterone in benign essential hypertension
  435. Plasma renin activity and plasma Aldosterone concentrations in untreated Nigerians with essential hypertension.
  436. Adrenal sensitivity to angiotensin II and undiscovered Aldosterone stimulating factors in hypertension
  437. Renin-angiotensin-Aldosterone system and sodium balance in experimental renal hypertension
  438. Interaction between Aldosterone secretion, sodium and potassium balance, and angiotensin activity in man: studies in hypertension and cirrhosis
  439. Coronary microvascular fluid flux and permeability: influence of angiotensin II, Aldosterone, and acute arterial hypertension
  440. Sodium sensitivity in essential hypertension: role of the renin-angiotensin-Aldosterone system and predictive value of an intravenous frusemide test.
  441. Altered renin-angiotensin-Aldosterone relationships in normal renin essential hypertension.
  442. Maternal hypertension and progeny blood pressure: role of Aldosterone and 11β-HSD
  443. Dysregulation of Aldosterone secretion and its relationship to the pathogenesis of essential hypertension
  444. Artificial mutations in P450c11AS (Aldosterone synthase) can increase enzymatic activity: a model for low-renin hypertension?
  445. Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-Aldosterone system
  446. Systemic systolic hypertension in the elderly: correlation of hemodynamics, plasma volume, renin, Aldosterone, urinary metanephrines and response to thiazide …
  447. Renin-angiotensin-Aldosterone system during chronic thiazide therapy of benign hypertension
  448. Angiotensin and Aldosterone in renovascular hypertension
  449. Studies of the renin-angiotensin-Aldosterone system in patients with hypertension and in normal subjects
  450. Metabolic cardiovascular risk factors and the renin-Aldosterone system in essential hypertension.
  451. Acromegaly and hypertension: prevalence and relationship to the renin-angiotensin-Aldosterone system
  452. Effects of angiotensin infusions on Aldosterone and electrolyte excretion in normal subjects and patients with hypertension and adrenocortical disorders
  453. Response of Aldosterone and 18-hydroxycorticosterone to angiotensin II in normal subjects and patients with essential hypertension, Conn’s syndrome, and …
  454. Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in Aldosterone-induced hypertension
  455. Calcium sensitivity of isometric force in intact and chemically skinned aortas during the development of Aldosterone-salt hypertension in the rat.
  456. Effect of posture on the plasma concentrations of Aldosterone in hypertension and primary hyperaldosteronism
  457. Altered Aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension
  458. Aldosterone receptor antagonists for hypertension
  459. … of angiotensin converting enzyme inhibitors in essential and renal hypertension: effects of captopril and enalapril on renin-angiotensin-Aldosterone, renal function and …
  460. The role of ACTH in the episodic release of Aldosterone in patients with idiopathic adrenal hyperplasia, hypertension, and hyperaldosteronism
  461. Low renin,“normal” Aldosterone and hypertension: Circadian rhythm of renin, Aldosterone, Cortisol and growth hormone
  462. Vascular responsiveness in rats resistant to Aldosterone-salt hypertension.
  463. hypertension with Aldosterone excess.
  464. Acute effects of the calcium antagonist, nifedipine, on blood pressure, pulse rate, and the renin-angiotensin-Aldosterone system in patients with essential hypertension
  465. The promise of selective Aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure
  466. Long-term effects of irbesartan and atenolol on the renin-angiotensin-Aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular …
  467. hypertension caused by an Aldosterone-secreting adenoma: occurrence in a 7-year-old child
  468. A delayed suppression of the renin-Aldosterone axis following saline infusion in human hypertension.
  469. The effect of low and high sodium diets on plasma atrial natriuretic factor, the renin‐Aldosterone system and blood pressure in subjects with essential hypertension
  470. Renin-angiotensin-Aldosterone system in pregnancy-induced hypertension
  471. Effect of angiotensin converting enzyme inhibition on blood pressure, plasma renin activity and plasma Aldosterone in essential hypertension
  472. Plasma renin activity (PRA) and Aldosterone (PA) in patients with chronic glomerulonephritis (GN) and hypertension.
  473. The renin—angiotensin—Aldosterone system and carotid artery disease in mild-to-moderate primary hypertension
  474. Renin-angiotensin-Aldosterone system, RR interval, and blood pressure variability during postural changes in borderline arterial hypertension
  475. Adenovirus-mediated human prostasin gene delivery is linked to increased Aldosterone production and hypertension in rats
  476. Aldosterone and corticosterone secretion rates in rats with experimental renal hypertension
  477. Aldosterone in sustained essential hypertension
  478. Rhythm characteristics of plasma renin, Aldosterone and cortisol in five subtypes of mesor-hypertension
  479. Triamterene-Induced Changes in Aldosterone and Renin Values in Essential hypertension: Evidence of a Role for Aldosterone in Preventing Blood Pressure …
  480. Renin and Aldosterone in essential hypertension
  481. Aldosterone and electrolyte balance in human hypertension
  482. Quadric analysis in the preoperative distinction between patients with and without adrenocortical tumors in hypertension with Aldosterone excess and low plasma …
  483. Body fluid volumes and the response of renin and Aldosterone to short‐and long‐term thiazide therapy of essential hypertension
  484. Aldosterone, the adrenal cortex, and hypertension
  485. hypertension and Aldosterone overproduction without renin suppression in Cushing’s syndrome from an adrenal adenoma
  486. Circadian changes in plasma renin activity and plasma Aldosterone concentration in two-kidney hypertension rats.
  487. Aldosterone-related genetic effects in hypertension
  488. Heritable abnormalities of the renin-angiotensin-Aldosterone system in essential hypertension.
  489. … hypertension with penbutolol (Hoe 893d). I. Effects on blood pressure, pulse rate, catecholamines in blood and urine, plasma renin activity and urinary Aldosterone …
  490. Regulation of Aldosterone receptors in hypertension
  491. Plasma Renin Activity and in vitro Synthesis of Aldosterone by the Adrenal Glands of Rats with Spontaneous, Renal, or Pinealectomy‐Induced hypertension
  492. Use of the converting enzyme inhibitor enalapril in renovascular hypertension. Effect on blood pressure, renal function, and the renin-angiotensin-Aldosterone system.
  493. Influence of Aldosterone vs endothelin receptor antagonism on renovascular function in liquorice‐induced hypertension
  494. Controlled study of circadian rhythm of blood pressure in patients with Aldosterone-producing adenoma compared with those with essential hypertension
  495. Different regulation of cardiac and renal corticosteroid receptors in Aldosterone-salt treated rats: effect of hypertension and glucocorticoids
  496. The Aldosterone to renin ratio in secondary hypertension
  497. Plasma deoxycorticosterone and Aldosterone in essential hypertension
  498. Urinary Aldosterone and hypertension
  499. Changes in the renin-angiotensin-Aldosterone system and in sodium and potassium balance during development of renal hypertension in rats
  500. Experimental Aldosterone hypertension in the rat
  501. The renin-angiotensin-Aldosterone system: focus on its distinct role in arterial hypertension and its various inhibitors as a therapeutic strategy to effectively lower blood …
  502. Activity of renin-angiotensin-Aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension
  503. … evidence on blocking the renin–angiotensin–Aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent …
  504. Aldosterone metabolic clearance is normal in low-renin essential hypertension
  505. Role of Aldosterone in the pathogenesis of hypertension
  506. Development of hypertension in rats treated with Aldosterone acetate
  507. Blunted Aldosterone responsiveness to angiotensin II in normotensive subjects with familial predisposition to essential hypertension.
  508. Relation between plasma renin activity, angiotensin, and Aldosterone and blood pressure in mild untreated hypertension.
  509. In vivo left ventricular function and collagen expression in Aldosterone/salt-induced hypertension
  510. Effects of long-term enalapril and losartan therapy of hypertension on cardiovascular Aldosterone
  511. Unilateral Page kidney hypertension in man: Studies of the renin-angiotensin-Aldosterone system before and after nephrectomy
  512. Captopril in hypertension with renal artery stenosis and in intractable hypertension; acute and chronic changes in circulating concentrations of renin, angiotensins I …
  513. … and calcium channel-blocking drugs on plasma Aldosterone responses to infusion of angiotensin II in normal subjects and patients with essential hypertension
  514. hypertension and hypokalemic alkalosis associated with underproduction of Aldosterone
  515. Perspectives on the renin-angiotensin-Aldosterone system in hypertension
  516. Aldosterone suppression with dopamine infusion in low-renin hypertension.
  517. Dissociation of plasma renin activity and Aldosterone in essential hypertension
  518. The relationship of Aldosterone synthase gene polymorphism with hypertension and left ventricular hypertrophy
  519. Plasma immunoreactive gamma melanotropin in patients with idiopathic hyperaldosteronism, Aldosterone-producing adenomas, and essential hypertension.
  520. Modifications of myocardial Na+,K+-ATPase isoforms and Na+/Ca2+ exchanger in Aldosterone/salt-induced hypertension in guinea pigs
  521. Nomograms relating Aldosterone excretion to urinary sodium and potassium in the pediatric population: Their application to the study of childhood hypertension
  522. Characteristics of adrenal-regeneration and Aldosterone hypertension.
  523. Renin–angiotensin–Aldosterone system polymorphisms and essential hypertension: where are we?
  524. Failure of chronic Aldosterone infusion to increase arterial pressure in dogs with angiotensin-induced hypertension.
  525. Renin-angiotensin-Aldosterone system in experimental renal hypertension in the rabbit
  526. Relationship of plasma renin activity and Aldosterone levels with hemodynamic functions in essential hypertension
  527. The renin-Aldosterone system in pre-eclampsia, essential and transient hypertension during pregnancy, and normotensive pregnant and non-pregnant control …
  528. Acute effects of captopril on cardiopulmonary hemodynamics and renin-angiotensin-Aldosterone and bradykinin profile in hypertension
  529. A study of urinary and intracellular sodium and potassium, renin, Aldosterone, and hypertension in blacks and Indians in Natal
  530. Dynamic Aldosterone and 18-hydroxydeoxycorticosterone studies in labile and stable benign essential hypertension
  531. Opposite associations of circulating Aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension
  532. Catecholamines and the renin-angiotensin-Aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension.
  533. Urinary Aldosterone and hypertension
  534. Effect of blood pressure angiotensin II and Aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with …
  535. The Role of Urinary PGE2 and Renin-Angiotensin-Aldosterone System in the Pathogenesis of Essential hypertension
  536. Dissociation in the excretion of different Aldosterone metabolites and unmetabolized (‘free’) Aldosterone in hypertension
  537. The Yucatan miniature swine: an improved pig model for the study of desoxycorticosterone-acetate (DOCA) and Aldosterone hypertension
  538. Relationship between plasma Aldosterone concentration and plasma potassium in patients with essential hypertension during alprenolol treatment
  539. hypertension with inappropriate Aldosterone stimulation: a syndrome
  540. The integrated concentration of plasma renin activity and Aldosterone in essential hypertension.
  541. Reduced Aldosterone metabolites in hypertension
  542. Relations between renin, Aldosterone and experimental hypertension in rats
  543. The gerontological decline of the renin-Aldosterone system: a chronobiological approach extended to essential hypertension
  544. Circulatory volume in essential hypertension. Relationships with age, blood pressure, exchangeable sodium, renin, Aldosterone and catecholamines.
  545. Abnormal urinary kallikrein in hypertension is not related to Aldosterone or plasma renin activity.
  546. Short‐term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma Aldosterone in patients with essential hypertension
  547. … Renin Activity Ratio in Hypertensive Patients with Increases of 11-Deoxycorticosterone and 18-Hydroxy-ll-Deoxycorticosterone: A Subtype of Essential hypertension?
  548. Renal function, body fluid volumes, renin, Aldosterone, and noradrenaline during treatment of hypertension with pindolol.
  549. The adrenal cortex and hypertension: some observations on a possible role for mineralocorticoids other than Aldosterone
  550. Suppression of plasma renin and Aldosterone in stress-salt hypertension in dogs
  551. Suppression of the Renin—Aldosterone System in Mild Essential hypertension
  552. Response of plasma Aldosterone to fludrocortisone in primary hyperaldosteronism and other forms of hypertension
  553. Dopaminergic regulation of circadian rhythms of blood pressure, renin and Aldosterone in essential hypertension
  554. The prevalence of hypertension in an unselected population, and the frequency of abnormalities of potassium, angiotensin II and Aldosterone in hypertensive subjects
  555. Antihypertensive and Aldosterone-lowering effects of synthetic atrial natriuretic factor in renin-dependent renovascular hypertension.
  556. The Renin‐Aldosterone System and Renal Hemodynamics in Patients with Posttransplant hypertension
  557. Aldosterone acts on the kidney, not the brain, to cause mineralocorticoid hypertension in sheep
  558. High-renin malignant hypertension secondary to an Aldosterone-producing adenoma
  559. Sodium balance, plasma renin, and Aldosterone in hypertension.
  560. Effects of enalapril maleate on blood pressure, renin-angiotensin-Aldosterone system, and peripheral sympathetic activity in essential hypertension.
  561. Aldosterone and magnesium in essential arterial hypertension.
  562. The effects of sodium loading and deprivation on plasma renin and plasma and urinary Aldosterone in hypertension
  563. hypertension due to coexisting pheochromocytoma and Aldosterone-producing adrenal cortical adenoma
  564. The renin-angiotensin-Aldosterone system and hypertension in primary hyperparathyroidism
  565. Altered Ca-dependent fluxes of 42K in rat aorta during Aldosterone-salt hypertension.
  566. Effects of ACTH and posture on Aldosterone metabolism in essential hypertension
  567. … and indirect measurement of urinary kallikrein excretion in patients with essential hypertension and normotensives: relation to age and plasma renin and Aldosterone …
  568. Aldosterone secretion by dogs during the developmental phase of Goldblatt hypertension
  569. Effect of chlorothiazide upon Aldosterone excretion and sodium and potassium balance in essential hypertension
  570. Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, Aldosterone and arginine vasopressin in essential hypertension
  571. Aldosterone in primary hypertension relationship to plasma renin activity and urinary electrolytes and a comparison with normotensive subjects
  572. The renin-Aldosterone system and thiazide-induced depletion of total body potassium in essential hypertension
  573. … enzyme inhibition on blood pressure, plasma renin activity (PRA) and plasma Aldosterone in hypertensive diabetics compared to patients with essential hypertension.
  574. The renin-Aldosterone system in exaggerated natriuresis of essential hypertension
  575. Role of Aldosterone in the antihypertensive effect of spironolactone in essential hypertension
  576. Central and renal circulation, renin and Aldosterone in plasma during prazosin treatment in essential hypertension
  577. Plasma Aldosterone in essential hypertension with low renin activity
  578. … of nicardipine, a calcium‐entry blocker: Effects on renal function, plasma renin activity, and Aldosterone concentration in mild‐to‐moderate essential hypertension
  579. The effect of indomethacin on plasma renin activity and urinary Aldosterone of patients with essential hypertension
  580. Effect of an Aldosterone antagonist on electrolytes and juxtaglomerular granularity in adrenal regeneration hypertension
  581. Candesartan cilexetil in hypertension: Effects of six weeks’ treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensin-Aldosterone system
  582. The metabolic clearance of Aldosterone decreases similarly during infusion of angiotensin II in patients with essential hypertension and in normal subjects
  583. Malignant hypertension and Aldosterone secretion: Influence of reversal and progression of the syndrome in two cases
  584. Prostanoids and Aldosterone-induced mild experimental hypertension in rats.
  585. … paper: the renin-angiotensin-Aldosterone system for blood pressure regulation and for subdividing patients to reveal and analyze different forms of hypertension
  586. Differences in adrenal cholesterol, ascorbic acid, circulating corticosterone and Aldosterone during the onset of hypertension in SHR vs WKy rats
  587. Responses of plasma catecholamines, renin-angiotensin-Aldosterone system, and atrial natriuretic peptide to exercise in patients with essential hypertension
  588. Efficacy of nicardipine slow release (SR) on hypertension, potassium balance and plasma Aldosterone in idiopathic aldosteronism.
  589. … beta adrenergic blockade with orally administered labetalol in hypertension: Studies on blood volume, plasma renin and Aldosterone and catecholamine excretion
  590. Effects of the selective mineralocorticoid receptor antagonist, eplerenone, in a model of Aldosterone-induced hypertension and cardiac fibrosis
  591. Renin, angiotensin II, Aldosterone, catecholamines, prostaglandins and vasopressin. The importance of pressor and depressor factors for hypertension in pregnancy
  592. The characterization of low renin hypertension by plasma renin activity and plasma Aldosterone concentration
  593. Plasma Aldosterone Response to Angiotensin II in Sodium‐Restricted Elderly Subjects with Essential hypertension
  594. Left ventricular hypertrophy and remodelling of resistance arteries: the role of activation of the renin–angiotensin–Aldosterone system in hypertension
  595. Blood volume and Aldosterone secretion in hypertension and primary aldosteronism.
  596. Solitary kidney and ageing as causes of low renin and Aldosterone concentrations: relevance to ‘low-renin’essential hypertension
  597. Effect of indapamide on the renin‐Aldosterone system, and urinary excretion of potassium and calcium in essential hypertension.
  598. Renin-Aldosterone system suppression during water immersion in renovascular hypertension.
  599. Relationships between sodium clearance, plasma renin activity, plasma Aldosterone, renal hemodynamics and blood pressure in essential hypertension
  600. An association between mineral metabolism and the renin-Aldosterone system in human hypertension.
  601. Dexamethasone-responsive hypertension in young women with suppressed renin and Aldosterone
  602. Abnormal vasopressin and Aldosterone response to furosemide in essential hypertension
  603. Effects of intravenous labetalol on blood pressure, angiotensin II and Aldosterone in hypertension: comparison with propranolol
  604. Circadian rhythm of renin and Aldosterone in unilateral renovascular hypertension: pre-and post-operative studies
  605. … between plasma Aldosterone and angiotensin II before and after noradrenergic inhibition in normal subjects and patients with mild essential hypertension
  606. Factors for postoperative persistent hypertension in patients with Aldosterone-producing adenoma
  607. Effects of experimental renal hypertension on Aldosterone biosynthesis by rat adrenal tissue
  608. Biochemical correction in the syndrome of hypertension and hyperkalaemia by severe dietary salt restriction suggests renin‐Aldosterone suppression critical in …
  609. Abnormal norepinephrine and Aldosterone responses to upright posture in nonmodulating hypertension
  610. … plasma renin activity and plasma Aldosterone concentration to long-term administration of captopril in patients with severe, treatment-resistant malignant hypertension
  611. Aldosterone-Induced hypertension: Effects of a Kininase Inhibitor
  612. Mechanism of inhibition of Aldosterone secretion by a Ca2+ channel blocker in patients with essential hypertension and patients with primary aldosteronism
  613. hypertension and mineralocorticoids. Usefulness of renin and Aldosterone measurements
  614. Hypotensive and natriuretic effects of nifedipine in essential hypertension. Role of renal kallikrein-kinin-prostaglandin and renin-angiotensin-Aldosterone systems.
  615. Captopril, Aldosterone and urinary kallikrein in primary hypertension
  616. Age-and sex-related differences in plasma Aldosterone in essential hypertension. Relationship to plasma renin activity
  617. The Renin-Angiotensin-Aldosterone System in hypertension.
  618. STRUCTURE‐FUNCTION RELATIONSHIPS OF Aldosterone SYNTHASE AND 11β‐HYDROXYLASE ENZYMES: IMPLICATIONS FOR HUMAN hypertension
  619. Effect of enalapril on renin, angiotensin converting enzyme activity, Aldosterone and prostaglandins in patients with hypertension.
  620. Aldosterone antagonism and hypertension
  621. The substitutive role of ACTH in supporting Aldosterone response to head-up tilt during acute renin suppression in patients with essential hypertension.
  622. Effect of a new mineralocorticoid antagonist mespirenone on Aldosterone-induced hypertension
  623. Functional aspects of the renin–angiotensin–Aldosterone system and angiotensin II receptor AT1 blockers in arterial hypertension
  624. Essential arterial hypertension: plasma and urinary Aldosterone alterations.
  625. Aldosterone responsiveness to angiotensin II after sodium restriction in subjects with low renin essential hypertension
  626. Renin-angiotension-Aldosterone system, urinary prostaglandins and kallikrein in pregnancy-induced hypertension: evidence for a dysregulation of the renin …
  627. Effects of felodipine on natriuresis, atrial natriuretic factor, the renin-angiotensin-Aldosterone system, and blood pressure in essential hypertension.
  628. Aldosterone response to prolonged ACTH infusion in juvenile hypertension
  629. Adrenal Cortex, Aldosterone, and hypertension: Report of an International Workshop
  630. The role of Aldosterone in the response to treatment of primary hypertension
  631. Metabolism of Aldosterone in dogs with renovascular hypertension
  632. Renin-angiotensin-Aldosterone system in arterial hypertension.
  633. Effect of propranolol therapy on Aldosterone responses to angiotensin II and adrenocorticotropic hormone in essential hypertension
  634. Renin-angiotensin and Aldosterone in Experimental hypertension
  635. Effects of the Calcium Antagonist Felodipine on the Sympathetic and Renin‐Angiotensin‐Aldosterone Systems in Essential hypertension
  636. Primary aldosteronism due to Aldosterone producing adenoma without hypertension
  637. The Acute and Chronic Effects of Betaxolol on Blood Pressure, Renin‐Aldosterone, and Renal Function in Essential hypertension
  638. Renin-hyporesponsiveness in essential hypertension dissociation between plasma renin and catecholamines or Aldosterone following furosemide
  639. Effects of nisoldipine on sympathetic activity, the renin-angiotensin-Aldosterone system, and water-sodium-calcium metabolism in patients with essential hypertension.
  640. Effect of angiotensin converting-enzyme inhibition on potassium-mediated Aldosterone secretion in essential hypertension
  641. … haemodynamics and the renin-angiotensin-Aldosterone system in normotensive subjects with a familial predisposition to hypertension: changes during increased salt …
  642. CAPTOPRIL IN PRIMARY hypertension: Effects related to the renin‐angiotensin‐Aldosterone and kallikrein‐kinin systems.
  643. … reduces Aldosterone and 18-hydroxycorticosterone response to angiotensin II in patients with essential low-renin hypertension and idiopathic hyperaldosteronism
  644. Perinephritis hypertension in Macaca fascicularis (cynomolgus monkey): studies of the renin-angiotensin-Aldosterone axis and renal hemodynamic function.
  645. … -angiotensin-Aldosterone, and cardiovascular response during exercise following acute and long-term calcium antagonism with felodipine in essential hypertension.
  646. Urinary excretion of renal prostaglandins, kallikrein, vasopressin and Aldosterone in essential hypertension
  647. Severe hypertension in a ten-year-old boy secondary to an Aldosterone-producing tumour identified by adrenal sonography.
  648. Aldosterone: clinical implications in essential hypertension
  649. Role of Aldosterone in the initial stage of two forms of experimental vasorenal hypertension
  650. The renin-angiotensin-Aldosterone system and arterial hypertension in patients with rheumatoid arthritis
  651. … for” Aldosterone” and” 18-hydroxycorticosterone” in unprocessed urine, and their use in screening to distinguish primary aldosteronism from hypertension.
  652. hypertension, angiotensin II, Aldosterone, and race
  653. Jejunal permeability to water and electrolytes in patients with chronic intrahepatic hypertension: evidence for a role of Aldosterone.
  654. Treatment of drug-resistant hypertension with minoxidil or angiotensin-converting enzyme inhibitor: blood pressure, renin, Aldosterone, and electrolyte responses.
  655. Aldosterone regulation in essential hypertension: altered adrenal responsiveness to angiotensin II.
  656. Aldosterone metabolism in the isolated perfused liver of R and S hypertension-prone Dahl rats
  657. The relationship of Aldosterone to mild essential hypertension.
  658. Effect of oral labetalol on plasma catecholamines, renin and Aldosterone in patients with severe arterial hypertension
  659. Urinary sodium and Aldosterone excretion following portocaval shunts for cirrhosis of liver and portal hypertension: effect of end-to-side and side-to-side anastomoses …
  660. Three cases of malignant hypertension: the roles of endothelin-1 and the renin-angiotensin-Aldosterone system.
  661. Dopaminergic regulation of Aldosterone secretion: assessment in different subtypes of primary aldosteronism and in essential hypertension
  662. Aldosterone and hypertension
  663. Acute effects of prizidilol on blood pressure, heart rate, catecholamines, renin and Aldosterone in essential hypertension
  664. Responsiveness of the renin‐Aldosterone system during exercise in young patients with essential hypertension
  665. A simple method for definition of incomplete suppression of Aldosterone and its association with hypertension and hypokalaemia in man
  666. Remikiren (Ro 42-5892)—An orally active renin inhibitor in essential hypertension Effects on blood pressure and the renin-angiotensin-Aldosterone system
  667. hypertension, oedema, and suppressed renin Aldosterone system due to unsupervised salt administration.
  668. Low-Renin Essential hypertension: Diminution of Aldosterone Suppression?
  669. Angiotensin II in primary hypertension, relationship to plasma renin activity, Aldosterone and urinary electrolytes
  670. Effect of coffee on blood pressure and activity renin-angiotensin-Aldosterone system and catecholamines concentration in patients with essential hypertension
  671. Effect of one year of thiazide therapy on plasma volume, renin, Aldosterone, lipids and urinary metanephrines in systolic hypertension of elderly patients
  672. Renal hypertension with Elevated Aldosterone: Case Due to Muscular Hypertrophy Cured by Nephrectomy with Decline of Aldosterone Levels to Normal
  673. Aldosterone: possible roles in sustaining essential hypertension and in determining response to antihypertensive treatment
  674. … ON BLOOD PRESSURE, RENAL FUNCTION, PLASMA RENIN ACTIVITY, AND PLASMA Aldosterone IN MILD‐TO‐MODERATE ESSENTIAL hypertension
  675. Captopril in the long-term treatment of essential hypertension: changes in the renin-angiotensin-Aldosterone system
  676. Humoral mechanisms in the pathogenesis of arterial hypertension with emphasis on the renin-angiotensin-Aldosterone system and natriuretic substances
  677. Does industrial environment influence the prevalence of arterial hypertension, plasma cholesterol and uric acid concentration and activity of the renin-Aldosterone …
  678. Abnormalities in the renin–angiotensin–Aldosterone system in normotensive subjects with a positive family history of hypertension
  679. Verapamil sustained-release in renal parenchymal hypertension: effect on blood pressure, kidney function, angiotensin II, Aldosterone, arginine vasopressin, atrial …
  680. On the Role of Aldosterone to hypertension; Especially an Extent of Its Participation
  681. … effects of angiotensin II infusion and variations in salt intake on plasma Aldosterone levels in normal subjects, patients with essential hypertension and patients with …
  682. Role of renin-angiotensin-Aldosterone system and of sympathetic activity in arterial hypertension associated with autosomal dominant polycystic kidney disease
  683. … of low-renin hypertension: Aldosterone response to sodium restriction and upright posture, angiotensin II, ACTH and potassium in patients with hypertension
  684. … pressure, Aldosterone and body fluids during enalapril treatment: a double‐blind randomized study vs hydrochlorothiazide plus propranolol in essential hypertension
  685. An Apraisal of the Role of Aldosterone and the Sympathetic Nervous System in Essential hypertension
  686. Effect of chronic beta-adrenergic blockade on blood pressure and release of renin, Aldosterone and cortisol in essential hypertension (author’s transl)
  687. Relationship between Plasma Renin-Angiotensin-Aldosterone and ANF Levels in Primary hypertension
  688. Morphological signs of hyperactivity of the renin-Aldosterone system in cadmium-induced experimental hypertension.
  689. Interrelations between plasma renin activity, Aldosterone, and sympathetic nervous system activity in essential hypertension.
  690. PLASMA RENIN ACTIVITY AND Aldosterone SECRETION RATE IN hypertension: The Distinction between Primary and Secondary Hyperaldosteronism
  691. hypertension due to a giant Aldosterone-secreting adenoma
  692. … –Aldosterone system in essential arterial hypertension in clinical practice. Activity of the renin-angiotensin-Aldosterone system during treatment of hypertension with …
  693. Aldosterone excess and essential hypertension
  694. The influence of a heparin-like compound on hypertension, electrolytes and Aldosterone in man.
  695. Relationship between vasopressin and the renin-angiotensin-Aldosterone system in essential hypertension: effect of converting enzyme inhibitor on plasma …
  696. Correlation between propranolol in plasma and urine, renin-Aldosterone system and blood pressure in essential hypertension
  697. … Effects of Dopamine on the Renin-Angiotensin-Aldosterone System in Conscious Rats: THE 10th CONFERENCE ON THE PATHOGENESIS OF hypertension
  698. Enhanced response of plasma Aldosterone to metoclopramide in essential hypertension.
  699. … 52: Comparison of selective Aldosterone blockade versus calcium antagonism on blood pressure, vascular compliance, and microalbuminuria in systolic hypertension …
  700. Effects of celiprolol on plasma renin, Aldosterone, norepinephrine and epinephrine in primary hypertension
  701. Inhibitory effect of enalapril on serum Aldosterone in essential hypertension
  702. Effects of Aldosterone on intralymphocytic sodium and potassium in patients with essential hypertension
  703. … metabolism, plasma renin activity and serum Aldosterone: a double-blind pilot comparison against hydrochlorothiazide in patients with essential hypertension.
  704. Relation between somatostatin, atrial natriuretic peptide, beta-endorphin, Aldosterone and pregnancy induced hypertension
  705. Renin/angiotensin/Aldosterone system in malignant hypertension
  706. Effects of corticotropin-releasing factor (CRF) on Aldosterone and 18-hydroxycorticosterone in essential hypertension and primary aldosteronism
  707. The renin-angiotensin-Aldosterone system in primary and secondary hypertension
  708. Molecular genetics of the renin-angiotensin-Aldosterone system in human hypertension
  709. Aldosterone, sodium and potassium in essential hypertension
  710. The state of the renin-angiotensin-Aldosterone system in various clinical forms of hypertension in aging
  711. Aldosterone-binding globulin-induced hypertension in the rat. A new experimental model.
  712. Hypotensive effect of intensifying Aldosterone metabolism in dogs with vasorenal hypertension
  713. The renin-angiotensin system and Aldosterone in hypertension: a brief review of some aspects.
  714. Plasma human atrial natriuretic peptide, endothelin-1, Aldosterone and plasma-renin activity in pregnancy-induced hypertension
  715. Changes in renin activity, Aldosterone level and electrolytes in pregnancy-induced hypertension.
  716. Daily profiles of Aldosterone levels during normal, high and low sodium intake in patients with essential hypertension
  717. Renin-Angiotensin-Aldosterone System of a Woman with Bartter’s Syndrome: Juxtaglomerular Cell Hyperplasia without hypertension
  718. Plasma catecholamines, renin and Aldosterone during combined alpha-and beta-adrenoceptor blockade in patients with severe arterial hypertension.
  719. Circadian variation of Aldosterone urinary excretion in idiopathic hypertension.
  720. Effect of pressor agents on blood pressure, plasma renin activity and plasma Aldosterone concentration in essential hypertension
  721. Studies on Plasma Renin and Aldosterone in Essential hypertension
  722. Plasma concentration of Aldosterone, 18-hydroxy-deoxycorticosterone and cortisol in adrenal veins of patients with low-renin hypertension
  723. Reduced response of plasma Aldosterone to acute ACTH stimulation during long-term treatment with spironolactone in essential hypertension
  724. Physiopathology of arterial hypertension. Significance of the renin-angiotensin-Aldosterone system and structural changes
  725. … agonist cianergoline on blood pressure, the renin-angiotensin-Aldosterone axis and the sympathetic nervous system in patients with essential hypertension
  726. Hyperplastic changes and Aldosterone content in the adrenal cortex in essential hypertension and primary aldosteronism
  727. Molecular genetics of the renin angiotensin Aldosterone system in human hypertension
  728. Role of the renin-angiotensjon-Aldosterone system in the pathogenesis of arterial hypertension
  729. … traditional Chinese medicine differential types and plasma levels of renin, angiotension II, Aldosterone, atrial natriuretic factor in patients with essential hypertension
  730. … -relationship of sympathetic nervous system and renin-angiotensin-Aldosterone system in three renin subgroups of borderline and persistent essential hypertension
  731. Regulation of Aldosterone Secretion by a New Aldosterone Stimulating Factor: THE 11th CONFERENCE ON THE PATHOGENESIS OF hypertension
  732. Behavior of the renin-angiotensin-Aldosterone system and vasopressin secretion in patients with renovascular hypertension or small kidney
  733. Isolation of a polar Aldosterone-like substance from the urine and adrenal incubates of patients with arterial hypertension
  734. P-70: The selective Aldosterone blocker eplerenone is safe and efficacious for the long-term treatment of mild-to-moderate hypertension
  735. Renin-angiotensin-Aldosterone system in essential hypertension. Inappropriately high plasma Aldosterone in young patients with severe hypertension and in older …
  736. Significance of the renin-angiotensin-Aldosterone system for pathogenesis and early diagnosis of pregnancy-induced hypertension with special reference to …
  737. The Relationship between the Upright Serum Aldosterone Level and the Left Ventricular Geometry in Essentioal hypertension
  738. The changes of serum-ACE, plasma renin activity and Aldosterone in the diabetics with hypertension
  739. Association between Aldosterone synthase gene polymorphism and primary hypertension in Chinese Han population [J]
  740. Arterial hypertension in acromegaly: altered dopaminergic control of Aldosterone secretion
  741. Effect of captopril on renal haemodynamics and the renin-angiotensin-Aldosterone and osmoregulatory systems in essential hypertension
  742. Altered coupling between aortic adrenergic-receptors and inositol phosphate accumulation in Aldosterone hypertension
  743. Restructuring of the collagen network in hypertension: role of the angiotensin-Aldosterone system
  744. … factor in high-altitude pulmonary hypertension: the influence of acute hypoxia on plasma atrial natriuretic factor, renin, and Aldosterone concentrations in highlanders …
  745. The acute effect of nicardipine on the renin-angiotensin-Aldosterone system in salt-sensitive essential hypertension
  746. Chronobiological evidence for an uncoupling of the Na, K-ATPase to Aldosterone in normal renin hypertension
  747. Selected components of the kallikrein-kinin system and of the renin-angiotensin-Aldosterone system in offspring of parents with hypertension
  748. Renal kallikrein-kinin system and prostaglandin in hypertension: their relation to renin-angiotensin-Aldosterone system.
  749. Essential hypertension and Aldosterone
  750. Aldosterone metabolism after prolonged ACTH administration in juvenile hypertension
  751. Dissociated Renin–Aldosterone Response to Acute Sodium Depletion in Patients with a Previous History of Pregnancy–Associated hypertension
  752. The level of plasma renin and plasma Aldosterone activity in normotensive women and in pregnancy-induced arterial hypertension in a group of women from …
  753. Effect of penbutolol on circadian blood pressure, and renin, Aldosterone and cortisol levels in patients with essential hypertension.
  754. Blood pressure, catecholamines, renin and Aldosterone during short and long-term treatnent of essential hypertension with verapamil
  755. Role of renin-angiotensin-Aldosterone system in pathogenesis of arterial hypertension in chronic renal failure
  756. Human salivary or plasma Aldosterone-and dehydroepiandrosterone-binding glycoprotein induces hypertension in the rat.
  757. Beta-adrenergic regulation of circadian rhythmicity of the renin-angiotensin-Aldosterone system in five subtypes of essential hypertension.
  758. The Role of Aldosterone in Pathogenesis of Artenal hypertension
  759. 14C-Aldosterone binding by plasma proteins in adolescents with primary arterial hypertension
  760. Genetic aspects of plasma Aldosterone binding globulins in families of patients with essential hypertension, including isolation of novel thermostable homologues from …
  761. Considerations of the renin-angiotensin Aldosterone system in the pathogenesis of hypertension in infancy
  762. hypertension with defective Aldosterone stimulation by sodium restriction: a new syndrome
  763. Aldosterone Receptors and Effector Mechanisms in Mononuclear Leukocytes in Different Forms of hypertension
  764. New frontiers in Aldosterone/mineralocorticoid biology: A reemerging force in target organ damage and hypertension
  765. Vasopressin and renin-Aldosterone system in patients with arterial hypertension
  766. Effects of losartan on the renin-angiotensin-Aldosterone system and erythrocytosis in patients with chronic obstructive pulmonary disease and systemic hypertension
  767. Changes in reactivity of the renin-angiotensin-Aldosterone system in old age as a risk factor in the development of hypertension
  768. Role of Aldosterone in the pathogenesis of hypertension
  769. Aldosterone secretion rate and electrolyte balance studies on three patients with hypertension: Influence of guanethidine, hydralazine and methyclothiazide
  770. Post-renal-transplant hypertension Urine volume, free water clearance and plasma concentrations of arginine vasopressin, angiotensin II and Aldosterone before and …
  771. Plasma renin activity, Aldosterone and cortisol levels during physical exercise in essential hypertension.
  772. Polymorphism of Aldosterone synthase gene CYP11B2 in hypertension in China
  773. Effects of various doses of captopril on plasma Aldosterone concentrations in patients with essential hypertension
  774. The renin-angiotensin-Aldosterone system and serum lipoproteins in patients with essential hypertension
  775. Role of Aldosterone in potassium secretion in chronic renal failure associated with hypertension (transtubular potassium gradient)
  776. Effect of Ac-SDKP on Cardiac and Renal Collagen Deposition in Aldosterone-Salt hypertension
  777. Determination of plasma atrial natriuretic peptide, angiotensin II, Aldosterone and efficacy of benazepril in patients with salt sensitive essential hypertension
  778. Role of steroids in hypertension: evaluation of plasma mineralocorticoid activity with Aldosterone receptors
  779. hypertension following subcutaneous and intraperitoneal injections of polyvinyl alcohol and the effect of Aldosterone
  780. The renin-angiotensin-Aldosterone system in hypertension of hypothalamic origin
  781. … on blood pressure, weight, plasma volume, the renin-angiotensin-Aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension.
  782. Renin-angiotensin-Aldosterone system and pulmonary hemodynamics in patients with pulmonary artery hypertension
  783. Urinary excretion of Aldosterone in patients with hypertension
  784. Aldosterone, Angiotensin, and hypertension
  785. Mineralocorticoid receptor activation by Aldosterone or corticosterone induces hypertension, myocardial infarction and proteinuria
  786. Deviation of plasmatic Aldosterone and significance of the stimulating (ACTH-cortrosyn) and inhibitory (propranolol) effects in hypertension and cardiovascular …
  787. … pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and Aldosterone in patients with essential hypertension.
  788. Changes of the renin-angiotensin-Aldosterone system under contraceptive steroids. Contribution to the etiology of hypertension under hormonal contraceptives
  789. The renin-angiotensin-Aldosterone system and the adrenergic system in normal pregnancy and hypertension induced by pregnancy
  790. Correlation of atrial natriuretic factor and renin-Aldosterone system with chronic pulmonary hypertension among residents in a high altitude
  791. Differential Effects of Acute and Chronic β-Adrenoreceptor Blockade on Blood Pressure and the Renin—Angiotensin—Aldosterone System in Essential hypertension
  792. Changes in the renin-Aldosterone system after unilateral portalization of adrenal and renal blood in patients with arterial hypertension
  793. Plasma Aldosterone and plasma renin activity in patients with essential and renal hypertension under acute stimulation with saline depletion and acute suppression …
  794. Development of a mouse hypertension model induced by Aldosterone excess
  795. The renin-Aldosterone profile in hypertension
  796. … central and peripheral sympathetic nervous system and the renin-Aldosterone system on the onset and maintenance of high blood pressure in essential hypertension
  797. The Relationship of Aldosterone to Mild Essential hypertension
  798. … BETWEEN Aldosterone SECRETION, SODIUM AND POTASSIUM BALANCE, AND ANGIOTENSIN ACTIVITY IN MAN: STUDIES IN hypertension AND …
  799. The renin-angiotensin-Aldosterone system and antidiuretic hormone secretion during plasmapheresis in patients with high arterial hypertension refractory to drug …
  800. Essential hypertension and left ventricular hypertrophy in cardiovascular disease: beyond overactivity of the renin–angiotensin–Aldosterone–sodium system
  801. Plasma Aldosterone concentration and vascular reactivity in hypertension
  802. Role of Aldosterone and the Aldosterone binding globulin in experimental and spontaneous hypertension
  803. Strategy for studying mineralocorticoids other than Aldosterone in arterial hypertension of hormonal origin
  804. Concentration of adrenocorticotrophic hormone and Aldosterone secretion in essential hypertension and hyperaldosteronism
  805. Effects of 1-sar-8-ala-angiotensin II on arterial pressure, renin and Aldosterone in hypertension.
  806. … on plasma renin activity, plasma Aldosterone concentration, urinary prostaglandin E excretion and blood pressure in patients with essential hypertension
  807. … increase of mineralocorticoids after furosemide in low-renin essential hypertension: Evidence for 18-hydroxycorticosterone to be a better marker than Aldosterone
  808. Erythrocyte cation transport in arterial hypertension: interrelation with the renin-angiotensin-Aldosterone system and the atrial natriuretic factor
  809. Role of Aldosterone in the initial stage of 2 forms of experimental vasorenal hypertension
  810. The kallikrein-kinin system in primary hypertension: dynamics of circulating components of the kallikrein-kinin system in relation to the renin-angiotensin-Aldosterone …
  811. Studies on kallikrein-kinin system in essential hypertension: urinary kallikrein-kinin system and renin-angiotensin-Aldosterone system (author’s transl)
  812. Kallikrein-kinin, enkephalin, renin-Aldosterone and catecholamine systems in the vanadate (as vanadyl)-induced arterial hypertension.
  813. The Relationship between the Upright Serum Aldosterone Level and the Left Ventricular Geometry in Essentioal hypertension.
  814. Plasma Renin and Aldosterone Profiles in Essential hypertension.
  815. … in peripheral venous distensibility and blood pressure modifications in borderline hypertension: evidence against a primary role for the renin-angiotensin-Aldosterone …
  816. Radioimmunologic determination of Aldosterone and renin in the blood in the diagnosis of different forms of arterial hypertension
  817. VI. RENIN, Aldosterone, AND hypertension: The Hepatic Metabolism of Renin and Aldosterone
  818. … renin-angiotensin-Aldosterone system and kinin system in hypertensive and normotensive youngsters with or without a family history of essential arterial hypertension
  819. Renin angiotensin Aldosterone system, urinary prostaglandins and kallikrein in pregnancy induced hypertension. Evidence for a disregulation of the renin-angiotensin …
  820. Negative noxiousness of Aldosterone analogue-induced hypertension and inhibition of Aldosterone by silver spike point electrical stimulation
  821. Effects of acebutolol on the renin-Aldosterone system in essential arterial hypertension
  822. Human Essential hypertension: Role of the Genes of the Renin-Aldosterone System
  823. The development and maintenance of experimental Aldosterone hypertension in the rat: evidence for a mechanism other than peripheral vascular …
  824. Radioimmunologic analysis of the state of the renin-angiotensin-Aldosterone-system in arterial hypertension
  825. Radioimmunologic analysis of the state of the renin-angiotensin-Aldosterone system in arterial hypertension
  826. Role of Aldosterone in essential arterial hypertension complicated by chronic renal insufficiency
  827. Factors for postoperative persistent hypertension in patients with Aldosterone producing adenoma
  828. hypertension: the role of renin, angiotensin and Aldosterone
  829. Plasma renin activity and Aldosterone in patients with essential hypertension
  830. Aldosterone reduces baroreceptor discharge in the dog. hypertension
  831. Aldosterone response to modulation of potassium in patients on dialysis or with essential hypertension.
  832. Rectal electrical potential difference and plasma Aldosterone in hyperaldosteronism and low-, normal-and high-renin hypertension
  833. Plasma renin activity and plasma Aldosterone in essential hypertension: effect of age and diastolic blood pressure
  834. Adrenal cancer with hypertension but low plasma renin and Aldosterone.
  835. Relationship between plasma Aldosterone and left ventricular structure and function in patients with essential hypertension
  836. Changes of Atrial Natriuretic Peptide and Aldosterone in Pregnancy-induced hypertension and Normal Pregnancy
  837. hypertension and the Renin-Angiotensin-Aldosterone Axis
  838. Saralasin-induced changes of blood pressure, renin and Aldosterone in essential and renal hypertension (author’s transl)
  839. Plasma renin activity, Aldosterone and adrenergic activity in patients with hypertension and in normotensives with a family history of hypertension
  840. Possible Implication of the Renin-Angiotensin-Aldosterone System in the hypertension of Phaeochromocytoma
  841. Hypotensive effect of intensification of Aldosterone metabolism in dogs with vasorenal hypertension
  842. Aldosterone Receptor Antagonism Normalizes Vascular Function in 11β-Hydroxysteroid Dehydrogenase Deficient hypertension
  843. The Renin-Angiotensin-Aldosterone System in hypertension its Biochemistry and Applications
  844. Plasma mineralocorticoids–Aldosterone and desoxycorticosterone–in patients with” low-renin” arterial hypertension
  845. Renin-angiotensin-Aldosterone system in hypertension patients who have had a cerebral stroke
  846. Changes in the renin-angiotensin-Aldosterone system in the development of hypertension in aging. 2
  847. Effects of Aldosterone antagonism on cardiac fibrosis in patients with essential hypertension
  848. Preliminary study on relationship between renin-angiotensin-Aldosterone system and hypertension in coal miners
  849. … de Recherche et d’Etudes sur les Genomes (GREG). Genetic determination of plasma Aldosterone levels in essential hypertension-comparison between urban and …
  850. P-489: Plasma renin activity and Aldosterone level in patients with essential hypertension
  851. Relations between blood insulin concentration, renin-angiotensin-Aldosterone system and clinical picture of hypertension
  852. Changes of the renin-angiotensin-Aldosterone system and immunologic parameters in essential and symptomatic arterial hypertension
  853. Alcohol and hypertension in sudden cardiac death, features of the status of the renin-angiotensin-Aldosterone system
  854. Renin-Aldosterone system in secretion of cortisol in patients with arterial hypertension in European North
  855. Low Renin hypertension: A State of Inappropriate Secretion of Aldosterone.
  856. The value of stimulation of the renin-angiotensin-Aldosterone system as a screening test for hypertension (author’s transl)
  857. A study on the serum angiotensin I angiotensin II atrial natriureticfactor and Aldosterone levels in essential hypertension
  858. Body fluid compartments, hypertension and the renin-angio-tensin-Aldosterone system (RAAS) in hemodialysed patients
  859. The effect of long-term treatment of arterial hypertension with Ca antagonists on the renin-angiotensin-Aldosterone system in diabetics. Hyporeninemic …
  860. VI. RENIN, Aldosterone, AND hypertension: Pseudo-primary Aldosteronism
  861. Effect of obzidan on hemodynamic indices and the renin and Aldosterone levels of the blood plasma in patients with juvenile hypertension
  862. Low renin variant of hypertension: functional relations of the renin-Aldosterone pressor system
  863. Aldosterone precursors and arterial hypertension with adrenal nodules not caused by aldosteronism
  864. Is there a relation between the renin-angiotensin-Aldosterone system and vasopressin secretion in essential hypertension?
  865. Levels of catecholamines and activity of the renin-Aldosterone system in women with hypertension in the period before and after menopause
  866. Essential’hypertension with hypokalemia: Caused by Aldosterone-secreting adrenal adenoma
  867. … –Aldosterone system in essential hypertension–hypotensive action of beta adrenergic blocking agents and variation of the renin-Aldosterone system (author’s transl)
  868. EVALUATION OF PRESSOR ASSAY, PLASMA RENIN ACTIVITY, AND Aldosterone EXCRETION IN RENAL VASCULAR hypertension.
  869. Behavior of the plasma renin activity and Aldosterone after salt restriction and upright posture in essential hypertension
  870. The renin-angiotensin-Aldosterone system in children and adolescents with nephrogenic hypertension
  871. Dopaminergic control of Aldosterone secretion is not mediated by atrial natriuretic factor in patients with essential hypertension.
  872. Observation of the Plasma Renin-Angiotensin-Aldosterone System and Prostaglandin System in Essential hypertension
  873. The renin-angiotensin-Aldosterone system in the diagnosis of renovascular arterial hypertension
  874. Clinical significance of renin-angiotensin-Aldosterone system, endothelin and nitric oxide in renal hypertension and adrenocorticoadenomas
  875. Basal and reactive renin and Aldosterone secretion in arterial hypertension of insulin dependent diabetics
  876. Continuous long-term treatment with diuretics of hypertension and the status of the renin-angiotensin-Aldosterone system
  877. Measurement and Significance of Calcitonin Gene-related Peptide. Neuropeptide Y and Aldosterone in Portal hypertension
  878. The correlation of atrial natriuretic peptide values with those of renin, angiotensin and Aldosterone in hypertension patients below and above 50
  879. Diazoxide test in the diagnosis of arterial hypertension: modifications in the levels of renin and Aldosterone in blood of patients with various restrains of the renal …
  880. The effects of capoten and nifedipine on plasma endothelin, renin activity, an-giotensin and Aldosterone in patients with essential hypertension
  881. Effect of inhibition of converting enzyme by captopril on arterial pressure, renin and Aldosterone in essential hypertension
  882. 163 ROLE OF THE RENIN-Aldosterone SYSTEM IN hypertension COARCTATION OF THE AORTA
  883. … cardiopulmonary hematic centralization (by immersion in water) on hydrosaline elimination and on the renin-angiotensin-Aldosterone system in essential hypertension
  884. Atrial natriuretic peptide inhibits the Aldosterone response to metoclopramide in patients with glomerular disease and essential hypertension
  885. The renin-angiotensin-Aldosterone system in hypertensive subjects. III-The use of beta-blockers in reno-vascular hypertension (author’s transl)
  886. Relation of myocardial fibrosis to circulating Aldosterone and endothelin in primary and secondary human hypertension: an ultrasonic study by acoustic densitometry
  887. A study of urinary and intracellular sodium and potassium, renin, Aldosterone and hypertension in Africans and Indians in Natal.
  888. Effect of nifedipine treatment on the renin-Aldosterone system and secretion of cortisol and growth hormone in patients with essential hypertension
  889. Plasma renin activity and Aldosterone excretion in patients with essential hypertension, with hypertension in bilateral adrenal cortex hyperplasia and with Aldosterone …
  890. Renin-angiotensin-Aldosterone system in the treatment of essential hypertension with a beta-adrenergic blocker: sotalol
  891. Acute combined alpha-and beta-adrenergic blockade in essential hypertension: effects on blood pressure, renal function, renin, and Aldosterone
  892. Adenovirus-mediated Human Prostasin Gene Delivery is Associated with Increased Aldosterone Production and hypertension in Rats
  893. The role of the kallikrein-kinin and renin-angiotensin-Aldosterone systems in the development of hypertension in glomerulonephritis
  894. Renin, Angiotensin and Aldosterone in Relation to Electrolyte Metabolism [Abridged] hypertension and Hyperaldosteronism with Low Plasma Renin …
  895. Inhibition of the renin-angiotensin-Aldosterone axis by low dose intravenous captopril as a treatment for accelerated phase hypertension.
  896. Blood level of free serotonin, catecholamines and the renin-angiotensin-Aldosterone system in patients with primary hypertension
  897. Behavior of Aldosterone and plasma renin activity after ACTH administration and insulin-induced hypoglycemia in patients with essential arterial hypertension
  898. Renin-Angiotensin-Aldosterone System and Adrenergic System in hypertension Induced by Pregnancy: Critical Role of the Stimulative Conditions and of the Lability …
  899. … -release nicardipine on blood pressure, renal function and the renin-angiotensin-Aldosterone system in patients with mild-to-moderate essential arterial hypertension
  900. Renin-Aldosterone and kallikrein-kinin systems in the patients with arterial hypertension who took part in elimination of aftereffects of the accident at Chernobyl Atomic …
  901. Atrial natriuretic peptide, left ventricular mass and renin-angiotensin-Aldosterone system in essential arterial hypertension of a mild or moderate degree
  902. … between atrial natriuretic factor and the renin-angiotensin-Aldosterone system in the renal reaction to acute volume loading in patients with essential hypertension
  903. Effects of pharmacological modulation of the renin-angiotensin-Aldosterone system on salt sensitivity in patients with borderline hypertension
  904. … of gene polymorphism of Aldosterone synthese gene CYP11B2 (-344T/C) on antihypertensive response to Valsartan in Han nationality essential hypertension …
  905. … –Aldosterone system, blood volume, serum uric acid and urinary excretion of prostaglandins and kallikrein in the arterial hypertension induced by pregnancy
  906. … /hypertension/Congestive Heart Failure: Angiotensin-Converting Enzyme Gene Polymorphism Has No Influence on the Circulating Renin-Angiotensin-Aldosterone …
  907. OR-78: White coat hypertension, microalbuminuria and renin-angiotensin-Aldosterone system gene variants in adolescents
  908. … , serum levels of sodium, potassium, Aldosterone, total catecholamines, 6-keto-PGF2alpha and plasma renin activity in patients with primary arterial hypertension …
  909. … to 9: 00 AM Aldosterone-A Common Link in Cardiac and Vascular Disorders*: Ability to selectively interfere with the effects of Aldosterone in patients with hypertension …
  910. … –Aldosterone system, sympathetic-adrenal system and the level of the 6-keto-PGF1 alpha metabolite of prostacyclin in patients with primary arterial hypertension
  911. … action by decreasing the production of angiotensin II and Aldosterone, are being extensively prescribed for the treatment of hypertension and congestive heart …
  912. P-243: Assessment of the novel selective Aldosterone blocker eplerenone using ambulatory and clinic BP in 400 patients with systemic hypertension: results from a …
  913. Case 39-1972: hypertension, Hypokalemia and Elevated Urinary Aldosterone Level
  914. (Supplementary) 19-Hydroxyandrostenedione, A New Amplifier of the Action of Aldosterone, in Low Renin Essential hypertension
  915. P-669: Screening for primary Aldosterone in older patients with hypertension
  916. P-392: Ultrasound tissue characterization in patients with primary and secondary hypertension: influence of the renin-angiotensin-Aldosterone system
  917. P-525: An interaction of insulin and renin-Aldosterone system responsible for left ventricular hypertrophy in patients with essential hypertension
  918. 736 Vascular hypertrophy and the renin-angiotensin-Aldosterone system in the initiation of hypertension caused by inhibition of nitric oxide synthesis
  919. 4. On the Role of Renin-Angiotensin System with Special Relation to Aldosterone for the Etiology of hypertension
  920. … of 5-month guanfacine treatment on the renin-angiotensin-Aldosterone system and some metabolic factors in patients with diabetes mellitus type II and hypertension
  921. P-387: Twenty-four hour pulse pressure, left ventricular mass, risk factors and Aldosterone in untreated essential hypertension
  922. Effect of a Single Dose of Ramipril (HOE 498) on the Renin Angiotensin-Aldosterone System in Essential Arterial hypertension
  923. 10 Dopaminergic Control of Aldosterone in Essential hypertension
  924. … OF NIFEDIPINE ON PLASMA RENIN ACTIVITY, PLASMA Aldosterone & CORTISOL CONCENTRATIONS IN PATIENTS WITH ESSENTIAL hypertension
  925. K+ channel mutations in adrenal Aldosterone-producing adenomas and hereditary hypertension
  926. Predictors of hyperkalemia risk following hypertension control with Aldosterone blockade
  927. Aldosterone in salt-sensitive hypertension and metabolic syndrome
  928. hypertension in blacks: individualized therapy based on renin/Aldosterone phenotyping
  929. Dysregulated renin–angiotensin–Aldosterone system contributes to pulmonary arterial hypertension
  930. Resistant hypertension and Aldosterone: an update
  931. Pathogenesis of hypertension: interactions among sodium, potassium, and Aldosterone
  932. The renin angiotensin Aldosterone system in hypertension: roles of insulin resistance and oxidative stress
  933. Aldosterone synthase inhibitors in hypertension: current status and future possibilities
  934. Sleep apnea, Aldosterone, and resistant hypertension
  935. Association of kidney function with residual hypertension after treatment of Aldosterone-producing adenoma
  936. Effects of a novel Aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo-and active-controlled phase 2 …
  937. Aldosterone, hypertension, and beyond
  938. The central role of the brain Aldosterone–“ouabain” pathway in salt-sensitive hypertension
  939. The effects of Aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies
  940. High prevalence of autonomous Aldosterone secretion among patients with essential hypertension
  941. Effectiveness of the selective Aldosterone blocker, eplerenone, in patients with resistant hypertension
  942. Therapeutic perspectives in hypertension: novel means for renin–angiotensin–Aldosterone system modulation and emerging device-based approaches
  943. … -angiotensin-Aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension
  944. hypertension, renin–angiotensin–Aldosterone system inhibition, and COVID-19
  945. Actions of circulating angiotensin II and Aldosterone in the brain contributing to hypertension
  946. Sex differences in angiotensin II-and Aldosterone-induced hypertension: the central protective effects of estrogen
  947. Role of brain Aldosterone and mineralocorticoid receptors in Aldosterone-salt hypertension in rats
  948. Stress-induced Aldosterone hyper-secretion in a substantial subset of patients with essential hypertension
  949. Recent update of renin-angiotensin-Aldosterone system in the pathogenesis of hypertension
  950. Aldosterone synthesis in the brain contributes to Dahl salt‐sensitive rat hypertension
  951. Aldosterone mediates cardiac fibrosis in the setting of hypertension
  952. Leptin induces hypertension and endothelial dysfunction via Aldosterone-dependent mechanisms in obese female mice
  953. The role of the renin-angiotensin-Aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series)
  954. Aldosterone, hypertension and heart failure: insights from clinical trials
  955. Plasma Aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study
  956. Use of Aldosterone antagonists for treatment of uncontrolled resistant hypertension
  957. … enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–Aldosterone system inhibitors involving 158 998 …
  958. Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseases
  959. Study of Aldosterone synthase inhibition as an add‐on therapy in resistant hypertension
  960. Aldosterone induces electrical remodeling independent of hypertension
  961. Spironolactone, eplerenone and the new Aldosterone blockers in endocrine and primary hypertension
  962. hypertension and renin-angiotensin-Aldosterone system inhibitors in patients with Covid-19
  963. Hypoadiponectinemia and Aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension
  964. The renin-angiotensin-Aldosterone system: a crossroad from arterial hypertension to heart failure
  965. Renal volume, renin-angiotensin-Aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease
  966. Long-term effects of Aldosterone blockade in resistant hypertension associated with chronic kidney disease
  967. Aldosterone acting through the central nervous system sensitizes angiotensin II-induced hypertension
  968. Relation of dietary salt and Aldosterone to urinary protein excretion in subjects with resistant hypertension
  969. Association of the− 344C/T Aldosterone synthase (CYP11B2) gene variant with hypertension and stroke
  970. Renoprotective effect of renin-angiotensin-Aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia
  971. Role of Aldosterone blockade in resistant hypertension
  972. Lessons from Africa: the importance of measuring plasma renin and Aldosterone in resistant hypertension
  973. The Effects of Aldosterone Synthase Inhibition on Aldosterone and Cortisol in Patients With hypertension: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled …
  974. A randomized controlled study of CPAP effect on plasma Aldosterone concentration in patients with resistant hypertension and obstructive sleep apnea
  975. Aldosterone contributes to sympathoexcitation in renovascular hypertension
  976. Salt, Aldosterone and hypertension
  977. hypertension and Aldosterone levels in women with early‐onset androgenetic alopecia
  978. Aldosterone excess or escape: Treating resistant hypertension
  979. Prospective validation of an automated chemiluminescence-based assay of renin and Aldosterone for the work-up of arterial hypertension
  980. Masked Uncontrolled hypertension Is Accompanied by Increased Out-of-Clinic Aldosterone Secretion
  981. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin–angiotensin–Aldosterone system
  982. High plasma Aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension
  983. Effect of Aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis
  984. hypertension in women: the role of progesterone and Aldosterone
  985. Aldosterone, hypertension, and antihypertensive therapy: insights from a general population
  986. Renin angiotensin Aldosterone system inhibitors in hypertension: is there evidence for benefit independent of blood pressure reduction?
  987. The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin–angiotensin–Aldosterone system …
  988. The renin–angiotensin–Aldosterone system in 2011: role in hypertension and chronic kidney disease
  989. Association of Aldosterone excess and apnea-hypopnea index in patients with resistant hypertension
  990. … the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension
  991. Effect of melatonin on the renin-angiotensin-Aldosterone system in L-NAME-induced hypertension
  992. Suppression of Aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension
  993. Sex differences and central protective effect of 17β-estradiol in the development of Aldosterone/NaCl-induced hypertension
  994. Effects of ARB or ACE-inhibitor administration on plasma levels of Aldosterone and adiponectin in hypertension
  995. Renin‐angiotensin‐Aldosterone system activity in hyperthyroid cats with and without concurrent hypertension
  996. Lack of suppression of Aldosterone production leads to salt-sensitive hypertension in female but not male balb/C mice
  997. Association between polymorphisms in the renin-angiotensin-Aldosterone system genes and essential hypertension in the Han Chinese population
  998. High plasma Aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations
  999. Renin-angiotensin-Aldosterone profiles in pregnant women with chronic hypertension
  1000. Aldosterone-induced hypertension is sex-dependent, mediated by T cells and sensitive to GPER activation
  1001. Haplotype-based association of the renin-angiotensin-Aldosterone system genes polymorphisms with essential hypertension among Han Chinese: the Fangshan …
  1002. Are genetic polymorphisms in the renin–angiotensin–Aldosterone system associated with essential hypertension? Evidence from genome-wide association studies
  1003. Statins, the renin–angiotensin–Aldosterone system and hypertension–a tale of another beneficial effect of statins
  1004. Role of central nervous system Aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats
  1005. Association between pituitary-adrenal axis dominance over the renin-angiotensin-Aldosterone system and hypertension
  1006. Salt, the renin–angiotensin–Aldosterone system and resistant hypertension
  1007. Aldosterone sensitivity: an opportunity for investigation into the pathogenesis of hypertension
  1008. Aldosterone synthase inhibition in hypertension
  1009. … dissection of sodium and potassium transport along the Aldosterone-sensitive distal nephron: importance in the control of blood pressure and hypertension
  1010. Atrial fibrillation and arterial hypertension: a common duet with dangerous consequences where the renin angiotensin-Aldosterone system plays an important role
  1011. The role of Aldosterone in mediating the dependence of angiotensin hypertension on IL-6
  1012. Renin–angiotensin–Aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and …
  1013. Primary aldosteronism and Aldosterone-associated hypertension
  1014. Activation of renin–angiotensin–Aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats
  1015. Aldosterone-related myocardial extracellular matrix expansion in hypertension in humans: a proof-of-concept study by cardiac magnetic resonance
  1016. Aldosterone in gynecology and its involvement on the risk of hypertension in pregnancy
  1017. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy
  1018. … in the renin-angiotensin-Aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure
  1019. Association between Aldosterone synthase CYP11B2 polymorphism and essential hypertension in Chinese: a meta-analysis
  1020. Polymorphisms in genes of the renin‐angiotensin‐Aldosterone system and renal cell cancer risk: Interplay with hypertension and intakes of sodium, potassium and …
  1021. Programming of hypertension: associations of plasma Aldosterone in adult men and women with birthweight, cortisol, and blood pressure
  1022. Adrenal tissue-specific deletion of TASK channels causes Aldosterone-driven angiotensin II–independent hypertension
  1023. Renin and Aldosterone measurements in the management of arterial hypertension
  1024. Interpreting stimulated plasma renin and Aldosterone to select physiologically individualized therapy for resistant hypertension: importance of the class of stimulating …
  1025. Effect of ivabradine on a hypertensive heart and the renin-angiotensin-Aldosterone system in L-NAME-induced hypertension
  1026. Role of brain corticosterone and Aldosterone in central angiotensin II–induced hypertension
  1027. hypertension, insulin resistance, and Aldosterone: sex‐specific relationships
  1028. … continuous positive airway pressure treatment on Aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled …
  1029. Association of Aldosterone synthase CYP11B2 (-344C/T) gene polymorphism with essential hypertension and left ventricular hypertrophy in the Egyptian population
  1030. The efficacy and safety of the novel Aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study
  1031. Plasma Aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: tissue-Doppler imaging study
  1032. The kidneys and Aldosterone/mineralocorticoid receptor system in salt-sensitive hypertension
  1033. Association of Aldosterone synthase (CYP11B2 C-344T) gene polymorphism & susceptibility to essential hypertension in a south Indian Tamil population
  1034. Renal denervation attenuates Aldosterone expression and associated cardiovascular pathophysiology in angiotensin II-induced hypertension
  1035. Bimodal Aldosterone distribution in low-renin hypertension
  1036. KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of Aldosterone-producing adenoma
  1037. … receptor-β in the paraventricular nucleus and rostroventrolateral medulla plays an essential protective role in Aldosterone/salt-induced hypertension in female rats
  1038. Association of the-344T/C Aldosterone synthase gene variant with essential hypertension.
  1039. Circulating Aldosterone levels and disease severity in pulmonary arterial hypertension
  1040. Factors affecting complete hypertension cure after adrenalectomy for Aldosterone-producing adenoma: outcomes in a large series
  1041. Aldosterone, sodium, and hypertension: lessons from torcetrapib?
  1042. Association of HSD3B1 and HSD3B2 gene polymorphisms with essential hypertension, Aldosterone level, and left ventricular structure
  1043. … of plasma renin concentration instead of plasma renin activity decreases the positive Aldosterone-to-renin ratio tests in treated patients with essential hypertension
  1044. Fluid retention, Aldosterone excess, and treatment of resistant hypertension
  1045. Central infusion of Aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in Wistar rats
  1046. Impact of Aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension
  1047. Contribution of four polymorphisms in renin-angiotensin-Aldosterone-related genes to hypertension in a Thai population
  1048. Influence of blood pressure control and application of renin‐angiotensin‐Aldosterone system inhibitors on the outcomes in COVID‐19 patients with hypertension
  1049. Association of Aldosterone with left ventricular mass in hypertension: interaction with plasma fibrinogen levels
  1050. Endogenous ouabain and Aldosterone are coelevated in the circulation of patients with essential hypertension
  1051. Atrial natriuretic peptide and Aldosterone synthase gene in essential hypertension: A case–control study
  1052. … extract of Hibiscus sabdariffa on the renin-angiotensin-Aldosterone system of Nigerians with mild to moderate essential hypertension: A comparative study …
  1053. Synergistic effects of gene polymorphisms of the renin–angiotensin–Aldosterone system on essential hypertension in Kazakhs in Xinjiang
  1054. Modulation of Aldosterone levels by− 344 C/T CYP11B2 polymorphism and spironolactone use in resistant hypertension
  1055. Renin-angiotensin-Aldosterone system inhibitors and mortality in patients with hypertension hospitalized for COVID-19: a systematic review and meta-analysis
  1056. Aldosterone and alterations of hypertension-related vascular function in African Americans
  1057. β‐Blocker withdrawal is preferable for accurate interpretation of the Aldosterone–renin ratio in chronically treated hypertension
  1058. … artery denervation improves pulmonary arterial hypertension induced right ventricular dysfunction by modulating the local renin-angiotensin-Aldosterone …
  1059. Upregulation of the renin-angiotensin-Aldosterone-ouabain system in the brain is the core mechanism in the genesis of all types of hypertension
  1060. Does the ratio of serum Aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO
  1061. Crosstalk between the heme oxygenase system, Aldosterone, and phospholipase C in hypertension
  1062. K+ and the renin–angiotensin–Aldosterone system: new insights into their role in blood pressure control and hypertension treatment
  1063. Effect of renin-angiotensin-Aldosterone system blockade on long-term outcomes in postacute kidney injury patients with hypertension
  1064. Aldosterone contributes to blood pressure variance and to likelihood of hypertension in normal-weight and overweight African Americans
  1065. Aldosterone, inactive matrix gla-protein, and large artery stiffness in hypertension
  1066. … –Aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind …
  1067. Discovery of spirocyclic Aldosterone synthase inhibitors as potential treatments for resistant hypertension
  1068. What “Drives” the Link Between the Renin–Angiotensin–Aldosterone System and the Prothrombotic State in hypertension?
  1069. Renin-angiotensin-Aldosterone system in the pathogenesis of pregnancy-induced hypertension
  1070. CNS neuroplasticity and salt-sensitive hypertension induced by prior treatment with subpressor doses of ANG II or Aldosterone
  1071. Pathophysiology and treatment of resistant hypertension: the role of Aldosterone and amiloride-sensitive sodium channels
  1072. Endogenous ouabain and the renin–angiotensin–Aldosterone system: distinct effects on Na handling and blood pressure in human hypertension
  1073. PVN adenovirus-siRNA injections silencing either NOX2 or NOX4 attenuate Aldosterone/NaCl-induced hypertension in mice
  1074. Renin–angiotensin–Aldosterone system gene polymorphisms in gestational hypertension and preeclampsia: A case–control gene-association study
  1075. Management of resistant hypertension: Aldosterone antagonists or intensification of diuretic therapy?
  1076. Urinary Aldosterone-to-active-renin ratio: a useful tool for predicting resolution of hypertension after adrenalectomy in patients with Aldosterone-producing adenomas
  1077. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of Aldosterone status
  1078. Sodium pumps, ouabain and Aldosterone in the brain: A neuromodulatory pathway underlying salt-sensitive hypertension and heart failure
  1079. Persistent hypertension after adrenalectomy for an Aldosterone-producing adenoma: weight as a critical prognostic factor for Aldosterone‘s lasting effect on the cardiac …
  1080. Combination therapy with renin‐angiotensin‐Aldosterone receptor blockers for hypertension: how far have we come?
  1081. Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy
  1082. The effect of catheter based renal synthetic denervation on renin-angiotensin-Aldosterone system in patients with resistant hypertension
  1083. … -and Aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension
  1084. CYP11B2 gene haplotypes independently and in concurrence with Aldosterone and Aldosterone to renin ratio increase the risk of hypertension
  1085. T allele of− 344C/T polymorphism in Aldosterone synthase gene is not associated with resistant hypertension
  1086. New drug therapies interfering with the renin–angiotensin–Aldosterone system for resistant hypertension
  1087. Effects of T-type calcium channel blockers on renal function and Aldosterone in patients with hypertension: a systematic review and meta-analysis
  1088. Clinical value of measuring the renin/Aldosterone levels: optimising the management of uncontrolled/resistant hypertension
  1089. β2-Adrenergic receptor genotype affects the renin-angiotensin-Aldosterone system response to the Dietary Approaches to Stop hypertension (DASH) dietary pattern
  1090. Clinical effects of eplerenone, a selective Aldosterone blocker, in Japanese patients with essential hypertension
  1091. Discovery of indazole Aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension
  1092. … Aldosterone synthase CYP11B2 (-344T/C) gene polymorphism and antihypertensive response to valsartan in Chinese patients with essential hypertension
  1093. Common genetic variations of the renin–angiotensin–Aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension
  1094. Five Reasons for the Failure to Diagnose Aldosterone Excess in hypertension
  1095. Graz Endocrine Causes of hypertension (GECOH) study: a diagnostic accuracy study of Aldosterone to active renin ratio in screening for primary …
  1096. Relationship between− 344T/C polymorphism in the Aldosterone synthase gene and atrial fibrillation in patients with essential hypertension
  1097. Microalbuminuria and plasma Aldosterone levels in nondiabetic treatment-naïve patients with hypertension
  1098. Serum Aldosterone is related to left ventricular geometry and function in young adults with never-treated primary hypertension
  1099. Aldosterone-producing adrenocortical carcinoma without hypertension
  1100. Association of− 344C/T polymorphism in the Aldosterone synthase (CYP11B2) gene with cardiac and cerebrovascular events in Chinese patients with hypertension
  1101. Targeting the Renin–Angiotensin–Aldosterone System to Prevent hypertension and Kidney Disease of Developmental Origins
  1102. Predictors of resolution of hypertension after adrenalectomy in patients with Aldosterone-producing adenoma
  1103. … of plasma renin, angiotensin, and Aldosterone levels to blood pressure variability and target organ damage in children with essential hypertension
  1104. Oestrogen receptors and T cells determine how sex affects Aldosterone-induced hypertension
  1105. Relationship of Aldosterone synthase gene (C-344T) and mineralocorticoid receptor (S810L) polymorphisms with gestational hypertension
  1106. Decreased mortality of COVID-19 with renin-angiotensin-Aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis
  1107. Aldosterone and stress-dependent arterial hypertension
  1108. Role of Aldosterone, mitogenic growth factors, apoptosis inducers and pulmonary arterial hypertension in the formation and progression of chronic pulmonary …
  1109. hypertension and depressed symptomatology: a cluster related to the activation of the renin–angiotensin–Aldosterone system (RAAS). Findings from population …
  1110. Body mass index predicts 24-hour urinary Aldosterone levels in patients with resistant hypertension
  1111. Pattern of adrenal hormonal secretion in patients with adrenal adenomas: the relevance of Aldosterone in arterial hypertension
  1112. Association of elevated plasma Aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension
  1113. Association of post-saline load plasma Aldosterone levels with left ventricular hypertrophy in primary hypertension
  1114. … association and synergistic effect of human Aldosterone synthase (CYP11B2) gene polymorphisms causing susceptibility to essential hypertension in Indian patients
  1115. Aldosterone and mineralocorticoid receptor antagonists on pulmonary hypertension and right ventricular failure: A review
  1116. Secondary hypertension due to concomitant Aldosterone-producing adenoma and parathyroid adenoma
  1117. Aldosterone excess and resistant hypertension: investigation and treatment
  1118. hypertension and longevity: role of genetic polymorphisms in renin-angiotensin-Aldosterone system and endothelial nitric oxide synthase
  1119. Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in Aldosterone-salt-treated rats
  1120. Association between urine Aldosterone and diastolic function in patients with primary aldosteronism and essential hypertension
  1121. Effect of postural changes on Aldosterone to plasma renin ratio in patients with suspected secondary hypertension
  1122. Arterial hypertension, Aldosterone, and Atrial Fibrillation
  1123. Associations of renin–angiotensin–Aldosterone system genes with blood pressure changes and hypertension incidence
  1124. … complex 1 subunit raptor by Aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension
  1125. … of Aldosterone blockade and diuretic reinforcement vs. dual renin–angiotensin blockade for left ventricular mass regression in patients with resistant hypertension
  1126. Aldosterone to active renin ratio is associated with nocturnal blood pressure in obese and treated hypertensive patients: the Styrian hypertension Study
  1127. … trial of azilsartan and olmesartan comparing effects on the renin-angiotensin-Aldosterone system in patients with essential hypertension after cardiac surgery (CHAOS …
  1128. … outcomes of laparoscopic‐based renal denervation plus adrenalectomy vs adrenalectomy alone for treating resistant hypertension caused by unilateral Aldosterone …
  1129. The role of the renin-angiotensin-Aldosterone system in renal artery stenosis, renovascular hypertension, and ischemic nephropathy: diagnostic implications
  1130. … renin activity and Aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension
  1131. Clinical features of COVID-19 in patients with essential hypertension and the impacts of renin-angiotensin-Aldosterone system inhibitors on the prognosis of COVID-19 …
  1132. Aldosterone-producing adrenal adenoma and idiopathic intracranial hypertension—a pathogenetic link for Aldosterone?
  1133. Unravelling drug-induced hypertension: molecular mechanisms of Aldosterone-independent mineralocorticoid receptor activation by posaconazole
  1134. Aldosterone a relevant factor in the beginning and evolution of arterial hypertension
  1135. Long-term effect of efonidipine therapy on plasma Aldosterone and left ventricular mass index in patients with essential hypertension
  1136. Serum potassium levels predict blood pressure response to Aldosterone antagonists in resistant hypertension
  1137. Association of the K173R variant and haplotypes in the Aldosterone synthase gene with essential hypertension
  1138. The Effects of Salt and Glucose Intake on Angiotensin II and Aldosterone in Obese and Nonobese Patients with Essential hypertension
  1139. Resistant hypertension characterized by increased Aldosterone levels and persistent intravascular volume expansion
  1140. … C-344T, angiotensin II type 1 receptor A1166C and 11-β hydroxysteroid dehydrogenase G534A gene polymorphisms and essential hypertension in the population of …
  1141. Predictors of hyperkalemia risk after hypertension control with Aldosterone blockade according to the presence or absence of chronic kidney disease
  1142. Clock genes and salt-sensitive hypertension: a new type of Aldosterone-synthesizing enzyme controlled by the circadian clock and angiotensin II
  1143. Dysregulation of renal transient receptor potential melastatin 6/7 but not paracellin-1 in Aldosterone-induced hypertension and kidney damage in a model of hereditary …
  1144. Immune system alterations by Aldosterone during hypertension: from clinical observations to genomic and non-genomic mechanisms leading to vascular damage
  1145. A novel haplotype of low-frequency variants in the Aldosterone synthase gene among northern Han Chinese with essential hypertension
  1146. Association of DNA polymorphisms within the CYP11B2/CYP11B1 locus and postoperative hypertension risk in the patients with Aldosterone-producing adenomas
  1147. Role of renin-angiotensin-Aldosterone system gene polymorphisms and hypertension-induced end-stage renal disease in autosomal dominant polycystic kidney …
  1148. Abnormal regulation of renin angiotensin Aldosterone system is associated with right ventricular dysfunction in hypertension
  1149. Microalbuminuria and hypertension in pregnancy: role of Aldosterone and inflammation
  1150. Galectin-3 and Aldosterone as potential tandem biomarkers in pulmonary arterial hypertension
  1151. The association of plasma resistin with dietary sodium manipulation, the renin‐angiotensin‐Aldosterone system, and 25‐Hydroxyvitamin D3 in human hypertension
  1152. The role of Aldosterone in myocardial dysfunction of Egyptian patients with essential hypertension
  1153. Aldosterone contributed to pulmonary arterial hypertension development via stimulating aquaporin expression and pulmonary arterial smooth muscle cells …
  1154. Renal ischemia-reperfusion leads to hypertension and changes in proximal tubule Na+ transport and renin-angiotensin-Aldosterone system: Role of NADPH oxidase
  1155. Inefficient arterial hypertension control in patients with metabolic syndrome and its link to renin–angiotensin–Aldosterone system polymorphisms
  1156. An overview of the classical and tissue-derived renin-angiotensin-Aldosterone system and its genetic polymorphisms in essential hypertension
  1157. A not-so-modest proposal that a “modest” increase in Aldosterone causes hypertension and more
  1158. Role of angiotensinogen and relative Aldosterone excess in salt-sensitive hypertension
  1159. Paradoxical increase of 24-hour urinary Aldosterone levels in obese patients with resistant hypertension on a high salt diet
  1160. … angiotensin II and Aldosterone secretion in patients with pressure overloaded systemic right ventricles are similar to those observed in systemic arterial hypertension
  1161. Effect of Renin-Angiotensin-Aldosterone System inhibitors on outcomes of COVID-19 patients with hypertension: Systematic review and Meta-analysis
  1162. Association of Aldosterone-to-renin ratio with hypertension differs by sodium intake: the Ohasama study
  1163. Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin–angiotensin–Aldosterone system blockers
  1164. Aldosterone and hypertension in African Americans
  1165. Central endogenous angiotensin-(1–7) protects against Aldosterone/NaCl-induced hypertension in female rats
  1166. Difficult-to-control hypertension due to bilateral Aldosterone-producing adrenocortical microadenomas associated with a cortisol-producing adrenal …
  1167. Role of pendrin in the pathophysiology of Aldosterone-induced hypertension
  1168. … Aldosterone synthase (CYP11B2) inhibitors: Old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hypertension
  1169. Aldosterone antagonists or renin-guided therapy for treatment-resistant hypertension: a comparative effectiveness pilot study in primary care
  1170. Genetic and functional analyses of Aldosterone synthase gene C-344T polymorphism with essential hypertension
  1171. A systemic review of the relationship between Aldosterone synthase–344 C/T polymorphism and hypertension in Han
  1172. … approach to the management of high blood pressure: efficacy and tolerability of the Aldosterone synthase inhibitor LCI699 in patients with stage 1-2 hypertension
  1173. Resistant hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-Aldosterone system …
  1174. Plasma Aldosterone concentration is positively associated with pulse pressure in patients with primary hypertension
  1175. New therapeutic options in patients prone to hypertension: a focus on direct renin inhibition and Aldosterone blockade
  1176. Association between elevated plasma Aldosterone concentration and left atrial conduit function in hypertension
  1177. Low plasma renin activity and high Aldosterone/renin ratio are associated with untreated isolated systolic hypertension
  1178. Association of the Aldosterone synthase gene− 344T> C polymorphism with essential hypertension and glucose homeostasis: A case–control study in a Han Chinese …
  1179. Effects of Olmesartan on the Renin-angiotensin-Aldosterone System for Patients with Essential hypertension after Cardiac Surgery—Investigation Using a …
  1180. Polymorphism of genes of renin-angiotensin-Aldosterone system in the development of hypertension in workers exposed to physical factors
  1181. Renin-angiotensin-Aldosterone system and pathobiology of hypertension
  1182. Ins and outs of Aldosterone-producing adenomas of the adrenal: from channelopathy to common curable cause of hypertension
  1183. … administration on the relationship between renin-angiotensin-Aldosterone system activity and plasma glucose in patients with hypertension
  1184. Effect of Aldosterone antagonists on obstructive sleep apnea in patients with resistant hypertension: a systematic review and meta-analysis
  1185. The role of Aldosterone in hypertension
  1186. The role of Aldosterone in kidney diseases and hypertension. Is it worth using mineralocorticoid receptor antagonists in clinical practice?
  1187. Sodium chloride and Aldosterone: harbingers of hypertension-related cardiovascular disease
  1188. Gene mutations that promote adrenal Aldosterone production, sodium retention, and hypertension
  1189. Elevated Renin and Aldosterone Levels in a Young Woman With hypertension
  1190. Endocrine causes of hypertension: Aldosterone
  1191. Acetaminophen increases Aldosterone secretion while suppressing cortisol and androgens: a possible link to increased risk of hypertension
  1192. Are” functionally related polymorphisms” of renin-angiotensin-Aldosterone system gene polymorphisms associated with hypertension?
  1193. Effect of felodipine on myocardial and renal injury induced by Aldosterone-high salt hypertension in uninephrectomized rats
  1194. Effect of electroacupuncture of different acupoints on blood pressure, plasma angiotensin II, Aldosterone and atrial natriuretic peptide in spontaneous hypertension …
  1195. The impact of an Aldosterone synthase (CYP11B2) polymorphism on vascular function and inflammatory biomarkers in essential hypertension
  1196. The Role of hypertension and Renin-angiotensin-Aldosterone System Inhibitors in Bleomycin-induced Lung Injury
  1197. Rates of hospitalization associated with the use of Aldosterone receptor antagonists in patients with pulmonary arterial hypertension
  1198. Differences of blood plasma renin activity, angiotensin II and Aldosterone levels in essential or secondary hypertension
  1199. The role of renin-angiotensin Aldosterone system related micro-ribonucleic acids in hypertension
  1200. Renin-angiotensin-Aldosterone system in the elderly: rational use of aliskiren in managing hypertension
  1201. A systematic review on randomized control trials on rennin angiotensin Aldosterone system inhibitors role in managing hypertension among hemodialysis patients
  1202. Gene expression profile of persistent postoperative hypertension patients with Aldosterone-producing adenomas
  1203. Increased plasma Aldosterone-to-renin ratio is associated with impaired left ventricular longitudinal functional reserve in patients with uncomplicated hypertension
  1204. Polymorphism of the Aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic …
  1205. Chronic kidney disease progression in patients with resistant hypertension subject to 2 therapeutic strategies: Intensification with loop diuretics vs Aldosterone …
  1206. What is the role of Aldosterone excess in resistant hypertension and how should it be investigated and treated?
  1207. Obstructive sleep apnea syndrome–related hypertension and sarcopenia: a brief glance on the renin-angiotensin-Aldosterone system
  1208. Of hammers and screws: renin–angiotensin–Aldosterone system inhibition to prevent atrial fibrillation in patients with hypertension
  1209. Preeclampsia: the role of Aldosterone in hypertension and inflammation
  1210. CaseReport: Aldosterone-secreting adrenal carcinoma complicating longstanding hypertension
  1211. Role of Nox2 and p22phox in persistent postoperative hypertension in Aldosterone-producing adenoma patients after adrenalectomy
  1212. Is renal denervation an alternative or a complement to Aldosterone antagonists in treatment of resistant hypertension?
  1213. … ‐based renal denervation plus unilateral laparoscopic adrenalectomy for the treatment of patients with resistant hypertension caused by unilateral Aldosterone …
  1214. Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary hypertension: Insights from the Veterans Affairs Clinical Assessment Reporting and …
  1215. … of Aldosterone on Senescence and Proliferation Inhibition of Endothelial Progenitor Cells Induced by Sirtuin 1 (SIRT1) in Pulmonary Arterial hypertension
  1216. The role of renin–angiotensin–Aldosterone system in etiology and pathogenesis of arterial hypertension and its systemic complications—what remains from Laragh …
  1217. Resistant hypertension in the elderly-second line treatments: Aldosterone antagonists, central alpha-agonist agents, alpha-adrenergic receptor blockers, direct …
  1218. … ineffective hypertension control in subjects treated with angiotensin-converting enzyme inhibitors is related to polymorphisms in the renin-angiotensin-Aldosterone …
  1219. Female sex hormones are associated with the reduction of serum sodium and hypertension complications in patients with Aldosterone-producing adenoma
  1220. Aldosterone, gut microbiome and hypertension: selected papers from APCH 2019
  1221. … of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: hypertension management and renin-angiotensin-Aldosterone system blockade in …
  1222. A cross-sectional study on factors associated with hypertension and genetic polymorphisms of renin-angiotensin-Aldosterone system in Chinese hui pilgrims …
  1223. Novel marker of myocardial remodeling ST2 and the influence of Aldosterone antagonist in patients with heart failure caused by hypertension and ischemic heart …
  1224. Untangling essential hypertension: the potential roles of Aldosterone and atrial natriuretic peptide
  1225. The role of Aldosterone receptor blocker therapy in hypertension and heart failure
  1226. Long-term use of Aldosterone-receptor antagonists in uncontrolled hypertension: a retrospective analysis
  1227. Role of vasopressin and Aldosterone in pulmonary arterial hypertension: A pilot study
  1228. Proinflammatory/profibrotic effects of Aldosterone in Gitelman’s syndrome, a human model opposite to hypertension
  1229. Progression of renal insufficiency in patients with essential hypertension treated with renin angiotensin Aldosterone system blockers: an electrocardiographic …
  1230. Polymorphic variation of CYP11B2 predicts postoperative resolution of hypertension in patients undergoing adrenalectomy for Aldosterone‐producing adenomas
  1231. Association of Aldosterone synthase (CYP11B2) gene-344T/C polymorphism with essential hypertension in Mongolian nationality
  1232. Estrogen receptor-beta (ERβ) in the PVN and RVLM plays an essential protective role in Aldosterone/salt-induced hypertension in female rats
  1233. Regulators of Epithelial Sodium Channels in Aldosterone-Sensitive Distal Nephrons (ASDN): Critical Roles of Nedd4L/Nedd4-2 and Salt-Sensitive hypertension
  1234. Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice
  1235. Cardiovascular responses to chronic baroreflex activation in Aldosterone hypertension
  1236. Blind spots in the new International Society of hypertension guidelines: physiologically individualized therapy for resistant hypertension based on renin/Aldosterone …
  1237. hypertension and the renin-angiotensin-Aldosterone system
  1238. Synergic effects of renin and Aldosterone on right ventricular function in hypertension: a tissue Doppler study
  1239. Aldosterone-salt hypertension depends on the SFO, central Aldosterone synthase and MR specifically in the PVN
  1240. … effects of renin-angiotensin-Aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta …
  1241. … regulation of blood pressure: focus on “Role of central nervous system Aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt …
  1242. Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with hypertension: A Nationwide Cohort Study
  1243. RENIN, Aldosterone, THE Aldosterone-TO-RENIN RATIO AND INCIDENT ARTERIAL hypertension AMONG NORMOTENSIVE SUBJECTS FROM THE …
  1244. Blockers of renin-angiotensin-Aldosterone system in the treatment of arterial hypertension: classics versus the modern
  1245. High Aldosterone, hypertension and adrenal adenoma in a 36-year-old pregnant patient: Is this primary aldosteronism?
  1246. P3486 Cytokine profile, renin-angiotensin Aldosterone system and left ventricular remodelling in essential arterial hypertension comorbid with chronic obstructive …
  1247. … the renin–angiotensin–Aldosterone system and reduces blood pressure and albuminuria in elderly chronic kidney disease patients with hypertension
  1248. SAT-224 Recurrent Co-Driver Mutation in CTNNB1-Mutant Aldosterone-producing Adenomas (APA), Causing Reversible hypertension in Puberty, Pregnancy or …
  1249. Stimulation of Aldosterone synthesis by angiotensin II in the brain: support for positive feedback in hypertension?
  1250. Na+-Cl− cotransporter-mediated chloride uptake contributes to hypertension and renal damage in Aldosterone-infused rats
  1251. Role of relative Aldosterone excess in salt-sensitive hypertension among African ancestry
  1252. Hormones other than Aldosterone may contribute to hypertension in 3 different subtypes of primary aldosteronism
  1253. P3568 The relationship between plasma renin and Aldosterone levels and the reduction of blood pressure with spironolactone in patients with resistant hypertension
  1254. Role of Aldosterone Antagonists in Treatment of Refractory hypertension [J]
  1255. INTERACTION OF Aldosterone AND SODIUM AFFECTS PREVALENCE OF ATRIAL FIBRILLATION IN PATIENTS WITH RESISTANT hypertension
  1256. Oxidative Stress in hypertension and Cardiovascular-Renal Remodeling: Focus on the Renin-Angiotensin-Aldosterone System
  1257. Evaluating the relationship of blood pressure, plasma angiotensin peptides and Aldosterone with cognitive functions in patients with hypertension
  1258. JS ISH-ECCR-4 The plasma Aldosterone/angiotensin II ratio for the screening of secondary hypertension
  1259. … characteristics of subclinical target organ damage in urban adult residents with hypertension in Tianjin and its relationships with renin-angiotensin-Aldosterone …
  1260. PRINCIPAL COMPONENTS OF POLYSOMNOGRAPHY POTENTIALLY EFFECT ON Aldosterone-RENIN-RATIO IN SNORERS WITH hypertension
  1261. Impaired Aldosterone response to the saline infusion test in patients with resistant hypertension and obstructive sleep apnea
  1262. Deficiency of T-type Ca2+ channels Cav3.1 and Cav3.2 has no effect on angiotensin II-induced hypertension but differential effect on plasma Aldosterone in mice
  1263. Aldosterone, hypertension, and Cardiovascular Disease
  1264. GW29-e0446 The Biomarker of Atrial Fibrillation in Patients with Essential hypertension–Aldosterone
  1265. Effects of Interactions among Gene Polymorphisms of the Renin–Angiotensin-Aldosterone System on hypertension in Turkish People from Southeast Anatolia
  1266. Effect of sodium–glucose cotransporter-2 inhibitors on Aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study
  1267. Aldosterone renin ratio in patients with resistant hypertension
  1268. Aldosterone escape in treatment of essential hypertension with RAS blockers [J]
  1269. Association of Urine Na: K with Renin and Aldosterone at Baseline in Pediatric hypertension
  1270. Diagnosis of Primary Aldosteronism and Usefulness of Aldosterone/Renin Ratio in Secondary hypertension
  1271. Increased Aldosterone release during head-up tilt in early primary hypertension
  1272. Polymorphic variants of the renin-angiotensin-Aldosterone system genes associated with the risk of hypertension development
  1273. Aldosterone-Renin Ratio Is Determinant of Arterial Stiffness in Large Cohort of Patients With Severe Essential hypertension: Pp. 10.410
  1274. Renin-angiotensin-Aldosterone inhibitors for treatment of hypertension with abnormal circadian rhythm of blood pressure
  1275. Direct versus enzymatic renin measurement for the calculation of Aldosterone/renin ratio in patients with essential hypertension and with primary hyperaldosteronism
  1276. Estimation of Serum Aldosterone and Electrolytes in Pregnancy Induced hypertension
  1277. Choice of an Optimal Blocker of the Renin-Angiotensin-Aldosterone System in Patients With Concomitant Arterial hypertension and Chronic Obstructive Pulmonary …
  1278. … Global Versus Renal-Specific Sympathoinhibition in Aldosterone-Induced hypertension: Implications for Medical Device-Based Treatment of Resistant hypertension
  1279. ALISKIREN, BOTH AS MONOTHERAPY AND IN COMBINATION WITH VALSARTAN, REDUCES PLASMA Aldosterone IN PATIENTS WITH hypertension: PP …
  1280. Estimation of the renin-angiotensin-Aldosterone system, water and electrolyte imbalance and endothelial function in newborns of women with chronic hypertension
  1281. … Chronic kidney disease progression in patients with resistant hypertension subject to two therapeutic strategies: intensification with loop diuretics vs Aldosterone …
  1282. Renin-angiotensin-Aldosterone System Blockers, hypertension and Clinical Outcomes
  1283. COVID‐19, hypertension, and renin‐angiotensin‐Aldosterone system inhibitors: Much ado about nothing or real problem to be solved?
  1284. Roles of Aldosterone Receptor Antagonists in Heart Failure, hypertension, and Chronic Kidney Disease
  1285. Is there truly a sympathetic component to Aldosterone hypertension?
  1286. Aldosterone Biosynthesis: Genetic Control and Contribution to the Development of Arterial hypertension
  1287. Letter by Zhou and Zhou Regarding Article,“hypertension: Renin–Angiotensin–Aldosterone System Alterations”
  1288. A5917 Principal Component Analysis and Correlated Effect on Aldosterone-renin-ratio in Snorers with hypertension
  1289. The blockade of renin-angiotensin-Aldosterone system in hemodialysis patients to control hypertension and prevent cardiovascular disease: optimal pharmacotherapy
  1290. Aldosterone-Producing Cell Clusters in Essential hypertension
  1291. Abstract MP13: TRPM7 Downregulation Contributes To Cardiovascular Injury And hypertension Induced By Aldosterone And Salt
  1292. P1872 Fixed combinations of renin-angiotensin-Aldosterone system inhibitors and calcium channel blockers in relation of patients adherence in hypertension
  1293. … between Chronic Use of Renin–Angiotensin-Aldosterone System Blockers and in-Hospital Adverse Events among COVID-19 Patients with hypertension
  1294. Vascular and endothelial function in human hypertension, and the importance of the renin-angiotensin-Aldosterone system
  1295. Association between polymorphism of the angiotensin-converting enzyme gene and the Aldosterone synthase gene in pedigreed primary hypertension.
  1296. Aldosterone synthase, polymorphism of its CYP11B2 gene in arterial hypertension and cardiovascular diseases associated with it (literature review)
  1297. Regulation of Biogenesis and Fusion/Fission Processes of Vascular Mitochondria In Aldosterone-Induced hypertension
  1298. Fibroblast Growth Factor-23, Heart Failure Risk, and Renin–Angiotensin–Aldosterone-System Blockade in hypertension: The MESA Study
  1299. Serum Aldosterone Levels in hypertension
  1300. Plasma renin activity, serum Aldosterone concentration and selected organ damage indices in essential arterial hypertension
  1301. Steroidogenic acute regulatory protein/Aldosterone synthase participates in signaling of angiotensin II/Aldosterone-induced aortic remodeling and hypertension
  1302. A6748 The Effect of Physiological Phenotyping with Plasma Renin and Aldosterone on Uncontrolled hypertension
  1303. Gender Differences in the Aldosterone Level of Young Obese Patients With hypertension
  1304. hypertension with Metabolic Alkalosis and Hypokalaemia-Could it be Aldosterone?
  1305. Abstract P249: Central Nervous System Control of Plasma Aldosterone and Endogenous Ouabain in Angiotensin II-Salt hypertension
  1306. Central injections of adeno‐associated virus‐siRNA gene to silence estrogen receptor beta (ERβ) augment Aldosterone‐induced hypertension in female rats
  1307. A14580 Predictors of the results of the diagnostic tests for the primary hyperaldosteronism in patients with hypertension and an Aldosterone-to-renin ratio greater than …
  1308. Roles of Aldosterone, mineralocorticoid inhibition and G6PD activity in microvascular endothelial dysfunction in African Americans with hypertension
  1309. Contribution of rennin-angiotensin-Aldosterone system genes and NO synthase gene to the development of arterial hypertension
  1310. Aldosterone–Renin Ratio and Side-Selective Renal Perfusion in Essential hypertension
  1311. A2074 FAILURE OF SUPPRESSION OF THE RENIN ANGIOTENSIN Aldosterone SYSTEM A POSSIBLE MECHANISM OF ESSENTIAL hypertension
  1312. Optimising Renin-Angiotensin-Aldosterone System Inhibitor Therapy In Heart Failure And Resistant hypertension: Challenges And Solutions
  1313. Response to Letter to Regarding Article,“Effects of Novel Aldosterone Synthase Inhibitor for Treatment of Primary hypertension: Results of a Randomized, Double …
  1314. The role of Aldosterone and Aldosterone blockade in hypertension
  1315. PREGNANCY INDUCED hypertension AND ITS RELATION TO VITAMIN D AND Aldosterone IN IRAQI PREGNANT WOMEN
  1316. G PROTEIN-COUPLED ESTROGEN RECEPTORS: NOVEL THERAPEUTIC TARGETS IN Aldosterone/SALT-INDUCED hypertension?
  1317. Aldosterone METABOLITES AND POSSIBLE Aldosterone PRECURSORS IN hypertension
  1318. Brain natriuretic peptide counteracting the Renin-angiotensin-Aldosterone system in accelerated malignant hypertension
  1319. Renin–angiotensin–Aldosterone system inhibitors may benefit patients with comorbid hypertension and COVID-19
  1320. A8790 nocturnal hypertension renin-angiotensin-Aldosterone activation target organ damage
  1321. Mutation of an anti‐aging gene klotho causes hypertension via upregulation of plasma Aldosterone levels
  1322. Relationship between Aldosterone escape phenomena and left ventricular hypertrophy in essential hypertension treated by RAS blocker
  1323. Role of Aldosterone in postmenopausal hypertension
  1324. Aldosterone antagonists in the treatment of hypertension
  1325. Relationship between the CYP11B_2-344T/C polymorphism of Aldosterone synthase gene and essential hypertension in Uygur, Han and Kazak population in …
  1326. Letter by Keidar and Gamliel-Lazarovich Regarding Article,“Effects of A Novel Aldosterone Synthase Inhibitor for Treatment of Primary hypertension: Results of a …
  1327. A5791 Analysis of biochemistry and angiotensin I, angiotensin II and Aldosterone in Kazakh and Uygur primary hypertension in Xinjiang
  1328. Mutation of Anti-aging Gene Klotho Causes hypertension via Upregulation of CYP11B2 Expression and Aldosterone Syhthesis
  1329. A11744 Parameters of carotid structure and renin-Aldosterone system in patients with resistance hypertension
  1330. Rates of Hospitalization Associated with the Use of Aldosterone Receptor Antagonists in Patients with Pulmonary Arterial hypertension
  1331. … the parameters of the renin-angiotensin-Aldosterone system, water-electrolyte metabolism, and endothelial function in newborns of women with chronic hypertension
  1332. The Role of Aldosterone in Pulmonary Venous hypertension
  1333. … ) polymorphism as a component of the renin-angiotensin-Aldosterone system in the pathogenesis of myocardial hypertrophy in hypertension: literature review and own …
  1334. OS 29-05 renal denervation attenuates Aldosterone expression and associated cardiovascular pathophysiology in angiotensin II-induced hypertension
  1335. The Role of Aldosterone in Pulmonary Venous hypertension: Response
  1336. The relationship between blood levels of Aldosterone and procollagen type Ⅲ amino-terminal peptide with Left ventricular geometry in essential hypertension patients
  1337. Association of the-344T/C polymorphism of Aldosterone synthase gene CYP11 B2 with essential hypertension in Xinjiang uygur isolated group
  1338. … AGES, OFFICE BLOOD PRESSURE, EGFR, RENIN, Aldosterone, METANEPHRYLS LEVELS IN PATIENTS WITH RESISTANT hypertension
  1339. Na+-Cl− cotransporter-mediated chloride uptake contributes to hypertension and renal damage in Aldosterone-infused rats 2
  1340. Are Aldosterone antagonists effective for treating hypertension?
  1341. Pulmonary hypertension and Right Ventricular Dysfunction Identify Subgroups of Patients With HFpEF That Benefit From Aldosterone Antagonist Therapy
  1342. … control with additive administration of eplerenone, an Aldosterone receptor blocker, in a patient with bilateral renovascular hypertension treated with angioplasty
  1343. Elevated Plasma Renin Activity Caused by Accelerated-malignant hypertension in a Patient with Aldosterone-producing Adenoma Complicated with Renal …
  1344. A10337 Intervention of Aldosterone antagonist on immune inflammatory injury in patients with essential hypertension
  1345. Abstract P313: Age and Response of Plasma Aldosterone to Saline Infusion in Primary hypertension
  1346. … AND THE RENIN ANGIOTENSIN Aldosterone SYSTEM: DISTINCT EFFECTS ON NA HANDLING AND BLOOD PRESSURE IN HUMAN hypertension: 2C. 04
  1347. Correlation between Aldosterone and hypertension among resistant hypertensive patients
  1348. … promotes apoptosis resistance in pulmonary artery smooth muscle cells to modulate adverse pulmonary vascular remodeling in pulmonary arterial hypertension
  1349. TRPM7 is Cardiovascular Protective in Aldosterone-Induced hypertension
  1350. Aldosterone levels and the-344t/c Aldosterone synthase in individuals with a family history of hypertension
  1351. … of renin-aniotensin-Aldosterone system is associated with improved left ventricular function in STEMI survivors without previous hypertension: a two dimensional …
  1352. Comparison of Aldosterone/plasma rennin activity ratio among hypertension patients in different posture
  1353. The relation of hypertension and Aldosterone-renin ratio with the severity of coronary artery disease in non-diabetic patients
  1354. Challenging hypertension: M-Atrial Natriuretic Peptide Enhances Antihypertensive Actions of Furosemide and Attenuates the Activation of Aldosterone
  1355. PP. 26.08: MANAGEMENT OF RESISTANT hypertension (RHT): Aldosterone ANTAGONISTS OR INTENSIFICATION OF DIURETIC THERAPY?
  1356. P4561 Patients adherence with fixed dose combinations of renin-angiotensin-Aldosterone system inhibitors in hypertension
  1357. Sacubitril/Valsartan Mitigates “Aldosterone Breakthrough” in Rats With Arterial hypertension While Valsartan and Enalapril Do Not
  1358. Effect of 3-month CPAP treatment on blood pressure and serum Aldosterone concentration in patients with resistant hypertension
  1359. Effects of irbesartan on the Aldosterone escape in essential hypertension
  1360. … six-month combination therapy using indapamide with amlodipine and renin-angiotensin-Aldosterone system blockers in patients with high-risk essential hypertension
  1361. Cholecalciferol supplementation is able to modulate hypertension and plasma Aldosterone in SHRSP rats.
  1362. Arterial hypertension progression and changing activity of reninangiotensin-Aldosterone and sympatho-adrenal systems
  1363. P616BNP and BMP4, two novel targets of Aldosterone in hypertension
  1364. Abstract P113: Early Life Stress-Induced Increases in Urinary Aldosterone Precedes Renal Dysfunction and hypertension in Male Mice Fed a High Fat Diet
  1365. Abstract P163: Masked Uncontrolled hypertension in Treated Hypertensive Patients Have Heightened Out-Of-Clinic Aldosterone Levels
  1366. Central blockade of Aldosterone synthase (AS) and lesion of the subfornical organ (SFO) attenuate subcutaneous (sc) Aldosterone‐induced hypertension
  1367. CHAPTER IV-Activation of the renal Aldosterone/MR system in aging and hypertension
  1368. Plasma Aldosterone, ANP, hypertension and Stage A and B Heart Failure in the General Community
  1369. Structural and Functional Insights into Aldosterone Synthase Interaction with Ligands and Redox Partner Proteins for Enhanced Treatment of hypertension
  1370. Study of the relationship between the depressurization of Aldosterone antagonists and plasma Aldosterone renin activity ratio (ARR) in refractoriness hypertension …
  1371. The Use of Renin and Aldosterone Profiling in the Treatment of Complex hypertension
  1372. Role of cardiac Aldosterone on the development of cardiac fibrosis in response to hypertension
  1373. Suppression of Aldosterone Mediates Left Ventricular Hypertrophy Regression in Patients With hypertension
  1374. Central AT1R stimulation increases hypothalamic Aldosterone: further evidence for a pivotal role of hypothalamic Aldosterone in Ang II induced hypertension
  1375. Leptin‐induced hypertension is Aldosterone Dependent in Obese Females
  1376. The Expression of Renin-angiotensin-Aldosterone System in Primary hypertension
  1377. G protein-coupled estrogen receptors: novel therapeutic targets in Aldosterone-induced hypertension?
  1378. Abstract P328: Evaluation of Hyperkalemia and the Use of Aldosterone Antagonists in Resistant and Secondary hypertension in a hypertension Referral Center
  1379. Decreased klotho expression in early Aldosterone‐induced hypertension
  1380. The Correlation between Essential hypertension and Renin-angiotensin-Aldosterone System
  1381. ALTERATION OF Aldosterone RESPONSE TO SALT OVERLOAD THROUGH CHRONIC KIDNEY DISEASE IN PATIENTS WITH hypertension
  1382. Severity of obstructive sleep apnea dependent upon Aldosterone status in subjects with resistant hypertension
  1383. Leptin-mediated Aldosterone Secretion Causes hypertension in Obese Females
  1384. Cilnidipine Decreases Insulin Resistance and Aldosterone Levels in Essential hypertension
  1385. An increased Aldosterone-to-renin ratio in patients with non-dipper hypertension
  1386. SEVERITY OF OBSTRUCTIVE SLEEP APNEA RELATED TO Aldosterone LEVELS IN SUBJECTS WITH RESISTANT hypertension: PP. 32.274
  1387. Response by Danser and van den Meiracker to Letter by Zhou and Zhou Regarding Article,“hypertension: Renin–Angiotensin–Aldosterone System Alterations”
  1388. Correction of Aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases
  1389. Oxidative Stress is Related to Increased Sodium-Aldosterone Product and Left Ventricular Dysfunction in Resistant hypertension
  1390. The measurement of the renin-angiotensin-Aldosterone system in patients with adrenal tumors with arterial hypertension
  1391. Autonomous Aldosterone secretion as a significant cause of arterial hypertension: the effectiveness of targeted therapy
  1392. Aldosterone‐Induced hypertension is T Lymphocyte‐Dependent and Attenuated by Activation of the G Protein‐Coupled Estrogen Receptor 1
  1393. Vascular Aging In Aldosterone Associated hypertension: Role Of NADPH Oxidase 1
  1394. Vascular Aging in Aldosterone Associated hypertension: Role of NADPH Oxidase 1
  1395. Metabolic disorders and the state of the renin–angiotensin–Aldosterone system in obese patients with resistant hypertension
  1396. OS 02-01 ROLE OF Aldosterone AND NADPH OXIDASE 1 IN hypertension-ASSOCIATED VASCULAR AGING
  1397. Absoluter Aldosteronexzess, Bluthochdruck und koronare Herzerkrankung/Arterial hypertension and cardiovascular disease–absolute Aldosterone excess is the tip of …
  1398. Variation of plasma Aldosterone level and histological ultrastructure change of adrenal gland in stress-induced hypertension rats
  1399. Relation between cardiac hemodynamics and Aldosterone content two years after myocardial infarction depending on arterial hypertension
  1400. Study of relationship between fibrinogen, Aldosterone and left ventricular mass index in patients with essential hypertension
  1401. … by Calhoun et al1 in which the authors tested the effect of a novel Aldosterone synthase inhibitor, LCI699, for treatment of primary hypertension. An 8-week …
  1402. Determination of Aldosterone Hormone and Alpa Feto-Protein Concentrations in Normal Pregnant Women and in Pregnancy Induced hypertension
  1403. Effects of Impaired Aldosterone Secretion on hypertension Development in the Spontaneously Hypertensive Rat (SHR).
  1404. Response to “role of relative Aldosterone excess in salt-sensitive hypertension in people of african ancestry”
  1405. The role of [ldquo] stress [rdquo] in Aldosterone-mediated hypertension: circumstantial evidence from the [ldquo] stress subtraction [rdquo] experiment of adrenal vein …
  1406. The role of central ROS and NO in Aldosterone (ALDO)/salt‐induced hypertension
  1407. AN INCREASED Aldosterone TO RENIN RATIO IN PATIENTS WITH NON-DIPPER hypertension: PP. 24.477
  1408. Somatic mutations in ATP1A1 and ATP2B3 lead to Aldosterone-producing adenomas and secondary hypertension
  1409. Association of the-344T/C Aldosterone synthase gene variant with essential hypertension
  1410. … OF QUINAPRIL ADD-ON TREATMENT ON Aldosterone BREAKTHROUGH IN PATIENTS WITH ESSENTIAL hypertension RECEIVING VALSARTAN: PP …
  1411. Aldosterone/Renin Ratio is a Predictor of Cardiovascular Events in Patients with Essential hypertension
  1412. Diagnostic accuracy of the Aldosterone to active renin ratio in detecting primary aldosteronism: the graz endocrine causes of hypertension (GECOH) study
  1413. Renin-Angiotensin-Aldosterone and Other Neurohumoral Factors in the Pathogenesis of Pulmonary hypertension
  1414. Response to Role of Angiotensinogen and Relative Aldosterone Excess in Salt-Sensitive hypertension
  1415. Aldosterone/renin Ratio is a Long-term Predicter of Cardiovascular Events in Patients With Essential hypertension
  1416. Aldosterone synthase gene polymorphism in patients with hypertension combined ischemic heart disease with in various left ventricular mass
  1417. RELATIONSHIPS OF SERUM URIC ACID WITH PLASMA RENIN ACTIVITY AND PLASMA Aldosterone IN PRIMARY hypertension.
  1418. Synthesis of Aldosterone in the brain contributes to the hypertension in the Dahl salt sensitive rat
  1419. Analysis of Renin-Angiotensin-Aldosterone System Gene Polymorphisms in Essential hypertension in Javanese Indonesian
  1420. Effect of Qingre Jiangya Granules on Plasma Angiotensin Ⅱ and Aldosterone in Spontaneous hypertension Rats [J]
  1421. GW25-e0782 Association between plasma Aldosterone with KCNJ5 gene polymorphisms in primary hypertension patients
  1422. Regulation of the Aldosterone synthase gene-role in human hypertension and adrenal corticosteroid production
  1423. 26 PREDICTORS OF COMPLETE RESOLUTION OF hypertension AFTER ADRENALECTOMY AMONG JAPANESE PATIENTS WITH Aldosterone …
  1424. The Influence of Juteng Capsule on Blood Pressure and Plasma Aldosterone and Catecholamine of Stress-induced hypertension in Rats
  1425. Blood Pressure Control and Dipping Patterns in Patients With Resistant hypertension: Combined Effects of Aldosterone and Sodium
  1426. Effects of Reduced Aldosterone Secretion on hypertension Development in the Spontaneously Hypertensive Rat (SHR) as Measured by Remote Monitoring
  1427. Aldosterone: With an Unhealthy Diet (High Sodium, Low Potassium) a Little Extra May Go a Long Way Toward Development of hypertension
  1428. Effects of Aldosterone Hormone on Endothelial Function With Carotid Intima-media Thickness Among Resistant and Early Onset hypertension Patients
  1429. Effect of Qingxuan Jiangya decoction on renin-angiotensin-Aldosterone system of primary hypertension patients
  1430. Study on the association of plasma rennin angiotensin, angiotensin II and Aldosterone in sleep apnea hypopnea syndrome patients with hypertension
  1431. Albumin may prevent hypertension by inhibiting renin angiotensin Aldosterone system
  1432. Impact of Polymorphisms in the Renin-Angiotensin-Aldosterone System on Vascular Alterations in Essential hypertension
  1433. Gender differences renin-angiotensin-Aldosterone system and its relation to humoral factors in patients with arterial hypertension
  1434. … response to mineralocorticoid-receptor blockade in aldosteronisms: primary hyperaldosteronism vs Aldosterone-associated hypertension/low-renin hypertension
  1435. … Impact of hypertension and Chronic Kidney Disease on the Acute Myocardial Infarction: Pathogenic Interactions of Cardiac Remodeling Using Aldosterone …
  1436. Target levels of renin-angiotensin-Aldosterone system components and their role in cardiovascular event development among patients with arterial hypertension
  1437. Magnesium supplementation attenuates Aldosterone‐induced hypertension, kidney damage and oxidative stress in genetically hypomagnesemic mice
  1438. Elevated Plasma Aldosterone/Renin Ratio Is Associated with Future Stroke in Japanese Patients with Essential hypertension
  1439. Abstract P027: Associations of Renin-Angiotensin-Aldosterone System Genes with Blood Pressure changes and hypertension Incidence: The GenSalt Study
  1440. Circulating Inactive Matrix Gla-Protein is Associated With High Aldosterone Levels and Arterial Stiffness in hypertension
  1441. Comparison of the role of the renin-angiotensin Aldosterone system in the genesis of hypertension between two groups of nonhunting dogs and hunting dogs
  1442. PLASMA Aldosterone LEVELS ON NORMAL, LOW AND HIGH SODIUM INTAKE IN PATIENTS WITH ESSENTIAL hypertension WITH NORMAL AND LOW …
  1443. Studies of Aldosterone renin ratio and genetic variation at the CYP11B1/CYP11B2 locus in human essential hypertension
  1444. Endocrine hypertension, Adrenal Steroids and Development of a Saliva Based Aldosterone Assay as a Potential Screening Method
  1445. Relationship between angiotensin converting enzyme and Aldosterone synthase gene polymorphisms and essential hypertension in Qiqihar Han population
  1446. Leptin Induces hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice
  1447. Twenty-four hour urine Aldosterone level predicts left ventricular hypertrophy in patients with primary aldosteronism and essential hypertension
  1448. Aldosterone and Salt Induces hypertension Associated with Increased Oxidative Stress in the Brain of Apolipoprotein E Knockout Mice
  1449. … Antagonists Regulate Mitochondrial Dynamics and Local Aldosterone Production Attenuating Right Ventricular Remodeling in Pulmonary Arterial hypertension
  1450. Baseline Aldosterone/Renin Ratios Predict Responses to Thiazide in Essential hypertension, Particularly for Already-Treated Patients
  1451. Aldosterone AND hypertension IN OVARIECTOMIZED FEMALE DAHL SALT SENSITIVE RATS ON LOW SALT DIET
  1452. Malignant hypertension Leading to a Diagnosis of an Aldosterone and Cortisol Co-Secreting Adrenal Tumor
  1453. Aldosterone-RECEPTOR ANTAGONISTS LEAD TO PROLONGED BLOOD PRESSURE REDUCTION IN UNCONTROLLED hypertension: A …
  1454. IRB Protocol: Rates of Practitioner Use of Aldosterone Antagonists for Resistant hypertension in an Academic Quaternary Referral Ambulatory Clinic Setting A …
  1455. Abstract P280: Butyric Acid Protects Against Aldosterone-salt-induced hypertension and Renal Injury via Suppression of (Pro) Renin Receptor
  1456. ZD100: BP Lowering, Renal Enhancing and Aldosterone Suppressing Properties via pGC-A in Human Resistant “Like” hypertension-A First in Human Study
  1457. Renin-angiotensin-Aldosterone system gene variants and their association with left ventricular function and vascular properties in essential hypertension
  1458. Aldosterone Targets Raptor to Promote Pulmonary Smooth Muscle Cell Proliferation and Modulate Pulmonary Arterial hypertension
  1459. Serum potassium levels predict blood pressure response to Aldosterone antagonists in resistant hypertension
  1460. Angiotensinogen Gene M235T Polymorphism and Serum Renin, Aldosterone Hormones Levels among Sudanese patients with Essential hypertension
  1461. Upregulation of Renin Angiotensin Aldosterone System (RAAS) by Methylglyoxal: Role in hypertension
  1462. Dietary Iron Restriction Attenuates hypertension and Renal Injury in Aldosterone/Salt-Induced Hypertensive Mice
  1463. The activity of the renin-Aldosterone system and arterial hypertension creation in patients with congenital vesicoureteral reflux and reflux nephropathy
  1464. … ACTIVATION OF MINERALCORTICOID RECEPTOR-SGK1 SYSTEMS IN URINARY EPITHELIUM FOR THE MODEL OF SODIUM SENSITIVE hypertension: PP …
  1465. Abstract P276:(Pro) Renin Receptor-dependent Renal Generation of Aldosterone Contributes to ENaC Activation During Angiotensin II-induced hypertension
  1466. THE CHANGES OF PLASMA RENIN AND Aldosterone LEVELS IN RESISTANT hypertension PATIENTS WITH OBSTRUCTIVE SLEEP APNOEA …
  1467. Anti-aging Gene Klotho Deficiency Causes hypertension Via Upregulation of CYP11B2 Expression and Aldosterone Synthesis
  1468. Endothelial function, the renin-angiotensin-Aldosterone axis (RAAS) and hypertension: the therapeutic role of potassium supplementation
  1469. CNS blockade of Aldosterone synthase prevents sympathetic hyperactivity and hypertension by central Na+ loading in Wistar rats
  1470. The induction of salt‐sensitiive hypertension (HTN) in rats by sensitizing pre‐treatments with either angiotensin II (ANG II) or Aldosterone (ALDO)
  1471. Influence of antihypertensive medication on the screening parameter Aldosterone to renin ratio in patients with essential hypertension and primary aldosteronism
  1472. Disruption of the WNK/SPAK pathway attenuates angiotensin II, but enhances Aldosterone‐induced hypertension (1136.3)
  1473. Resistant hypertension, Elevated Aldosterone/Renin Ratio and Reduced RGS2: A Pathogenetic Link Deserving Further Investigations?
  1474. A Study of a Proposed Molecular Mechanism for Idiopathic Cases of hypertension: Detection of Aldosterone-receptor Complex at Period Homolog 1 (Per1) Promoter …
  1475. TRPM7-kinase Modulates Renal and Splenic Macrophage and T-lymphocyte Infiltration in Aldosterone-salt-induced hypertension
  1476. Function of dynamically stimulated endothelium and renin–angiotensin–Aldosterone system in normotensive subjects with a family history of hypertension
  1477. Effect of Circadian Variability of Dipper Blood Pressure Induced by Irbesartan in Patients with Non-Dipper Essential hypertension on Levels of Aldosterone
  1478. Aldosterone Activates Raptor to Promote Pulmonary Artery Smooth Muscle Cell Proliferation and Pulmonary Arterial hypertension
  1479. The changes of plasma renin and Aldosterone levels in resistant hypertension patients with obstructive sleep apnea syndrome before and after continuous positive …
  1480. Renin-angiotensin-Aldosterone System Polymorphisms-based Risk Score In Resistant Arterial hypertension And Adverse Cardiovascular Events: The Genhart-rio …
  1481. Dyssynchrony and Fibrosis in a Canine Model of hypertension Correlates with Aldosterone-Mediated Depletion in Circulating Progenitor Cell Counts
  1482. Primary Prevention of Atrial Fibrillation Using Renin-Angiotensin-Aldosterone System Inhibitors among Medicare Beneficiaries with hypertension
  1483. Endothelial function, the renin-angiotensin-Aldosterone axis (RAAS) and hypertension: diagnostic strategies and therapeutic role of potassium supplementation
  1484. Effect of renin-angiotensin-Aldosterone system blockers on myocardial remodeling processes and risk for atrial fibrillation in patients with arterial hypertension
  1485. Aldosterone Inactivates the Endothelin-B Receptor via a Thiol Redox Switch to Modulate Pulmonary Arterial hypertension
  1486. … of Pulmonary Artery Endothelial Catechol-o-methyltransferase Activity by Aldosterone Increases Norepinephrine Levels in Pulmonary Arterial hypertension
  1487. Effects of chronic receptor blockade on intracardiac angiotensin II and Aldosterone content in an angiotensin II-infused model of hypertension
  1488. 5972 The renin and Aldosterone levels at resistant hypertension and its connection with other clinical features
  1489. Association and Interrelation of Angiotensinogen, ACE, ACE-2, and Aldosterone Synthase Gene Polymorphism in Essential hypertension
  1490. Selective Aldosterone Blocker Enhances Protective Effects of Calcium Channel Blocker (CCB) Against Salt-sensitive hypertension-induced Cardiovascular Injury …
  1491. Aldosterone (Aldo) Interacts with PKA, MAPKs and PLC Pathway to Sensitize Angiotensin (ANG) II‐Induced hypertension
  1492. … Prevents the Arterial Stiffness Elevation Resulting in the Amelioration of Inappropriate Cardiovascular Response During Exercise in Patients With hypertension
  1493. … Peripheral Blood 18-oxo-cortisol Can Differentiate the Patients With Aldosterone Producing Adenoma From Those With Essential hypertension.-omitting many steps …
  1494. … CATHETER BASED RENAL SYMTHETIC DENERVATION ON RENIN-ANGIOTENSION-Aldosterone SYSTEM IN PATIENTS WITH RESISTANT hypertension
  1495. … et al,“The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin hypertension and Elevated Aldosterone …
  1496. Novel description of Aldosterone synthase CYP11B2 -344 T>C gene polymorphism related to hypertension in Mexican Amerindians: Teenek, Mixtec and Mayans
  1497. … Application of a New Chemiluminescent Method for Direct Renin Measurement to the Calculation of Aldosterone/Renin Ratio in Patients with Essential hypertension
  1498. PVN injections of adeno‐associated virus‐siRNA to silence either NOX2 or NOX4 attenuates Aldosterone/NaCl‐induced hypertension in mice
  1499. Relationship between Aldosterone and complement c1q tumor necrosis factor-related protein 1 in sleep apnea-related hypertension
  1500. … -ATPASE INHIBITION WITH SALT-SENSITIVITY OF BLOOD PRESSURE IN RESISTANT hypertension AND EFFECTS OF Aldosterone ANTAGONIST: 8A. 06
  1501. … injections of adeno‐associated virus‐siRNA to silence estrogen receptor β (ERβ) produces augmentation of Aldosterone/NaCl‐induced hypertension in female rats
  1502. … Acute Regulatory Protein (StAR) is Associated With Connective Tissue Growth Factor-Mediated Pulmonary Vascular Fibrosis in Pulmonary Arterial hypertension In …
  1503. … the Endothelin-B Receptor to Decrease Pulmonary Endothelial Nitric Oxide Levels and Promote Pulmonary Vascular Remodeling in Pulmonary Arterial hypertension
  1504. … Modification of Endothelin-B Receptor Cysteinyl Thiol (s) by Aldosterone Decreases Pulmonary Endothelial Nitric Oxide Levels in Pulmonary Arterial hypertension
  1505. … AND EXPRESSION OF ATRIAL NATRIURETIC PEPTIDE AND Aldosterone SYNTHASE GENE IN PATIENTS WITH ESSENTIAL hypertension
  1506. … SYSTEM WITH COMBINATIONS OF ALISKIREN AND AMLODIPINE, RAMIPRIL AND AMLODIPINE IN PATIENTS WITH ESSENTIAL hypertension
  1507. … ,“The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin hypertension and Elevated Aldosterone …
  1508. … -OXO-CORTISOL PRACTICALLY DIFFERENTIATE Aldosterone PRODUCING ADENOMA FROM BILATERAL HYPERPLASIA AND PRIMARY hypertension …
  1509. 1020 EFFECTS OF Aldosterone BLOCKADE ON LIPIDS, GLUCOSE AND VISCERAL FAT IN PATIENTS WITH ESSENTIAL hypertension
  1510. 9.11 Association between Plasma Aldosterone, Metabolic Syndrome and Left Ventricular Mass in Essential hypertension
  1511. … IN ANGIOTENSIN II RECEPTOR GENES WITH POSTOPERATIVE hypertension RISK FOR Aldosterone PRODUCING ADENOMA PATIENTS
  1512. … HIGH Aldosterone-RENIN RATIO (ARR) IS ASSOCIATED WITH THE DEVELOPMENT OF ESSENTIAL hypertension FROM WHITE COAT hypertension
  1513. 1c. 12: Dietary salt intake and Aldosterone-related organ damage in hypertension
  1514. … patients with uncomplicated hypertension/EY Choi, JW Ha, SJ Yoon [et al.]//Am. Soc. Echocardiogr.–2008.–Vol. 21, N 3.–P. 251–256. 19. Jonar S. Aldosterone …
  1515. … OF DNA POLYMORPHISMS WITHIN CYP11B2/CYP11B1 LOCUS AND POSTOPERATIVE hypertension RISK IN THE PATIENTS WITH Aldosterone …
  1516. … D AND PARATHYROID HORMONE WITH AMBULATORY hypertension AND THEIR INTERACTIONS WITH SERUM Aldosterone AND SALT INTAKE
  1517. Lipocalin‐2 Deficiency Protects against Aldosterone‐Induced hypertension and Organ Damages by Inhibiting Mineralocorticoid Receptor Signaling
  1518. 2 Renin-angiotensin-Aldosterone profiles predictive of superimposed preeclampsia: Chronic hypertension
  1519. … LAND: CLINICAL STUDIES IN PULMONARY hypertension: Galectin-3 And Aldosterone As Potential Tandem Biomarkers In Pulmonary Arterial hypertension
  1520. PP. LB01. 20: PROSPECTIVE ASSESSMENT OF THE DIRECT RENIN AND Aldosterone ASSAY IN THE WORK-UP OF ARTERIAL hypertension
  1521. … -47 EFFECTS OF RENIN-ANGIOTENSIN-Aldosterone SYSTEM BLOCKADE MEDICATIONS ON COGNITION FUNCTION IN hypertension: HEAD-TO-HEAD …
  1522. MicroRNA‐21 Overexpression Attenuates Aldosterone‐Mediated Cardiac Injury and hypertension
  1523. LBOS 02-01 hypertension, Aldosterone AND EPC-MEDIATED ENDOTHALIAL INJURY REPAIR
  1524. … CARDIOVASCULAR REMODELING EFFECTS OF Aldosterone: INSIGHTS FROM GITELMAN SYNDROME, A HUMAN MODEL OPPOSITE TO hypertension
  1525. … 17-38 CORRELATION OF Aldosterone-RENIN RATIO AND NIGHTTIME BLOOD PRESSURE AND TARGET ORGAN DAMAGE IN ESSENTIAL hypertension
  1526. A3401 A case report of a 33-year-old man with resistant hypertension and slightly elevated cortisol and Aldosterone
  1527. Effects of Lysine-specific Demethylase 1 Deficiency on Aldosterone Production and Salt-sensitive hypertension in Female Mice
  1528. … OF GALECTIN-3 AND Aldosterone ON DIFFERENT CLINICAL CHARACTERISTICS IN MALE AND FEMALE PATIENTS WITH ARTERIAL hypertension.
  1529. 301 ADIPONECTIN AND Aldosterone LEVELS IS ASSOCIATED WITH ARTERIAL STIFFNESS IN RESISTANT hypertension
  1530. [PP. 17.24] THE RESPONSE OF PLASMA Aldosterone TO SALINE INFUSION IS UNDER THE INFLUENCE OF AGE IN PRIMARY hypertension
  1531. … PLASMA RENIN ACTIVITY, PLASMA Aldosterone AND SELECTED ASYMPTOMATIC ORGAN DAMAGE INDICES IN ESSENTIAL ARTERIAL hypertension
  1532. … activation induces the expression of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in dendritic cells in vitro and during the Aldosterone-dependent hypertension
  1533. … The renin–angiotensin–Aldosterone system and superimposed pre-eclampsia in women with chronic kidney disease and chronic hypertension: Chronic hypertension
  1534. Intracerebroventricular injections of adeno‐associated virus‐siRNA gene to silence angiotensin type 1 receptors (AT1) prevent Aldosterone‐induced hypertension
  1535. PS-82 GENDER FEATURES OF THE RENIN-ANGIOTENSIN-Aldosterone SYSTEM (RAAS) IN PATIENTS WITH ARTERIAL hypertension IN UZBEKISTAN.
  1536. 32 Premature vascular ageing in hypertension: role of Aldosterone and nadph oxidases
  1537. … aldosteronism in the COAR and SIE cohorts. To compare the numbers of patients who showed positive hormonal results or had hypertension between the COAR and …
  1538. PP. 32.15: POST-SALINE LOAD PLASMA Aldosterone LEVEL IS A DETERMINANT OF LEFT VENTRICULAR MASS IN ESSENTIAL hypertension
  1539. Deficiency of the T‐type Calcium Channel Cav 3.1 attenuates Plasma Aldosterone and Cardiac Hypertrophy despite similar Ang II‐induced hypertension
  1540. 1091 CLOCK GENE, Aldosterone AND hypertension
  1541. PS 17-65 THE C344T GENE POLYMORPHISM OF Aldosterone SYNTHASE IS RISK FACTOR OF EARLY RENAL DAMAGE IN hypertension IN A CHINESE …
  1542. Kir5. 1‐Mediated Changes in Renin‐Angiotensin‐Aldosterone System Balance in Salt Sensitive hypertension
  1543. Galectin-3 And Aldosterone As Potential Tandem Biomarkers In Pulmonary Arterial hypertension
  1544. 6.9 Plasma Aldosterone and Albumin Urinary Excretion in hypertension
  1545. … :[PP. 04.11] RELATIONSHIP BETWEEN PLASMA Aldosterone LEVELS AND LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN ESSENTIAL hypertension
  1546. MPS 14-03 Effects of Azilsartan medoxomil compared to other angiotensin II receptor blocker on plasma Aldosterone levels in patients with essential hypertension
  1547. 9B. 07: EFFECT OF POSTURAL CHANGES ON Aldosterone TO PLASMA RENIN RATIO IN PATIENTS WITH SUSPECTED SECONDARY hypertension
  1548. … OF THE RENIN ANGIOTENSIN Aldosterone SYSTEM AND ITS IMPACT ON KIDNEY OXIDATIVE STRESS, RENAL FUNCTION AND hypertension IN …
  1549. … IMPROVE ENDOTHELIAL GLYCOCALYX AND PWV AFTER 1 YEAR SUCCESSFUL TREATMENT IN UNTREATED PATIENTS WITH ESSENTIAL hypertension
  1550. GPER is involved in the stimulatory effects of Aldosterone in breast cancer cells and breast tumor-derived endothelial cells
  1551. Aldosterone mediates metastatic spread of renal cancer via the G protein‐coupled estrogen receptor (GPER)
  1552. Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/Aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks
  1553. Renin-angiotensin-Aldosterone system-based antihypertensive agents and the risk of colorectal cancer among medicare beneficiaries
  1554. Primary hyperparathyroidism associatiated with Aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene
  1555. Resistance to antihypertensive drugs targeting Renin-Angiotensin-Aldosterone-System in cancer patients: a case series
  1556. Aldosterone-and cortisol-cosecreting adrenal adenoma, ovarian hyperthecosis and breast cancer
  1557. Urinary excretion of components of the renin-angiotensin-Aldosterone system in patients having localized renal cancer.
  1558. RETRACTED: Relationship Between Aldosterone Synthase CYP1A1 MspI Gene Polymorphism and Prostate Cancer Risk
  1559. Drugs affecting renin-angiotensin-Aldosterone system and the cancer risk: A meta-analysis of nested case-control studies.
  1560. Cancer progression in COVID-19: integrating the roles of renin angiotensin Aldosterone system, angiopoietin-2, heat shock protein-27 and epithelial …
  1561. … use of renin-angiotensin-Aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional …
  1562. Aldosterone-Producing Adrenal Cortical Cancer
  1563. Effect of Aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines
  1564. Aldosterone mediates a mineralocorticoid receptor‐mediated increase in prostate cancer cell migration
  1565. Resistance to Antihypertensive Drugs Targeting Renin Angiotensin Aldosterone System in Cancer patients: A Case Series
  1566. Treatment-related Aldosterone changes in cancer of the middle part of the larynx
  1567. Blood-ACTH, cortisole and Aldosterone levels following complex radiation treatment for cancer of the uterine cervix
  1568. Regulation of mineralocorticoid receptor and its downstream targets by estrogen and Aldosterone in breast cancer
  1569. The effect of combined radiotherapy on blood levels of ACTH, cortisol and Aldosterone in cervical cancer
  1570. … -10: Glucocorticoid and Aldosterone mimic progestin-induction of a therapy-resistant cytokeratin-5 positive cell population in estrogen receptor-positive breast cancer …
  1571. The Aldosterone Antagonist Spironolactone Improves Cardiac Function in Experimental Cancer Cachexia
  1572. Lower Aldosterone–renin ratio is a risk factor for total and cancer death in Japanese individuals: the Takahata study
  1573. The changes of serum cortisol and Aldosterone in patients with cancer of vestibular section of larynx after irradiation and with and without surgery
  1574. Levels of growth hormone, prolactin, cortisone, Aldosterone and insulin in the blood of patients with stomach cancer, before and after gastrectomy
  1575. Postoperative change of atrial natriuretic peptide and renin-angiotensin-Aldosterone system after pulmonary resection for lung cancer
  1576. … between SNPs in the renin-angiotensin-Aldosterone system and hypertension, obesity, and blood pressure-related dietary exposures regarding renal cell cancer risk
  1577. Enhanced Aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors
  1578. Relationship between visceral fat and plasma Aldosterone concentration in patients with primary aldosteronism
  1579. Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice
  1580. Periarterial fat from two human vascular beds is not a source of Aldosterone to promote vasoconstriction
  1581. Significant association of Aldosterone and liver fat among HIV-infected individuals with metabolic dysregulation
  1582. Increased Aldosterone among HIV-infected women with visceral fat accumulation
  1583. Role of potassium excretion and percent body fat on ethnic differences in plasma Aldosterone levels
  1584. Aldosterone levels in patients on haemodialysis: Relationship with body fat mass and adipocytokines
  1585. System renin-Aldosterone in fat tissue and other organ and tissues
  1586. The renin-angiotensin-Aldosterone system (RAAS)-new pathogenetic and therapeutic aspects Part. I. Prorenin and renin and its receptors, convertase 2 of angiotensin …
  1587. Aldosterone production by the mouse adrenal gland is compromised by a high fat diet and 11 [beta]-hydroxysteroid dehydrogenase type 1 deficiency
  1588. … and glucagon-like peptide-1 and 2 receptors expression in stable patients with multivessel coronary artery disease: an association with renin-angiotensin-Aldosterone …
  1589. Neuropeptide Y (NPY) receptor 2 deletion in adipocytes blunts fat‐derived Aldosterone production in female mice exposed to chronic stress
  1590. Primary aldosteronism
  1591. Clinical characteristics of primary aldosteronism from an analysis of 145 cases
  1592. High incidence of primary aldosteronism in 199 patients referred with hypertension.
  1593. Primary aldosteronism
  1594. Primary aldosteronism: diagnostic evaluation
  1595. Presidential address: part I. Painting background Part II. Primary aldosteronism, a new clinical syndrome
  1596. Primary aldosteronism: diagnosis, localization, and treatment
  1597. The changing clinical spectrum of primary aldosteronism
  1598. Factors influencing outcome of surgery for primary aldosteronism
  1599. Primary aldosteronism: diagnosis and treatment
  1600. Cardiovascular complications in patients with primary aldosteronism
  1601. High prevalence of primary aldosteronism in the Tayside hypertension clinic population
  1602. Primary aldosteronism, a new clinical entity
  1603. The diagnosis of primary aldosteronism and separation of two major subtypes
  1604. Reliability of screening methods for the diagnosis of primary aldosteronism
  1605. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism
  1606. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore
  1607. Potentially high prevalence of primary aldosteronism in a primary-care population
  1608. Further evaluation of saline infusion for the diagnosis of primary aldosteronism.
  1609. Suppression of plasma renin activity in primary aldosteronism: distinguishing primary from secondary aldosteronism in hypertensive disease
  1610. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism
  1611. Primary aldosteronism: update on diagnosis and treatment.
  1612. Remodeling of the left ventricle in primary aldosteronism due to Conn’s adenoma
  1613. Primary aldosteronism. Results of surgical treatment.
  1614. Clinical and pathological diversity of primary aldosteronism, including a new familial variety
  1615. Normokalemic primary aldosteronism: a detectable cause of curable essential hypertension
  1616. Primary aldosteronism: A common and curable form of hypertension.
  1617. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers.
  1618. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension
  1619. Outpatient screening tests for primary aldosteronism
  1620. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype
  1621. Hypokalemia in the hypertensive patient: with observations on the incidence of primary aldosteronism
  1622. Primary aldosteronism: hypertension with a genetic basis
  1623. Association of hypokalemia, aldosteronism, and renal cysts
  1624. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital
  1625. Primary aldosteronism: adrenal venous sampling
  1626. Single dose captopril as a diagnostic test for primary aldosteronism
  1627. Successful surgical treatment of a cat with primary aldosteronism
  1628. Plasma renin activity in primary aldosteronism: importance in differential diagnosis and in research of essential hypertension
  1629. Pheochromocytoma and primary aldosteronism: diagnostic approaches
  1630. Primary aldosteronism: learning from the study of familial varieties
  1631. Albuminuria in untreated patients with primary aldosteronism or essential hypertension.
  1632. Hemodynamic characteristics of primary aldosteronism
  1633. Calcium metabolism and parathyroid function in primary aldosteronism
  1634. Glucocorticoid-remediable aldosteronism
  1635. Primary aldosteronism. Issues in diagnosis and management.
  1636. Laparoscopic adrenalectomy for primary aldosteronism: a new operative method
  1637. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism
  1638. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism.
  1639. Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism?
  1640. Screening for primary aldosteronism with a logistic multivariate discriminant analysis*
  1641. Primary aldosteronism (Conn’s syndrome) in a cat; a case report and review of comparative aspects
  1642. The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism
  1643. Cloning and expression of a cDNA for human cytochrome P-450aldo as related to primary aldosteronism
  1644. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism
  1645. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism
  1646. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: Aldosterone response to dexamethasone and long polymerase chain reaction for …
  1647. Renal changes in primary aldosteronism
  1648. Success of surgery for primary aldosteronism judged by residual autonomous Aldosterone production
  1649. Correctable subsets of primary aldosteronism Primary adrenal hyperplasia and renin responsive adenoma
  1650. Adjustment of the osmostat in primary aldosteronism
  1651. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism?
  1652. CT in the diagnosis of primary aldosteronism: sensitivity in 29 patients.
  1653. Primary aldosteronism
  1654. Primary aldosteronism—some genetic, morphological, and biochemical aspects of subtypes
  1655. Aldosteronism and hypertension: primary aldosteronism versus hypertensive disease with secondary aldosteronism
  1656. Normotensive primary aldosteronism: report of a case
  1657. Circadian rhythm of plasma Aldosterone concentration in patients with primary aldosteronism
  1658. Therapeutic outcome of primary aldosteronism: adrenalectomy versus enucleation of Aldosterone-producing adenoma
  1659. Therapeutic effect of calcium channel blockade in primary aldosteronism
  1660. The syndrome of primary aldosteronism
  1661. Pathology of primary aldosteronism
  1662. Primary aldosteronism: Photoscanning of tumors after administration of 131I-19-iodocholesterol
  1663. Control of plasma Aldosterone in primary aldosteronism: distinction between adenoma and hyperplasia
  1664. Commentary on incidence of primary aldosteronism: current estimations based on objective data
  1665. Use of the saline infusion test to diagnose the cause of primary aldosteronism
  1666. Aldosteronism in Man: Some Clinical and Climatological Aspects Part I
  1667. Use of computed tomography in diagnosing the cause of primary aldosteronism
  1668. Laparoscopic adrenalectomy for primary aldosteronism: report of initial ten cases.
  1669. Glucocorticoid-remediable aldosteronism and pregnancy
  1670. Reassessment of the predictive value of the postural stimulation test in primary aldosteronism
  1671. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of Aldosterone …
  1672. Normokalemic Primary Aldosteronism: Its Masquerade as Essential hypertension
  1673. Primary aldosteronism: clinical staff conference at the National Institutes of Health
  1674. Left ventricular systolic function in primary aldosteronism and hypertension
  1675. Effect of ketanserin in primary aldosteronism.
  1676. Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism
  1677. Increased disorderliness and amplified basal and pulsatile Aldosterone secretion in patients with primary aldosteronism
  1678. Primary aldosteronism: clinical management
  1679. Evolution of the surgical management of primary aldosteronism.
  1680. Non-tumorous” primary” aldosteronism. I. Type relieved by glucocorticoid (glucocorticoid-remediable aldosteronism).
  1681. Is Aldosterone/renin ratio useful to screen a hypertensive population for primary aldosteronism?
  1682. Primary aldosteronism in pregnancy
  1683. Aldosteronism in man: some clinical and climatological aspects Part II
  1684. Primary reninism: hypertension, hyperreninemia, and secondary aldosteronism due to renin-producing juxtaglomerular cell tumors
  1685. Aldosteronism in hypertension: Spironolactone Response Test.
  1686. Primary aldosteronism with malignant hypertension
  1687. Diagnosis and treatment of primary aldosteronism
  1688. Primary aldosteronism in pregnancy
  1689. Primary aldosteronism presenting as myoglobinuric acute renal failure
  1690. Adrenalectomy in primary aldosteronism: a long-term follow-up study in 52 patients
  1691. Pregnancy and primary aldosteronism
  1692. The prediction of anatomical morphology of primary aldosteronism using serum 18-hydroxycorticosterone levels
  1693. Circadian rhythm and effect of posture on plasma Aldosterone concentration in primary aldosteronism
  1694. Primary aldosteronism due to adrenal hyperplasia: Occurrence in a boy aged 10 years
  1695. How common is primary aldosteronism? Is it the most frequent cause of curable hypertension?
  1696. Postoperative studies of adrenal function in primary aldosteronism
  1697. The regulation of Aldosterone secretion in primary aldosteronism
  1698. Diagnosis and surgical treatment of primary aldosteronism in pregnancy: a case report
  1699. Changes in the circadian rhythm of blood pressure in primary aldosteronism in response to dietary sodium restriction and adrenalectomy
  1700. Suppression of Aldosterone by cyproheptadine in idiopathic aldosteronism
  1701. Possibility of normokalaemic primary aldosteronism as reflected in the frequency of adrenal cortical adenomas
  1702. Evolution of primary aldosteronism as a highly specific clinical entity
  1703. Renal function in primary aldosteronism
  1704. An association of primary aldosteronism and adrenaline-secreting phaeochromocytoma.
  1705. Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis
  1706. Normotensive primary aldosteronism.
  1707. Left ventricular structural characteristics in unilateral renovascular hypertension and primary aldosteronism
  1708. Leptin levels are suppressed in primary aldosteronism
  1709. Diagnosis and localization in primary aldosteronism
  1710. Plasma renin activity in the diagnosis of primary aldosteronism: failure to distinguish primary aldosteronism from essential hypertension
  1711. Pseudohypo-aldosteronism and cholelithiasis: coincidence or pathogenetic correlation?
  1712. Primary aldosteronism
  1713. Impaired potassium-stimulated Aldosterone production: a possible explanation for normokalemic glucocorticoid-remediable aldosteronism
  1714. Studies on the expanded extracellular fluid and the responses to various stimuli in primary aldosteronism
  1715. Plasma levels of atrial natriuretic peptide in primary aldosteronism and essential hypertension
  1716. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism
  1717. Clinical implications of primary aldosteronism with resistant hypertension.
  1718. Spironolactone as a nonspecific treatment for primary aldosteronism
  1719. Secondary aldosteronism
  1720. Activation of Aldosterone secretion in primary aldosteronism
  1721. Normotensive primary aldosteronism
  1722. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension
  1723. Evaluation of diagnostic tests in the differential diagnosis of primary aldosteronism: unilateral adenoma versus bilateral micronodular hyperplasia
  1724. Useful parameters in the diagnosis of primary aldosteronism
  1725. Plasma Aldosterone response to ACTH in subtypes of primary aldosteronism
  1726. Primary aldosteronism.
  1727. Spironolactone-induced inhibition of Aldosterone biosynthesis in primary aldosteronism: morphological and functional studies
  1728. Primary aldosteronism: changing concepts in diagnosis and management
  1729. Primary aldosteronism due to unilateral adrenal hyperplasia
  1730. New insights into the medical management of primary aldosteronism.
  1731. Abnormalities of renal function and circulatory reflexes in primary aldosteronism
  1732. Paralytic myopathy–a leading clinical presentation for primary aldosteronism in Taiwan
  1733. Normotensive primary aldosteronism
  1734. The detection of adrenal tumors and hyperplasia in patients with primary aldosteronism: comparison of scintigraphy, CT, and MR imaging
  1735. High sodium sensitivity and glomerular hypertension/hyperfiltration in primary aldosteronism.
  1736. Idiopathic aldosteronism in pregnancy.
  1737. Intralymphocyte free magnesium in patients with primary aldosteronism: Aldosterone and lymphocyte magnesium homeostasis
  1738. Glucocorticoid-remediable aldosteronism
  1739. Scintigraphic localization of adrenal lesions in primary aldosteronism
  1740. Clinical evaluation of the captopril screening test for primary aldosteronism
  1741. Prevalence of extracranial carotid artery lesions at duplex in primary aldosteronism
  1742. Bilateral adrenal hyperplasia as a cause of primary aldosteronism with hypertension, hypokalemia and suppressed renin activity
  1743. Preoperative diagnosis of primary aldosteronism: Including a comparison of operative findings and preoperative tumor localization by adrenal phlebography
  1744. Circulating factor with ouabain-like immunoreactivity in patients with primary aldosteronism
  1745. Plasma Aldosterone-plasma renin activity ratio A simple test to identify patients with primary aldosteronism
  1746. Severe hypertension in primary aldosteronism and good response to surgery
  1747. Primary aldosteronism: pathophysiology, diagnosis and treatment
  1748. Selection of patients and operative approach in primary aldosteronism.
  1749. Primary aldosteronism: a new understanding
  1750. Identification and differentiation of surgically correctable hypertension due to primary aldosteronism
  1751. Adrenalectomy in primary aldosteronism: a long-term follow-up study
  1752. Primary aldosteronism: experience with current diagnostic criteria and surgical treatment in fourteen patients.
  1753. Similarity of idiopathic aldosteronism and essential hypertension. A statistical comparison.
  1754. Diagnosis of primary aldosteronism
  1755. IN VIVO AND IN VITRO STUDIES OF ADRENAL SECRETIONS IN CUSHING’S SYNDROME AND PRIMARY ALDOSTERONISM
  1756. A Kindred with Familial Glucocorticoid–Suppressible Aldosteronism
  1757. The blood pressure response to unilateral adrenalectomy in primary aldosteronism
  1758. Laparoscopic adrenalectomy for Cushing’s syndrome: comparison with primary aldosteronism.
  1759. Identifying the adrenal lesion in primary aldosteronism
  1760. Primary aldosteronism
  1761. Primary aldosteronism: implications of a new familial variety
  1762. Primary aldosteronism as a cause of severe postpartum hypertension in two women
  1763. Hormone and blood pressure relationships in primary aldosteronism
  1764. Aldosterone: review of its physiology and diagnostic aspects of primary aldosteronism
  1765. Adrenalectomy for primary aldosteronism: long-term follow-up study in 29 patients
  1766. Familial forms broaden the horizons for primary aldosteronism
  1767. Myopathy and primary aldosteronism: electronmicroscopic study
  1768. Primary aldosteronism: how hard should we look?
  1769. Primary aldosteronism with unusual secretory pattern
  1770. Primary aldosteronism in a hypertensive acromegalic patient
  1771. Primary aldosteronism and its variants
  1772. Primary aldosteronism in a 9-year-old child
  1773. Primary aldosteronism: a review of medical literature from 1955 to June 1958
  1774. Coexistence of aldosteronoma and contralateral nonfunctioning adrenal adenoma in primary aldosteronism
  1775. Primary aldosteronism: preoperative tumor visualization by scintillation scanning
  1776. Physiologic and surgical problems in the management of primary aldosteronism
  1777. Normalization of high plasma level of ouabain-like immunoreactivity in primary aldosteronism after removal of adenoma.
  1778. Primary Aldosteronism Diagnosis and Surgical Treatment
  1779. Pregnancy complicated by primary aldosteronism.
  1780. Adrenal arteriography and venography in primary aldosteronism
  1781. Low Renin Essential hypertension: A Variant of Classic Primary Aldosteronism?
  1782. Acute effects of intravenous sodium chloride load on calcium metabolism and on parathyroid function in patients with primary aldosteronism compared with subjects …
  1783. Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and Aldosterone in primary aldosteronism
  1784. Observations on a case of primary aldosteronism
  1785. Primary aldosteronism: an endocrine perspective.
  1786. Acute and chronic effect of nifedipine in primary aldosteronism
  1787. Triamterene‐thiazide combination: Alternative therapy for primary aldosteronism
  1788. Laparoscopic adrenalectomy for primary aldosteronism
  1789. Evidence of exercise-induced myocardial ischemia in patients with primary aldosteronism: The Cross-Sectional Primary Aldosteronism and Heart Italian Multicenter …
  1790. Hypokalemic myopathy associated with primary aldosteronism and glycyrrhizine-induced pseudoaldosteronism
  1791. Isolated clinical syndrome of primary aldosteronism in a patient with adrenocortical carcinoma
  1792. Stimulation and suppression of Aldosterone in plasma of normal man and in primary aldosteronism
  1793. Primary adrenocortical carcinoma causing aldosteronism
  1794. Plasma adrenomedullin in patients with primary aldosteronism
  1795. Differential diagnosis in primary aldosteronism
  1796. Selective hypoaldosteronism despite prolonged pre-and postoperative hyperreninemia in primary aldosteronism
  1797. Primary aldosteronism: A study in contrasts
  1798. Myocardial scintigraphic characteristics in patients with primary aldosteronism.
  1799. Primary Aldosteronism due to Unilateral Adrenal Hyperplasia Report of Two Cases and Review of the Literature
  1800. Postoperative transient aldosteronism
  1801. Intra-adrenal hemorrhage as a complication of adrenal venography in primary aldosteronism
  1802. Plasma renin activity and blood volume in uncontrolled diabetes: ketoacidosis, a state of secondary aldosteronism
  1803. Long-term results of surgical and conservative treatment of patients with primary aldosteronism
  1804. Variation of phenotype in patients with glucocorticoid remediable aldosteronism.
  1805. Primary aldosteronism
  1806. Primary aldosteronism is comprised of primary adrenal hyperplasia and adenoma.
  1807. Malignant hypertension in association with primary aldosteronism
  1808. Primary aldosteronism: report of a case and discussion of the pathogenesis
  1809. Primary aldosteronism: experience with thirty-eight patients
  1810. Laparoscopic adrenalectomy in patients with primary aldosteronism.
  1811. Primary aldosteronism: difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands
  1812. Impaired baroreflex function and arterial compliance in primary aldosteronism
  1813. Primary aldosteronism
  1814. Primary aldosteronism due to an adrenal carcinoma
  1815. A preliminary evaluation for primary aldosteronism
  1816. Is single oral administration of captopril beneficial in screening for primary aldosteronism?
  1817. Clinical implications of renal cyst in primary aldosteronism
  1818. Primary aldosteronism
  1819. Surgical management of primary aldosteronism
  1820. Isolated clinical syndrome of primary aldosteronism in four patients with adrenocortical carcinoma
  1821. Aldosterone to renin ratios in the evaluation of primary aldosteronism.
  1822. Glucocorticoid-suppressible aldosteronism: a disorder of the adrenal transitional zone
  1823. Preoperative lateralisation of Aldosterone-producing tumours in primary aldosteronism
  1824. Evaluation of plasma Aldosterone to plasma renin activity ratio in patients with primary aldosteronism
  1825. Asymptomatic normotensive primary aldosteronism. Case report.
  1826. Plasma β-endorphin levels in primary aldosteronism
  1827. In primary aldosteronism the circadian blood pressure rhythm is similar to that in primary hypertension
  1828. Primary aldosteronism: diagnosis and noninvasive lateralization procedures
  1829. Some Aldosterone-producing adrenal tumours also secrete cortisol, but present clinically as primary aldosteronism.
  1830. A case of primary aldosteronism with chronic renal failure undergoing hemodialysis treatment
  1831. Primary aldosteronism: treatment with trilostane
  1832. Plasma levels of atrial natriuretic peptide in man in primary aldosteronism, in Gordon’s syndrome and in Bartter’s syndrome.
  1833. Nature of renal escape from the sodium-retaining effect of Aldosterone in primary aldosteronism and in normal subjects
  1834. Genetics of primary aldosteronism
  1835. Intermittent aldosteronism in periodic paralysis: Dependence of attacks on retention of sodium, and failure to induce attacks by restriction of dietary sodium
  1836. Primary aldosteronism in pregnancy—should it be treated surgically?
  1837. Primary aldosteronism with suppressed plasma renin activity due to bilateral nodular adrenocortical hyperplasia
  1838. Synthesis and separation of 18β-glycyrrhetyl monoglucuronide from serum of a patient with glycyrrhizin-induced pseudo-aldosteronism
  1839. The Salivary Sodium-Potassium Ratio: A Useful Screening Test for Aldosteronism in Hypertensive Subjects
  1840. PRIMARY ALDOSTERONISM: OBSERVATIONS IN SIX CASES AND REVIEW OF DIAGNOSTIC PROCEDURES: 1
  1841. Primary aldosteronism.
  1842. Erythrocytosis and primary aldosteronism
  1843. Malignant hypertension in a patient with primary aldosteronism with elevated active renin concentration
  1844. Episodic secretion of Aldosterone in primary aldosteronism: relationship to cortisol
  1845. The sympathetic nervous system and hypertension in primary aldosteronism.
  1846. Primary aldosteronism
  1847. Plasma renin activity and Aldosterone secretion in a pregnant woman with primary aldosteronism
  1848. … human adrenal medulla and its messenger ribonucleic acid expression along with that of atrial natriuretic peptide are enhanced in patients with primary aldosteronism
  1849. Urinary kallikrein excretion and plasma renin activity in patients with essential hypertension and primary aldosteronism
  1850. The dexamethasone-modified adrenal scintiscan in hyporeninemic aldosteronism (tumor versus hyperplasia). A comparison with adrenal venography and adrenal …
  1851. Primary aldosteronism: diagnosis and differentiation of subtypes
  1852. Aldosterone synthase cytochrome P-450 expressed in the adrenals of patients with primary aldosteronism
  1853. Circadian rhythm of blood pressure in primary aldosteronism and renovascular hypertension: analysis by the cosinor method
  1854. A Case of Normotensive Primary Aldosteronism Comparison with 13 Previously Experienced Cases with hypertension
  1855. Aldosteronism and precocious puberty due to an ovarian androblastoma (Sertoli cell tumor)
  1856. Submaxillary potassium concentration in true and pseudoprimary aldosteronism
  1857. Primary aldosteronism
  1858. Glucocorticoid-remediable aldosteronism.
  1859. Hyperplasia of the juxtaglomerular complex with secondary aldosteronism without hypertension (Bartter’s syndrome)
  1860. Case studies of siblings with juxtaglomerular hyperplasia and secondary aldosteronism associated with severe azotemia and renal rickets—Bartter’s syndrome or …
  1861. Primary aldosteronism: its diagnosis and surgical management
  1862. The management of patients with primary aldosteronism
  1863. Primary aldosteronism in a patient with familial adenomatous polyposis
  1864. Left ventricular anatomy and function in primary aldosteronism and renovascular hypertension
  1865. Primary aldosteronism with cortisol overproduction from bilateral multiple adrenal adenomas
  1866. Primary aldosteronism aggravated during peripartum period
  1867. Primary aldosteronism detected after renal transplantation
  1868. Diagnosis of an Aldosterone-producing adenoma in primary aldosteronism: an evaluative maneuver
  1869. DOCA test for aldosteronism: its usefulness and implications.
  1870. Aldosterone regulation in primary aldosteronism: differences between adenoma and bilateral hyperplasia
  1871. Differential response to thiazides and spironolactone in primary aldosteronism
  1872. Laparoscopic adrenalectomy for primary aldosteronism: clinical experience in 12 patients.
  1873. Are calcium antagonists helpful in the management of primary aldosteronism?
  1874. Free and conjugated dopamine in pheochromocytoma, primary aldosteronism and essential hypertension.
  1875. The Gordon Wilson Lecture. Some Clinical and Climatological Aspects of Aldosteronism in Man
  1876. Pre-operative evaluation of the prognosis of hypertension in primary aldosteronism owing to adenoma
  1877. Observations on a presumptive case of primary aldosteronism
  1878. Unilateral adrenal hyperplasia as a cause of primary aldosteronism.
  1879. Elevated urinary excretion of 18-oxocortisol in glucocorticoid-suppressible aldosteronism
  1880. Hormonal characteristics of primary aldosteronism due to unilateral adrenal hyperplasia
  1881. Spectral characteristics of heart rate and blood pressure variability in primary aldosteronism
  1882. Occurrence of primary aldosteronism in a group of ambulatory hypertensive patients
  1883. Screening for primary aldosteronism
  1884. Glucocorticoid-remediable aldosteronism
  1885. Primary aldosteronism: new approaches to diagnosis and management.
  1886. Medical treatment of low-renin aldosteronism
  1887. Primary aldosteronism and primary reninism
  1888. The evolution of primary aldosteronism from 1954 to 1960
  1889. hypertension due to renal artery occlusion simulating primary aldosteronism
  1890. The relationship of adrenal gland iodomethylnorcholesterol uptake to zona glomerulosa function in primary aldosteronism
  1891. Studies of impaired Aldosterone response to spironolactone-induced renin and potassium elevations in adenomatous but not hyperplastic primary aldosteronism.
  1892. Primary aldosteronism with uncommon complications.
  1893. Diagnosis and treatment of primary aldosteronism
  1894. Adrenal transitional zone steroids, 18‐oxo and 18‐hydroxycortisol, useful in the diagnosis of primary aldosteronism, are ACTH‐dependent
  1895. Primary aldosteronism and malignant adrenocortical neoplasia.
  1896. Surgical treatment of primary aldosteronism.
  1897. Thyrotoxic periodic paralysis complicated with primary aldosteronism
  1898. Reduced Aldosterone secretion during spironolactone treatment in primary aldosteronism: report of a case
  1899. A case of normoreninemic, normotensive primary aldosteronism associated with essential hypertension and nephrocalcinosis
  1900. Adrenomedullin levels are high in primary aldosteronism due to adenoma and decline after surgical cure
  1901. Effects of sodium intake on the captopril test for primary aldosteronism
  1902. Primary aldosteronism: A case with severe hypertension
  1903. Endoscopic adrenalectomy by retroperitoneal approach for primary aldosteronism
  1904. Lateralization procedures in primary aldosteronism
  1905. Primary aldosteronism
  1906. Primary aldosteronism: preoperative preparation with spironolactone
  1907. The significance of elevated levels of plasma 18-hydroxycorticosterone in patients with primary aldosteronism
  1908. Relationship between postoperative blood pressure change and renal pathophysiology in primary aldosteronism
  1909. Endothelin stimulates Aldosterone secretion in vitro from normal adrenocortical tissue, but not adenoma tissue, in primary aldosteronism
  1910. … -secreting adenomas: a prospective comparison of computed tomography and magnetic resonance imaging in 27 patients with suspected primary aldosteronism.
  1911. Coronary artery aneurysms, aortic dissection, and hypertension secondary to primary aldosteronism: A rare triad: A case report
  1912. Functional black adenoma of the adrenal cortex: a rare cause of primary aldosteronism
  1913. Comparison of five modalities in localization of primary aldosteronism.
  1914. Primary aldosteronism with Aldosterone-producing adrenal adenoma in a pregnant woman
  1915. Incidence of suppressed renin activity and of normokalemic primary aldosteronism in hypertensive negro patients
  1916. Screening for surgically correctable hypertension caused by primary aldosteronism
  1917. Elevation of plasma renin activity during pregnancy and rupture of a dissecting aortic aneurysm in a patient with primary aldosteronism
  1918. Primary aldosteronism associated with chronic renal failure
  1919. Urinary free Aldosterone in healthy people and in patients with primary aldosteronism
  1920. Primary aldosteronism and its importance to the anaesthetist.
  1921. Solving the adrenal lesion (s) of primary aldosteronism
  1922. Calcium channel blockade with nifedipine in primary aldosteronism
  1923. Aldosteronism in pregnancy: association with virilization of female offspring.
  1924. Pseudoprimary aldosteronism from the topical application of 9-alpha-fluorprednisolone to the skin.
  1925. Dietary sodium change in primary aldosteronism. Atrial natriuretic factor, hormonal, and vascular responses.
  1926. Primary aldosteronism and its relationship to diabetes mellitus
  1927. Primary aldosteronism: inability to differentiate unilateral from bilateral adrenal lesions by various routine clinical and laboratory data and by peripheral plasma …
  1928. Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism
  1929. Aldosteronism
  1930. Existence of a slowly exchangeable pool of body sodium in normal subjects and its diminution in patients with primary aldosteronism
  1931. Adrenal steroid responses to ACTH in glucocorticoid-suppressible aldosteronism.
  1932. Effect of saline infusions on Aldosterone secretion and electrolyte excretion in normal subjects and patients with primary aldosteronism
  1933. Preoperative tumor localization by adrenal venography in patients with primary aldosteronism: a comparison with operative findings
  1934. Primary aldosteronism due to a malignant ovarian tumour
  1935. Coexisting renal artery stenosis and primary aldosteronism.
  1936. Primary aldosteronism: review of the anaesthetic experience in sixty patients
  1937. Prominent peripheral edema associated with primary aldosteronism due to an adrenocortical adenoma
  1938. Association of accelerated (malignant) hypertension in a patient with primary aldosteronism
  1939. Multiple plasma steroid responses to graded ACTH infusions in patients with primary aldosteronism
  1940. Problems related to aldosteronism during cesarean section
  1941. High Plasma Renin Activities in Primary Aldosteronism with Malignant hypertension A Case Report
  1942. … of sodium-retaining steroids by the zona glomerulosa is adrenocorticotropin-dependent and mediates hypertension in dexamethasone-suppressible aldosteronism
  1943. Surgical treatment of aldosteronism: Combined experiences at the Massachusetts Memorial and the Peter Bent Brigham Hospitals
  1944. The usefulness of the captopril test as a simultaneous screening for primary aldosteronism and renovascular hypertension
  1945. Adrenal adenomata causing primary aldosteronism
  1946. Concurrence of primary aldosteronism and renal artery stenosis.
  1947. Heterotopic adrenocortical adenoma producing primary aldosteronism
  1948. Primary aldosteronism
  1949. In vitro studies in primary aldosteronism
  1950. Primary aldosteronism in general practice
  1951. Effect of spironolactone on urinary kallikrein excretion in patients with essential hypertension and in primary aldosteronism
  1952. Primary aldosteronism: Study of twenty-six operated cases
  1953. Idiopathic aldosteronism masquerading as discrete Aldosterone-secreting adrenal cortical neoplasms among patients with primary aldosteronism
  1954. Primary aldosteronism: computerized tomography in preoperative evaluation.
  1955. PRODUCTION OF 18‐OXO‐CORTISOL IN SUBTYPES OF PRIMARY ALDOSTERONISM
  1956. Primary aldosteronism: the etiologic spectrum of disorders and their clinical differentiation
  1957. A case of secondary aldosteronism induced by pheochromocytoma
  1958. Non-tumorous” primary” aldosteronism: II. Type not relieved by glucocorticoid.
  1959. Autosomal dominant polycystic kidney disease complicated by primary aldosteronism
  1960. Aldosteronism and arterial hypertension
  1961. Changes in salivary electrolytes following treatment of primary aldosteronism
  1962. Improvement of growth hormone response to stimulation in primary aldosteronism with correction of potassium deficiency
  1963. The syndrome of hypertension, hyperreninemia and secondary aldosteronism associated with renal juxtaglomerular cell tumor (primary reninism)
  1964. Childhood primary aldosteronism due to an adrenal adenoma: Preoperative localization by adrenal vein catheterization
  1965. Surgical treatment of hypertension—primary aldosteronism: a review of 13 cases
  1966. Mechanism of impaired urinary concentrating ability in normokalemic primary aldosteronism.
  1967. A study of the juxtaglomerular body in primary aldosteronism
  1968. Normal sympathetic vasomotor and cardiac parasympathetic activities in patients with primary aldosteronism: assessment by spectral analysis
  1969. Primary aldosteronism with bilateral adrenal adenomas
  1970. Management of primary aldosteronism: evaluation of potassium and sodium balance, technic of adrenalectomy and operative results in 24 cases.
  1971. Absorption and secretion of water and electrolytes by the intact colon in a patient with primary aldosteronism.
  1972. The effect of tyramine, noradrenaline, and angiotensin on the blood pressure in hypertensive patients with aldosteronism and low plasma renin
  1973. Increased gain in baroreceptor-heart rate reflex in patients with primary aldosteronism.
  1974. Efficacy of iodine-131 6β-methyl-iodo-19-norcholesterol scintigraphy and computed tomography in patients with primary aldosteronism
  1975. Aldosteronism updated
  1976. Renal kininases in primary aldosteronism.
  1977. Aldosterone regulation in primary aldosteronism: influence of salt balance, posture and ACTH
  1978. Time-related changes in plasma adrenal steroids during treatment with spironolactone in primary aldosteronism
  1979. Primary aldosteronism
  1980. Effect of a spirolactone on plasma and urinary Aldosterone in primary aldosteronism
  1981. Outpatient screening procedures for primary aldosteronism
  1982. … prolactin stimulation of Aldosterone in normal human subjects and patients with primary aldosteronism, including a patient with primary aldosteronism and a prolactin …
  1983. Primary aldosteronism with normal Aldosterone levels in blood and urine
  1984. Exaggerated natriuresis in primary aldosteronism.
  1985. Bilateral adrenal tumours in primary aldosteronism: localization of a unilateral aldosteronoma by dexamethasone suppression scan
  1986. Primary aldosteronism treated by trilostane (3, β-hydroxysteroid dehydrogenase inhibitor)
  1987. Primary Aldosteronism: A Follow‐up Study of 28 Cases of Surgically Treated Aldosterone‐producing Adenomas
  1988. Study on uric acid metabolism in patients with primary aldosteronism
  1989. Primary aldosteronism: remission and development of adrenal insufficiency after adrenal venography
  1990. ACTH-dependent Aldosterone excess due to adrenocortical adenoma: a variant of primary aldosteronism
  1991. Steroid hormone production in a case of Cushing’s syndrome with electrolyte changes simulating primary aldosteronism
  1992. Clinical implications of postoperative transient aldosteronism
  1993. Adrenal scintigraphy in primary aldosteronism. Spironolactone as a cause of incorrect classification between adenoma and hyperplasia
  1994. Simple screening procedure for the diagnosis of primary aldosteronism
  1995. Adrenal scintigraphy in primary aldosteronism
  1996. Abolished nocturnal blood pressure fall in a boy with glucocorticoid-remediable aldosteronism
  1997. Primary aldosteronism due to bilateral nodular hyperplasia: CT demonstration.
  1998. Normotensive primary aldosteronism due to adrenocortical carcinoma
  1999. A syndrome resembling primary aldosteronism (Conn syndrome) in untreated HIV disease
  2000. Primary aldosteronism due to adrenal cortical carcinoma
  2001. Aldosterone-producing adenomas do not contain glucocorticoid-remediable aldosteronism chimeric gene duplications
  2002. Usefulness of atrial natriuretic peptide assay in primary aldosteronism
  2003. Decreased blood pressure variability at rest in patients with primary aldosteronism
  2004. Action of antidiuretic hormone in potassium-depleted rats; relation to aldosteronism
  2005. Pheochromocytoma and primary aldosteronism
  2006. Sodium transport parameters in erythrocytes of patients with primary aldosteronism.
  2007. Does prolonged pretreatment with large doses of spironolactone hasten a recovery from juxtaglomerular-adrenal suppression in primary aldosteronism?
  2008. Plasma renin in primary aldosteronism
  2009. Hyper‐responsiveness of Aldosterone to metoclopramide in aldosteronism
  2010. Estimation of the intrarenal hemodynamics in patients with primary aldosteronism
  2011. Primary aldosteronism with diabetes mellitus
  2012. The electrocardiogram and potassium metabolism: electrocardiographic abnormalities in primary aldosteronism and familial periodic paralysis
  2013. Dopaminergic regulation of Aldosterone secretion: its pathophysiologic significance in subsets of primary aldosteronism
  2014. Childhood primary aldosteronism with bilateral adrenocortical hyperplasia: Plasma renin activity as an aid to diagnosis
  2015. Primary aldosteronism due to adrenal carcinomas
  2016. Unilateral hypersecretion of Aldosterone associated with adrenal hyperplasia as a cause of primary aldosteronism
  2017. Idiopathic aldosteronism: a possible disease of the intermediate lobe of the pituitary
  2018. Screening for aldosteronism
  2019. Primary aldosteronism CT, MRI, scintigraphic correlation
  2020. Regulation of Aldosterone secretion in primary aldosteronism
  2021. Role of atrial natriuretic peptide in mineralocorticoid escape phenomenon in patients with primary aldosteronism
  2022. Therapeutic results of primary aldosteronism with special reference to renal or renovascular lesions
  2023. Increased Na+-H+ Exchange in Red Blood Cells of Patients With Primary Aldosteronism
  2024. The absence of long-term therapeutic effect of calcium channel blockade in the primary aldosteronism of adrenal adenomas
  2025. Primary Aldosteronism with Ipsilateral Adrenal Cyst Report of a Case
  2026. Adrenal vein epinephrine levels: a useful aid in venous sampling for primary aldosteronism
  2027. Glucocorticoid-remediable aldosteronism
  2028. Are plasma Aldosterone surges in primary aldosteronism due to a loss of an inhibitory dopaminergic control?
  2029. Fludrocortisone suppression test in normal subjects, in patients with essential hypertension and in patients with various forms of aldosteronism
  2030. Primary aldosteronism associated with a primary double cancer of the thyroid and rectum: report of a case
  2031. Effect of verapamil on Aldosterone secretion in primary aldosteronism
  2032. Experience with primary aldosteronism
  2033. Adrenal venous sampling analysis of primary aldosteronism: value of ACTH stimulation in the differentiation of adenoma and hyperplasia
  2034. Interference by spironolactone on adrenocortical scintigraphy and other pitfalls in the location of adrenal abnormalities in primary aldosteronism.
  2035. Primary aldosteronism caused by Aldosterone-producing adenoma in pregnancy–complicated by EPH gestosis.
  2036. Primary tumorous aldosteronism due to a black adrenal adenoma: a light and electron microscopic study.
  2037. Localization of Aldosterone‐producing tumours in primary aldosteronism by adrenal and renal vein catheterization
  2038. Hypokalemia, aldosteronism, and renal cysts
  2039. Pathophysiology and diagnosis of primary aldosteronism
  2040. Is aldosteronism important in the maintenance of arterial blood pressure and electrolyte balance during sodium depletion?
  2041. Effect of metoclopramide on plasma Aldosterone in normal subjects, primary aldosteronism and hypopituitarism
  2042. The effect of heparin on Aldosterone secretion and metabolism in primary aldosteronism (1)
  2043. Ultrastructural studies of adrenal adenoma causing primary aldosteronism
  2044. Parallel biochemical and histochemical studies of an adrenocortical adenoma from a patient with primary aldosteronism
  2045. A reappraisal of the diagnostic criteria for primary aldosteronism
  2046. Pseudoprimary Aldosteronism.
  2047. Increased adrenal medullary atrial natriuretic polypeptide synthesis in patients with primary aldosteronism.
  2048. Left ventricular myocardial structure and function in patients with primary aldosteronism
  2049. High resolution MRI of adrenal glands in patients with primary aldosteronism.
  2050. Captopril before and after spironolactone therapy in primary aldosteronism
  2051. Significance of renal kininases in patients with primary aldosteronism
  2052. Cardiovascular, renal and endocrine effects of alpha-human atrial natriuretic peptide in patients with Cushing’s syndrome and primary aldosteronism.
  2053. An easy diagnostic approach to primary aldosteronism
  2054. Potassium-losing nephritis and primary aldosteronism
  2055. Renin gene expression in the adrenal and kidney of patients with primary aldosteronism
  2056. Plasma atrial natriuretic peptide concentration in patients with primary aldosteronism
  2057. Lobular pattern of choriocapillaris in pre-eclampsia with aldosteronism.
  2058. Primary aldosteronism due to unilateral adrenal hyperplasia: a case report.
  2059. Adrenocortical adenoma with primary aldosteronism in culture
  2060. Erythrocyte Na+‐H+ exchanger and Na+‐Li+ countertransport activity in primary aldosteronism
  2061. Low dose atrial natriuretic factor in primary aldosteronism: renal, hemodynamic, and vascular effects.
  2062. Effects of Aldosterone on intralymphocytic sodium and potassium in patients with primary aldosteronism
  2063. Some observations on the mechanism of postoperative transient aldosteronism with special reference to early changes in serum electrolyte levels
  2064. Study of the predictive factors of postoperative blood pressure in cases with primary aldosteronism
  2065. Primary aldosteronism: a review of 8 cases
  2066. Postoperative improvement of hypertension in primary aldosteronism and Cushing’s syndrome
  2067. Aldosterone response to adrenocorticotrophin and furosemide in primary aldosteronism after prolonged spironolactone treatment
  2068. Dopaminergic regulation of Aldosterone secretion in primary aldosteronism: a clinical study
  2069. A case of normotensive primary aldosteronism with hypopituitarism, epilepsy, and medullary sponge kidney
  2070. Effect of α-human atrial natriuretic peptide in low renin essential hypertension and primary aldosteronism
  2071. Unusual renal function associated with saluresis accompanying water loading in a case of primary aldosteronism
  2072. Evaluation of the localizing procedures of primary aldosteronism
  2073. A novel low-activity form of carbonic anhydrase I in erythrocytes of patients with primary aldosteronism. Evidence for the presence of a mixed disulfide with glutathione.
  2074. A case of primary aldosteronism with renovascular hypertension
  2075. hypertension: when to suspect underlying pheochromocytoma or aldosteronism
  2076. Surgical management of primary aldosteronism (Conn’s syndrome), a correctable cause of hypertension
  2077. … article Oct 19, 1964: Suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. By …
  2078. Failure to visualize bilateral adrenal glands in a patient with primary aldosteronism
  2079. Metabolic and hormonal studies in a patient with primary aldosteronism, presenting with acute hypokalaemic paresis induced by chlorothiazide
  2080. Prognostic factors of primary aldosteronism.
  2081. Primary aldosteronism with bilateral multiple Aldosterone-producing adrenal adenomas
  2082. The adrenal cortex (excluding aldosteronism)
  2083. Aldosteronism
  2084. Single oral administration of captopril may not bring an improvement in screening of primary aldosteronism
  2085. Isolated primary aldosteronism in a patient with adrenal carcinoma and XY/XXY mosaic Klinefelter’s syndrome
  2086. Aldosterone regulation in primary aldosteronism
  2087. Primary aldosteronism caused by adrenal cortical carcinoma
  2088. Atrial Natriuretic Peptide Infusion in Primary Aldosteronism: Renal, Hemodynamic and Hormonal Effects
  2089. Primary aldosteronism by carcinoma of the adrenal cortex
  2090. Captopril Test in the Evaluation of Primary Aldosteronism.
  2091. Aldosteronism after severe trauma.
  2092. Effects of change in body posture on plasma and serum electrolytes in normal subjects and in primary aldosteronism
  2093. Renal and adrenal sparing surgery for patients with primary aldosteronism and primary reninoma
  2094. Variant forms of primary aldosteronism: reconsideration of the differential diagnosis and treatment
  2095. Primary aldosteronism: Observations on water and electrolyte changes during partial immersion
  2096. The kidney in endocrine hypertension: Cushing’s syndrome, pheochromocytoma, and aldosteronism
  2097. Evidence for a defect in urinary concentrating ability in primary aldosteronism and its reversal by adrenal surgery
  2098. Two uncommon causes of mineralocorticoid excess: syndrome of apparent mineralocorticoid excess and glucocorticoid-remediable aldosteronism
  2099. Use of amiloride in preoperative management of a patient with primary aldosteronism
  2100. Effect of spironolactone on urinary excretion of immunoreactive prostaglandin E in essential hypertension and primary aldosteronism
  2101. Manipulation by corticotropin and cortisol of Aldosterone secretion in primary aldosteronism
  2102. Localization of Aldosterone-producing adenoma: venous sampling in primary aldosteronism
  2103. Plasma renin activity in primary aldosteronism
  2104. Cytosolic free calcium concentration in platelets in patients with renovascular hypertension and primary aldosteronism.
  2105. Infusion of Chlorothiazide in a Patient With Primary Aldosteronism: Observations on Potassium Clearance
  2106. Primary Aldosteronism Associated with Acute Intermittent Porphyria: Report of a Case
  2107. Adrenal venography and sampling in the diagnosis and treatment of primary aldosteronism.
  2108. Abnormality of Aldosterone and cortisol late pathways in glucocorticoid-remediable aldosteronism
  2109. The syndrome of juxtaglomerular hyperplasia with aldosteronism, hypokalemic alkalosis and normal blood pressure.
  2110. … in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral …
  2111. The Diagnostic Implication of Restriction of Salt Intake and Adminitstration of Various Drugs in Primary Aldosteronism
  2112. Adrenal imaging with iodomethyl-norcholesterol (I-131) in primary aldosteronism.
  2113. Plasma ouabain-like activity in essential hypertensive patients and in subjects with primary aldosteronism.
  2114. Glucocorticoid-remediable aldosteronism.
  2115. Primary aldosteronism: diagnosis, surgical management, and report of two cases operated upon
  2116. Lack of Aldosterone inhibition by atrial natriuretic factor in primary aldosteronism: in vitro studies
  2117. Non-surgical therapy of primary aldosteronism: transcatheter arterial infusion of ethanol into an aldosteronoma
  2118. Renal dopaminergic activity in patients with primary aldosteronism
  2119. Ultrastructural types of cell in adrenal cortical adenoma with primary aldosteronism.
  2120. Hypokalemic alkalosis, hyperreninemia, aldosteronism, normal blood pressure and normal juxtaglomerular apparatus–a new syndrome of renal alkalosis.
  2121. Coexistence of Primary Aldosteronism and Pheochromocytoma in a Vietnamese Patient.
  2122. … of electrolyte excretion in normal and hypertensive subjects before and after saline infusions: a simple electrolyte formula for the diagnosis of primary aldosteronism
  2123. The effect of adrenal surgery on plasma atrial natriuretic factor and sodium escape phenomenon in patients with primary aldosteronism
  2124. Treatment of primary aldosteronism
  2125. Adrenal scintiscanning and aldosteronism
  2126. Spironolactone Prevents Na+/H+ Exchange Enhancement in Primary Aldosteronism
  2127. Nocturnal, daytime, and postural changes of plasma Aldosterone before and during dexamethasone in adenomatous and idiopathic aldosteronism
  2128. Secondary aldosteronism documented by plasma renin and Aldosterone circadian rhythm in subjects with kidney or heart transplantation
  2129. Renal electrolyte cycles and mechanism of nocturia in primary aldosteronism
  2130. Effect of naloxone on the adrenal cortex in primary aldosteronism
  2131. Effects of stilbestrol on the renal pressor system as modified by adrenalectomy and secondary aldosteronism
  2132. A simulation study on renin and Aldosterone secretions in primary aldosteronism.
  2133. Adrenocortical carcinoma manifesting pure primary aldosteronism: a case report and analysis of steroidogenic enzymes
  2134. Immunohistochemical localization of atrial natriuretic peptide in primary aldosteronism.
  2135. Primary aldosteronism: effects of inhibition of ACTH and potassium administration on plasma Aldosterone concentration
  2136. Isolated primary aldosteronism in adrenocortical carcinoma: a case report and review of literature
  2137. Influence of unilateral adrenalectomy on renin-angiotensin-Aldosterone system in primary aldosteronism
  2138. A case of bilateral adrenal cortical adenomas causing Cushing’s syndrome and primary aldosteronism
  2139. The molecular basis of a hereditary form of hypertension, glucocorticoid-remediable aldosteronism
  2140. A rare case of primary aldosteronism due to bilateral functioning adrenocortical adenomas
  2141. Anorexia nervosa, secondary aldosteronism and angiopathy
  2142. α-h-ANP injection in normals, low renin hypertension and primary aldosteronism
  2143. A new diagnostic test for primary aldosteronism
  2144. A case of primary aldosteronism presenting hypokalemic myopathy induced by benidipine hydrochloride; a dihydropyridine calcium channel blocker
  2145. Aldosteronism associated with adrenal cortical adenoma
  2146. Recurrence of hypertension in primary aldosteronism after discontinuation of spironolactone. Time course of changes in cardiac output and body fluid volumes
  2147. Primary aldosteronism
  2148. Adrenocortical carcinoma presenting as primary aldosteronism in a young man
  2149. Impaired vasopressin suppression and enhanced atrial natriuretic hormone release following an acute water load in primary aldosteronism
  2150. Increased plasma renin activity, secondary aldosteronism, and hypertension
  2151. A case of primary aldosteronism due to unilateral multiple adrenal adenomas
  2152. A probable relationship between an endogenous digitalis-like substance and concentric cardiac hypertrophy in primary aldosteronism
  2153. Primary aldosteronism: case observed in a patient subjected previously to thoracolumbar sympathectomy
  2154. Primary aldosteronism in a patient with an Aldosterone-producing adenoma
  2155. Urinary kallikrein excretion in patients with primary aldosteronism: differentiation of adrenal adenoma from idiopathic adrenal hyperplasia
  2156. Reduced renal extraction of atrial natriuretic peptide in primary aldosteronism
  2157. Primary Aldosteronism
  2158. I027: Saline infusion test in the diagnosis of primary aldosteronism
  2159. Diagnosis of primary aldosteronism
  2160. Comparative study of diagnosis for location of adrenal adenoma in patients with primary aldosteronism (author’s transl)
  2161. Primary aldosteronism. A report of 2 cases.
  2162. Withdrawal of endogenous sympathetic drive lowers blood pressure in primary aldosteronism
  2163. Multiple forms of immunoreactive renin in human adrenocortical tumour tissue from patients with primary aldosteronism
  2164. A SIMPLIFIED SCREENING TEST FOR DIFFERENTIATING PRIMARY ALDOSTERONISM FROM ESSENTIAL HYPERTENTION WITH LOW PLASMA RENIN …
  2165. Evaluation of select criteria for the diagnosis of primary aldosteronism in normokalemic hypertension
  2166. Primary aldosteronism: Importance of the level of plasma renin as an adjunct in diagnosis
  2167. Syncope as a manifestation of primary aldosteronism
  2168. Activity of [des-Aspartyl1]-Angiotensin II in Primary Aldosteronism
  2169. Glucocorticoid-remediable aldosteronism
  2170. Endogenous dopaminergic inhibition of Aldosterone and prolactin secretion is apparently not increased in primary aldosteronism
  2171. Surgical management of primary aldosteronism–progress in localization studies and operative treatment
  2172. Detection of primary aldosteronism by the 6-hour integrated Aldosterone/renin ratio.
  2173. Approach to a patient with suspected primary aldosteronism.
  2174. Diagnosis and Treatment of Primary Aldosteronism (120 Cases Report)
  2175. Primary aldosteronism due to hyperplasia of zona glomerulosa: failure of suppression by DOCA or stimulation by angiotensin
  2176. Importance of atrial natriuretic hormone in an exaggerated natriuresis during acute sodium load in primary aldosteronism
  2177. Clinical and pathological aspects of primary aldosteronism
  2178. Adrenal Imaging with 131I-19-Iodocholesterol in the Diagnostic Evaluation of Patients with Aldosteronism
  2179. Macronodule associated with bilateral adrenal hyperplasia. A rare misleading cause of primary aldosteronism (two cases)
  2180. Effects of naloxone on adrenal cortex regulation in patients with primary aldosteronism
  2181. … ROLE OF HYPOKALEMIA IN THE MANIFESTATION OF HIGH QRS VOLTAGE AND SINUS RADYCARDIA IN PATIENTS WITH PRIMARY ALDOSTERONISM
  2182. Cyproheptadine in Idiopathic Aldosteronism
  2183. A case of primary aldosteronism, nephrotic syndrome and chronic renal failure: a diagnostic dilemma
  2184. Regulation of Atrial Natriuretic Peptide in Primary Aldosteronism and in Cushing’s Disease
  2185. A case report of obstructive sleep apnea syndrome associated with primary aldosteronism
  2186. Three cases of primary aldosteronism including one case with postoperative ventricular tachycardia
  2187. Aldosteronism
  2188. Restoration of renin-Aldosterone dynamics to normal following surgery in primary aldosteronism
  2189. Anesthetic Experience of Adrenalectomy with Primary Aldosteronism-Report of two cases.
  2190. Diagnosing primary aldosteronism with frusemide stimulation test in hypertensive patients with raised Aldosterone to renin ratio
  2191. Captopril v Aldosterone to plasma renin activity ratio in screening for primary aldosteronism
  2192. Lateralisation of Aldosterone-producing adenoma in primary aldosteronism
  2193. … of glutathione-peroxidase (GSH-PO) in human adrenal gland–studies on adrenocortical adenomas associated with primary aldosteronism and Cushing’s syndrome.
  2194. Primary aldosteronism in pregnancy
  2195. Plasma cortisol and primary aldosteronism
  2196. Comparison of steroidogenesis in adrenal tissue and adrenal adenoma from a case of primary aldosteronism
  2197. Evaluation of a test using saralasin to differentiate primary aldosteronism due to an Aldosterone-producing adenoma from idiopathic hyperaldosteronism
  2198. Anesthetic Management of a patient with Primary Aldosteronism caused by Adrenal Adenoma.
  2199. Salt loading in renal aldosteronism before and after nephrectomy
  2200. Urinary excretion of catecholamines in patients with primary aldosteronism before and after unilateral adrenalectomy.
  2201. Adrenal adenoma with primary aldosteronism in a child: a case report.
  2202. Anesthetic management of adrenalectomy in a patient with aldosteronism complicated with hypertrophic cardiomyopathy
  2203. Concomitant laparoscopic treatment for primary aldosteronism and cholelithiasis
  2204. Glucocorticoid remediable aldosteronism: a case report.
  2205. Pituitary peptides other than ACTH may not be Aldosterone secretagogue in primary aldosteronism
  2206. Urinary citrate excretion in primary aldosteronism
  2207. Morphofunctional characteristics of endocrine nephropathy in primary aldosteronism
  2208. A Cardiac Arrest during Surgery for Adrenal Tumor Causing Primary Aldosteronism.
  2209. Simplified screening procedures for primary aldosteronism. Studies on the mechanism of the hyper-responsiveness to furosemide and standing
  2210. A case of normotensive primary aldosteronism in association with non-functioning adenoma and Aldosterone producing adenoma in ipsilateral adrenal gland
  2211. In primary aldosteronism hypertensive patients endothelial dysfunction is caused by an impairment in no availability
  2212. Diagnosis, localization, and treatment of primary aldosteronism.
  2213. Secretory regulation and episodic secretion of Aldosterone in patients with primary aldosteronism (author’s transl)
  2214. Plasma concentration and urinary excretion of arginine-vasopressin in primary aldosteronism during the fluid deprivation tests
  2215. Effect of spironolactone on cytosolic free sodium concentration in platelets from hypertensive patients with primary aldosteronism
  2216. Biosynthesis of various steroids in vitro by isolated adrenal cells in primary aldosteronism, Cushing’s syndrome, and adrenogenital syndrome due to adrenocortical …
  2217. Faecal sodium/potassium ratio and aldosteronism in experimental hypertension in the rat
  2218. British Medical Association (Mashonaland branch): Primary syndromes of aldosteronism
  2219. STUDY ON CLINICAL CHARACTERISTICS OF hypertension IN PATIENTS WITH PRIMARY ALDOSTERONISM
  2220. Diagnostic value of imaging in localizing primary aldosteronism
  2221. 19-Nor-deoxycorticosterone excretion in primary aldosteronism and low renin hypertension
  2222. Does a digoxin-like substance participate in vascular and pressure control during dietary sodium changes in patients with primary aldosteronism?
  2223. Image diagnosis of adrenal disorders–I. CT images of control subjects and image diagnosis of primary aldosteronism
  2224. Elevated ‘free’18-hydroxy-corticosterone excretion as a possible indicator for early diagnosis of primary aldosteronism
  2225. Enzyme histocytochemical studies in human adrenocortical adenomas.[I]. Primary aldosteronism.
  2226. Effect of captopril on Aldosterone response to potassium infusion in primary aldosteronism.
  2227. A case of neurinoma of the pancreas in a patient with primary aldosteronism
  2228. Studies on the in vitro production of Aldosterone and other corticoids in the adrenal adenoma of a primary aldosteronism
  2229. Expression of cytochrome P-450 mRNAs in steroidogenesis of adrenocortical adenomas from patients with primary aldosteronism
  2230. Primary Aldosteronism
  2231. Anesthesiological management of a patient with primary aldosteronism complicated with hypertrophic cardiomyopathy
  2232. Pattern classification of renal electrolyte cycles in primary aldosteronism
  2233. Effects of metoclopramide, a dopamine antagonist, on secretion of Aldosterone and renin release in patients with primary aldosteronism
  2234. … natriuretic peptide responses to upright posture and furosemide administration in patients with normal-, low renin essential hypertension and primary aldosteronism
  2235. Fecal and salivary electrolytes in the diagnosis of primary aldosteronism
  2236. Primary aldosteronism
  2237. Primary aldosteronism-A Report of 26 cases
  2238. Primary aldosteronism at Henry Ford Hospital in the 1980s
  2239. A case of secondary aldosteronism similar to Bartter’s syndrome with no abnormality in renal chloride reabsorption
  2240. Adrenal scintigraphy in primary aldosteronism
  2241. In vivo and in vitro studies on steroid metabolism in a case of primary aldosteronism with multiple lesions of adenoma and nodular hyperplasia
  2242. Hypertensive crisis during the resection of an adrenal tumor in primary aldosteronism
  2243. Renin content of the kidney in primary aldosteronism
  2244. Hyperpigmentation on Cortisone After Adrenalectomy for Primary Aldosteronism
  2245. Night-Day Variations of Renin-Activity in Primary Aldosteronism
  2246. … on clinical and endocrine characteristics of dexamethasone-suppressible hyperaldosteronism compared with those in primary aldosteronism owing to Aldosterone …
  2247. Primary aldosteronism in childhood due to primary adrenal hyperplasia
  2248. When To Hospitalize for Primary Aldosteronism
  2249. Primary Aldosteronism Caused by Unilateral Adrenal Hyperplasia
  2250. Urinary Arginine Esterase Activity in the Patients with hypertension, Chronic Nephritis and Primary Aldosteronism
  2251. Effects of salt restriction, spironolactone, and ammonium chloride on acid-base relations in a case of primary aldosteronism
  2252. Change in plasma renin activity by cold storage of plasma in normal subjects and patients with essential hypertension and primary aldosteronism
  2253. Primary aldosteronism caused by an adrenal tumor: a correctable cause of hypertension.
  2254. Plasma renin in primary aldosteronism
  2255. Conn’s syndrome: case report and a review of the syndrome of primary aldosteronism (SOPA)
  2256. Heterogeneous blood pressure response to furosemide and captopril in primary aldosteronism.
  2257. Primary Aldosteronism, Recumbent Posture, and Salt Loading Are Associated with Higher Levels of Atrial Natriuretic Peptide
  2258. Primary Aldosteronism
  2259. Primary Aldosteronism
  2260. Primary Aldosteronism
  2261. Primary Aldosteronism and the Effects of Two Mineralocorticoid Inhibitors—Triamterene and Spironolactone (Aldactone)
  2262. Primary aldosteronism
  2263. Report: Primary Aldosteronism.
  2264. Primary aldosteronism due to adrenocortical adenoma (Conn’s syndrome)
  2265. Ultrastructural and biochemical studies in human adrenocortical adenomas associated with primary aldosteronism.
  2266. Therapy of primary aldosteronism with trilostane
  2267. Secondary Aldosteronism
  2268. Primary Aldosteronism: 13 Cases Analysis
  2269. A case of nephrotic syndrome with diabetes mellitus and primary aldosteronism
  2270. Surgery of primary aldosteronism
  2271. TWO CASES OF PRIMARY ALDOSTERONISM
  2272. The syndrome of primary aldosteronism: a case study.
  2273. Screening for Aldosteronism
  2274. Renin in aldosteronism: relating kidney and adrenal
  2275. Primary Aldosteronism: A Challenging Case
  2276. Bilateral renal artery stenosis with aldosteronism
  2277. Primary Aldosteronism and Other Mineralocorticoid Excess Syndromes in hypertension: Incidence, Screening, and Diagnosis
  2278. Mineralocorticoid and prolactin response to the dopamine antagonist metoclopramide in patients with primary aldosteronism
  2279. General anesthesia for a patient with primary aldosteronism complicated with hypertrophic nonobstructive cardiomyopathy
  2280. Diurnal variation and responses of corticoids to dexamethasone and ACTH before and after adrenal surgery in primary aldosteronism
  2281. Synchronous changes in active and inactive renin secretion after furosemide in patients with primary aldosteronism
  2282. Adrenal Scintigraphy in Primary Aldosteronism Caused by an Aldosterone Producing Adenoma
  2283. Diagnosis and treatment of primary aldosteronism
  2284. Primary aldosteronism. Diagnostic aspects and treatment
  2285. The spitting image of primary aldosteronism
  2286. Primary Aldosteronism: Report of 38 Cases
  2287. The syndrome of mineralocorticoid excess: Primary aldosteronism
  2288. Pathological and clinical studies on primary aldosteronism
  2289. Plasma Aldosterone concentration in patients with primary aldosteronism in the last decade
  2290. Computer tomographic localisation in primary aldosteronism. Comparison with adrenal scintigraphy (author’s transl)
  2291. Primary Reninism: hypertension, Hyperreninaemia and Secondary Aldosteronism Due to Juxtaglomerular Renal Cell Tumours
  2292. Diagnosis of Primary Aldosteronism: Clinical Analysis of 26 Cases
  2293. Diagnosis and Treatment of Primary Aldosteronism
  2294. Formation of steroid hormones in the adrenal adenoma and adjacent adrenal tissue of a patient with primary aldosteronism
  2295. Effects on muscle electrolytes of potassium and magnesium infusions, spironolactone medication and operation in a case of primary aldosteronism
  2296. Intravenously Administered Chlorothiazide For Aldosteronism
  2297. Surgical management of primary aldosteronism: Experience of 9 cases
  2298. Primary Aldosteronism─ Clinical Experiences and Literature Review
  2299. Surgical Therapy of Primary Aldosteronism
  2300. Urinary 18, 19-dihydroxycorticosterone and 18-hydroxy-19-norcorticosterone excretion in patients with primary and secondary aldosteronism
  2301. Primary aldosteronism in general practice
  2302. Kinins in relation to renin activity in renal and inferior caval veins in normal individuals and patients with primary aldosteronism
  2303. A direct enzyme immunoassay for 18-hydroxycortisol in urine: a new tool for screening primary aldosteronism
  2304. … system: studies on histological changes in adrenal and renal tissue; a follow-up study of postoperative blood pressure in primary and idiopathic aldosteronism
  2305. The plasma Aldosterone/plasma renin activity ratio at different salt intakes has a limited value for the diagnosis of primary aldosteronism.
  2306. Eccrine sweat gland sensitivity to catecholamines in patients with pheochromocytoma and primary aldosteronism
  2307. Differences between adrenal adenoma causing primary aldosteronism and other adrenal tissues in the incorporation of labeled steroid precursors into their products
  2308. PREGNANCY AND PRIMARY ALDOSTERONISM
  2309. An Autopsy Case of Primary Aldosteronism
  2310. Endocrine characterization of the adrenal adenomas in a case of primary aldosteronism.
  2311. Suppressed Plasma Renin Activity in Hypertensive Patients-Its Evaluation for the Diagnosis of Primary Aldosteronism
  2312. ATYPICAL ALDOSTERONISM
  2313. Primary Aldosteronism: Changing Concepts in Diagnosis and Management
  2314. M010: Primary aldosteronism: A clinical profile based in 294 cases
  2315. Current concepts of primary aldosteronism
  2316. Intracellular sodium and potassium concentrations in erythrocytes of patients with primary aldosteronism
  2317. … adrenal steroid biosynthesis, on blood pressure, plasma Aldosterone and other steroid hormones, serum potassium and plasma renin activity in primary aldosteronism …
  2318. Is the Aldosterone-renin ratio useful in screening for primary aldosteronism?
  2319. Primary Aldosteronism by Adenoma 1 Case
  2320. Anesthetic Experience with Primary Aldosteronism: Report of a case.
  2321. Primary Aldosteronism with Uncommon Complications
  2322. An Anesthetic Experience with Primary Aldosteronism.
  2323. Primary aldosteronism and adrenal incidentaloma.
  2324. Primary aldosteronism: complete remission after adrenal venography
  2325. Inactive form of carbonic anhydrase I in erythrocytes from primary aldosteronism.
  2326. Effect of dibutyryl cyclic AMP on plasma renin activity in normal men and patients with primary aldosteronism
  2327. Primary aldosteronism–screening, diagnosis and therapy.
  2328. Fallacy of the Aldosterone: renin ratio (ARR) used to screen for primary aldosteronism
  2329. The Recognition, Confirmation, and Course of Primary Aldosteronism.
  2330. CLINICOPATHOLOGIC STUDIES OF PRIMARY ALDOSTERONISM
  2331. Multiple calcified adrenal myelolipoma suggestive of association of primary aldosteronism: report of a case
  2332. Utility of Iodocholesterol Scanning in Primary Aldosteronism
  2333. Therapeutic experience of primary aldosteronism associated with chronic renal failure
  2334. Screening for primary aldosteronism in hypertensive patients
  2335. Determination of urinary 18-hydroxycortisol in the diagnosis of primary aldosteronism
  2336. Primary Aldosteronism: A Clinical Profile Based in 294 Cases: P1. 75
  2337. Aldosteronism after hypokalemia in diuretic therapy of systemic arterial hypertension
  2338. Circulatory reflexes in primary aldosteronism (author’s transl)
  2339. … : Effect of the Antihypertensive Agent Diazoxide on Plasma Renin Activity and its Clinical Application, especially in Screening Primary Aldosteronism and its Similar …
  2340. Direct radioimmunoassays for” Aldosterone” and” 18-hydroxycorticosterone” in unprocessed urine, and their use in screening to distinguish primary aldosteronism …
  2341. Cardiac Arrest Induced by Primary Aldosteronism
  2342. I004: Diagnostic value of the post-captopril test in primary aldosteronism
  2343. Renal kininase I, kininase II and neutral endopeptidase 24.11 activities in patients with essential hypertension, primary aldosteronism and Cushing’s syndrome
  2344. Asymptomatic Normotensive Primary Aldosteronism
  2345. Primary aldosteronism and arterial hypertension
  2346. Systemic hemodynamics in primary aldosteronism
  2347. … antibodies specific for 18-hydroxycortisol and their use in an enzyme immunoassay for human urinary 18-hydroxycortisol for diagnosis of primary aldosteronism
  2348. Detection of primary aldosteronism using the captopril test
  2349. M011: A follow-up study of patients with primary aldosteronism treated medically
  2350. Unexpected incidence of low blood pressure 2 years after unilateral adrenalectomy for primary aldosteronism
  2351. Prolactin in primary aldosteronism
  2352. Studies on Curable hypertension: Special Reference to Renovascular hypertension and Primary Aldosteronism: Panel Discussion on Some Problems in the …
  2353. Some Recent Contributions to Pathogenesis and Diagnosis of The Syndrome of Primary Aldosteronism
  2354. Some remaining problems of aldosteronism from personal case
  2355. Studies on abnormalities of adrenal steroidogenesis in essential hypertension, primary aldosteronism and renovascular hypertension: responses of plasma steroids to …
  2356. A CASE OF GRAVES’DISEASE ASSOCIATED WITH PRIMARY ALDOSTERONISM TREATED BY SIMULTANEOUS SUBTOTAL THYROIDECTOMY AND …
  2357. Aldosterone and Aldosteronism
  2358. PLASMA RENIN IN ALDOSTERONISM.
  2359. USE OF COMPUTED TOMOGRAPHY IN DIAGNOSING THE CAUSE OF PRIMARY ALDOSTERONISM
  2360. Crisis of arterial hypertension in patients with primary aldosteronism
  2361. Primary aldosteronism is an independent determinant of albumin excretion.
  2362. Insulin resistance and abnormal glucose metabolism in patients with primary aldosteronism
  2363. Effect of SK&F-12185 [dl-2(p-Aminophenyl)-2-phenylethylamine] on Adrenocortical Function in Primary Aldosteronism
  2364. Aldosteronism and Spironolactone
  2365. Changes of urinary kallikrein excretion and plasma natriuretic factor in a patient with primary aldosteronism with special reference to adrenal histology
  2366. … ADRENOCORTICAL GLOMERULAR ZONE BY INCOMPLETE LIGATION OF BILATERAL URETERS OF RATS: An Experimental Model for Secondary Aldosteronism
  2367. 21-DeoxyAldosterone excretion in patients with primary aldosteronism and 21-hydroxylase deficiency
  2368. DEXAMETHASONE SUPPRESSION SCINTISCAN IN PRIMARY ALDOSTERONISM WITH SCINTADREN
  2369. Investigation of the prevalence and genetic characterisation of patients with glucocorticoid remediable aldosteronism
  2370. Primary aldosteronism due to adrenal carcinomas. Klin Wochenschr.
  2371. Plasma Renin Activity in Primary Aldosteronism-Reply
  2372. I-131 NP-59 adrenal cortical scintigraphy in suspected primary aldosteronism.
  2373. Radioimmunoassay of urinary 21-deoxytetrahydroAldosterone in primary aldosteronism and 21-hydroxylase deficiency
  2374. Crisis of arterial hypertension in patients with primary aldosteronism. Krizovoe techenie arterial’noj gipertonii u bol’nykh pervichnym al’dosteronizmom
  2375. Aldosterone and Aldosteronism
  2376. Presidential address: Part I. Painting background part II primary aldosteronism, a new clinical syndrome
  2377. Use of the Saline Infusion Test to Diagnose the Cause of Primary Aldosteronism
  2378. Computer tomographic localisation in primary aldosteronism. Comparison with renal scintigraphy
  2379. A SUCCESSFUL CASE OF ADRENALECTOMY FOR PRIMARY ALDOSTERONISM
  2380. The clinical use of captopril in the diagnosis and treatment of primary aldosteronism
  2381. Coexisting primary aldosteronism and pheochromocytoma (report of 4 cases)
  2382. hypertension Controlled by Adrenalectomy: A Case of Primary Aldosteronism
  2383. Localization of te Adrenal Lesions in Primary Aldosteronism
  2384. … of single-administration captopril on plasma and urinary vasopressin in normotensive subjects and patients with essential hypertension and primary aldosteronism
  2385. Aldosterone-producing microadenoma in a patient with primary aldosteronism.
  2386. Suppressed plasma renin activity and primary aldosteronism.
  2387. The diagnosis and surgical management of primary aldosteronism: Joseph C. Cerny, Detroit, Michigan
  2388. The significance of sodium intake in postoperative aldosteronism
  2389. Clinical study on primary aldosteronism–localization of adrenal tumors
  2390. … the hypochloremic state and postural change (from supine posture to standing and walking)–new diagnostic criteria for primary aldosteronism (with normal potassium …
  2391. The prediction of blood pressure after adrenalectomy in primary aldosteronism
  2392. Twenty-Four Hour Blood Pressure Profile in Subjects with Different Subtypes of Primary Aldosteronism
  2393. Five cases of primary aldosteronism: a comparative study on diagnosis for localization of adrenal tumor
  2394. Effect of spironolactone on circadian rhythm of plasma renin activity, plasma Aldosterone and cortisol in primary aldosteronism
  2395. Primary aldosteronism: diagnosis, laterality and regulation of hormone secretion
  2396. Anesthetic Experience of Adrenalectomy with Primary Aldosteronism.
  2397. Significance of single-dose captopril test in the differential diagnosis of primary aldosteronism
  2398. PRIMARY ALDOSTERONISM RELATIONS BETWEEN PATHOLOGICAL FINDINGS AND LOCALIZATION OF THE TUMOR AND FOLLOW-UP RESULTS
  2399. Anesthetic Experience of a Patient with Primary Aldosteronism Complicated with Aortic Dissection: A case report.
  2400. Primary Aldosteronism: An Anesthetic Experience with Adrenalectomy.
  2401. ANALYSIS OF THE DIURNAL BLOOD PRESSURE VARIATION IN PRIMARY ALDOSTERONISM: P1. 133
  2402. I002: Primary aldosteronism; a community based survey in 3 ethnic communities in cape town, south africa
  2403. The circadian rhythm of serum Aldosterone in the diagnostics of primary aldosteronism
  2404. Clinical study of one Chinese pedigree with glucocorticoid-remediable aldosteronism
  2405. Primary Aldosteronism and Effects of Two Mineralocorticoid Inhibitors
  2406. … suppression test and long-PCR of chimeric gene for the diagnosis of glucocorticoid-remediable aldosteronism (GRA) in patients with primary aldosteronism (PA)
  2407. M012: Positive screening for primary aldosteronism in blacks and whites with essential hypertension
  2408. Corticoids secretion in primary aldosteronism. I. Diurnal variation and the effect of dexamethasone (author’s transl)
  2409. Scintigraphic Localization of Adrenal Lesions in Primary Aldosteronism
  2410. Fimilial primary aldosteronism with delayed glucocorticoid responsiveness: A new sndrome
  2411. D016: Aldosterone synthase gene polymorphisms in primary aldosteronism
  2412. Localization of adrenal adenomas in primary aldosteronism
  2413. A Case Report of Primary Aldosteronism with Sustained hypertension After Adrenalectomy
  2414. Primary Aldosteronism Versus Other Forms of hypertension Associated with Hypokalemia.
  2415. A case of primary aldosteronism with severe hypokalemic myopathy
  2416. Diurnal Blood Pressure Changes in Primary Aldosteronism-A Study of Ambulatory Blood Pressure Monitoring and Neurohormonal Changes
  2417. Radioimmunological determination of Aldosterone in the serum. New method for the localization of aldosteronism
  2418. Isolated Clinical Syndrome of Primary Aldosteronism in Four Patients With Adrenocortical Carcinoma
  2419. Nuclear medicine diagnostic localization in primary aldosteronism and Cushing syndrome
  2420. Nonnokalemic Primary Aldosteronism. A Detectable Cause of Curable Essential hypertension
  2421. Plasma Levels of Atrial Natriuretic Peptide in Primary Aldosteronism and Essential hypertension
  2422. The role of endogenous dopamine on mineralocorticoids secretion in normal subjects, patients with primary aldosteronism, and idiopathic hyperaldosteronism
  2423. CLINICAL SIGNIFICANCE OF CHANGES OF ATRIAL NATRIURETIC POLYPEPTIDE (ANP) IN PRIMARY ALDOSTERONISM AND THEIR RELATION WITH THE
  2424. Plasma Aldosterone and electrolytes in primary and secondard aldosteronism (author’s transl)
  2425. A possible role for intermediate lobe peptides in the pathogenesis of idiopathic aldosteronism.
  2426. Variations in severity of hypertension in a large pedigree with glucocorticoid-remediable aldosteronism
  2427. … -Adosterol (NCL-6-131I) by Diverging and Pinhole Methods III. Comparative Studies of Baseline and Dexamethasone Suppression Imaging in Aldosteronism
  2428. Whole body computed tomographic findings of each one case with primary aldosteronism and Cushing syndrome
  2429. The x-ray endovascular treatment of renin-dependent arterial hypertension with secondary aldosteronism in patients without vasorenal involvement
  2430. Studies on the mechanism of secretion of adrenal steroid hormones from adenomas of primary aldosteronism and Cushing’s syndrome (author’s transl)
  2431. M014: Identification of the aetiology of primary aldosteronism (PA) with adrenal vein sampling (AVS) in a CT and MRI era: Results in 104 consecutive cases
  2432. PLASMA Aldosterone RESPONSE TO LONG TERM SPIRONOLACTONE TREATMENT IN PRIMARY ALDOSTERONISM
  2433. Response of several adrenal steroids to rapid ACTH stimulation test in essential hypertension and primary aldosteronism (author’s transl)
  2434. Abnormality of circulatory reflex and Aldosterone response during head-up tilting in patients with primary aldosteronism
  2435. ROLE OF NATRIURETIC FACTORS IN MINERALOCORTICOID ESCAPE PHENOMENON IN PATIENTS WITH PRIMARY ALDOSTERONISM
  2436. Hyperkalaemia secondary to hypo-aldosteronism-a report of 2 cases differentiating hyperreninaemic from hyporeninaemic hypo-aldosteronism
  2437. Dietary sodium change in primary aldosteronism. Atrial natriuretic factor, hormonal, and vascular responses. hypertension.
  2438. Prevalence and determinants of non-rheumatic Atrial Fibrillation (AF) in patients with primary aldosteronism
  2439. Effect of captopril on Aldosterone response to potassium infusion in primary aldosteronism
  2440. Clinical analysis on 40 cases of primary aldosteronism–long-term follow-up of blood pressure
  2441. Corticoid secretion in primary aldosteronism. II. The renin releasing test and the angiotensin II analog infusion test (author’s transl)
  2442. Effects of surgical treatment on circadian variations of arterial pressure in patients with primary aldosteronism and renovascular hypertension
  2443. A CASE OF PRIMARY ALDOSTERONISM TREATED BY ADRENAL ARTERY EMBOLIZATION USING ABSOLUTE ETHANOL
  2444. A Case of Primary Aldosteronism due to Bilateral Adrenal Hyperplasia with Hidden Undiagnosed Adrenal Adenoma for Eight Years
  2445. Prostaglandin E2 and the renin-angiotensin system in primary aldosteronism and Cushing’s syndrome
  2446. Multiple Endocrine Neoplasia Type I: A Case of Parathyroid Adenoma, Colloid Nodules and Aldosteronism
  2447. Glucocorticoid remediable aldosteronism: a rare hereditary form of adrenocorticotropic hormone regulated mineralocorticoid hypertension
  2448. Adrenal venous sampling analysis of primary aldosteronism: value of ACTH stimulation in the differentiation of adenoma and hyperplasia
  2449. Diagnosis and roentgeno-endovascular treatment of patients with renin-dependent arterial hypertension and secondary aldosteronism without damage to the main …
  2450. Morphology of the juxtaglomerular appartus in Bartter’s syndrome (hyperplasia of the juxtaglomerular complex with secondary aldosteronism without hypertension)
  2451. An unexpected rise in plasma Aldosterone to furosemide-upright test in primary aldosteronism due to Aldosterone producing adenoma.
  2452. Current problems in primary aldosteronism–4 cases of normokalemic primary aldosteronism (1st degree) caused by adenoma and 3 cases of aldosteronism, 1st …
  2453. … and dopamine on Aldosterone secretion in cultured adrenocortical adenoma cells and adjacent non-adenoma cells from patients with primary aldosteronism
  2454. … and Urinary Aldosterone Excretion in Hypertensive Patients: with Special Reference to Incidence of Normokalemic Primary Aldosteronism in Essential hypertension
  2455. A clinicopathological and ultrastructural study on 147 cases of primary aldosteronism
  2456. Endocrinopathies of hyperfunction: Cushing’s syndrome and aldosteronism
  2457. DIAGNOSTIC APPROACH TO 144 PATIENTS WITH PRIMARY ALDOSTERONISM: P2. 130
  2458. Results of Treatment in 68 Patients with Idiopathic Aldosteronism in Japan
  2459. DIAGNOSTIC AND THERAPEUTIC UNDERSTANDING OF 37 CASES OF PRIMARY ALDOSTERONISM [J]
  2460. 1 Case of Primary Aldosteronism Caused by Adrenal Hyperplasia
  2461. … 131/I-adosterol (NCL-6-/sup 131/I) by diverging and pinhole methods, 3. Comparative studies of baseline and dexamethasone suppression imaging in aldosteronism
  2462. Clinical observation of 12 cases of primary aldosteronism, special reference to the diagnostic problem (author’s transl)
  2463. 24 hours ambulatory blood pressure in primary aldosteronism
  2464. Follow up of 123 patients submitted to adrenalectomy in primary aldosteronism
  2465. A clinical analysis of 146 cases of primary aldosteronism
  2466. Analysis of the Pre and Post operative Blood Pressure and Blood Biochemical Changes in 40 Cases of Primary Aldosteronism
  2467. The diagnosis of unilateral adrenal adenoma in 123 patients with primary aldosteronism
  2468. The Diagnostic Value of Urinary Free 18-Hydroxycorticosterone in Primary Aldosteronism
  2469. 60 Primary Aldosteronism-Treatment with Trilostane, an Inhibitor of Steroid Biosynthesis
  2470. Adrenal scintigraphy with 131I-19-iodocholesterol in primary aldosteronism
  2471. 1.4 Characteristics of patients with glucocorticoid remediable aldosteronism in the North East of Scotland
  2472. 109 Improvement of arterial baroreflex function by adrenalectomy and its effect on the variability of arterial pressure in primary aldosteronism
  2473. Primary aldosteronism: renaissance of a syndrome
  2474. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
  2475. Primary aldosteronism: diagnostic and treatment strategies
  2476. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
  2477. Primary aldosteronism and hypertensive disease
  2478. Renal damage in primary aldosteronism: results of the PAPY Study
  2479. Minireview: primary aldosteronism—changing concepts in diagnosis and treatment
  2480. Cardiovascular outcomes in patients with primary aldosteronism after treatment
  2481. A review of the medical treatment of primary aldosteronism
  2482. Diagnosis and management of primary aldosteronism
  2483. Update in primary aldosteronism
  2484. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism
  2485. Primary aldosteronism—careful investigation is essential and rewarding
  2486. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents
  2487. A comprehensive review of the clinical aspects of primary aldosteronism
  2488. Long-term renal outcomes in patients with primary aldosteronism
  2489. Comparison of confirmatory tests for the diagnosis of primary aldosteronism
  2490. Primary aldosteronism: an update on screening, diagnosis and treatment
  2491. Insulin sensitivity in patients with primary aldosteronism: a follow-up study
  2492. Primary aldosteronism: management issues
  2493. Role for adrenal venous sampling in primary aldosteronism
  2494. Primary aldosteronism: cardiovascular, renal and metabolic implications
  2495. The current epidemic of primary aldosteronism: causes and consequences
  2496. Primary aldosteronism
  2497. Psychological aspects of primary aldosteronism
  2498. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline
  2499. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies–a review of the current literature
  2500. Guidelines for the diagnosis and treatment of primary aldosteronism-The Japan Endocrine Society 2009
  2501. Primary aldosteronism: factors associated with normalization of blood pressure after surgery
  2502. Diagnosis and treatment of primary aldosteronism
  2503. Laboratory investigation of primary aldosteronism
  2504. Diagnosis of primary aldosteronism: from screening to subtype differentiation
  2505. Observational study mortality in treated primary aldosteronism: the German Conn’s registry
  2506. Aldosteronism and hypertension
  2507. Prevalence and diagnosis of primary aldosteronism
  2508. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism
  2509. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol
  2510. Bone involvement in aldosteronism
  2511. Confirmatory testing in primary aldosteronism
  2512. Excess ldosterone Is Associated With Alterations of Myocardial Texture in Primary Aldosteronism
  2513. Risk factors associated with a low glomerular filtration rate in primary aldosteronism
  2514. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism
  2515. Primary aldosteronism: current knowledge and controversies in Conn’s syndrome
  2516. Kidney impairment in primary aldosteronism
  2517. Glucocorticoid-remediable aldosteronism
  2518. Relative glomerular hyperfiltration in primary aldosteronism
  2519. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism
  2520. Primary aldosteronism and metabolic syndrome
  2521. A clinical prediction score to diagnose unilateral primary aldosteronism
  2522. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’screening of hypertensive patients
  2523. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry
  2524. Drug effects on Aldosterone/plasma renin activity ratio in primary aldosteronism
  2525. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies
  2526. Primary aldosteronism: are we diagnosing and operating on too few patients?
  2527. Psychological assessment of primary aldosteronism: a controlled study
  2528. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment
  2529. Comorbidities in primary aldosteronism
  2530. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms)
  2531. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s Registry
  2532. Long-term follow-up after adrenalectomy for primary aldosteronism
  2533. Prevalence, Clinical, and Molecular Correlates of KCNJ5 Mutations in Primary Aldosteronism
  2534. Response to Is There an Unrecognized Epidemic of Primary Aldosteronism?(Pro)
  2535. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism?
  2536. Primary aldosteronism in diabetic subjects with resistant hypertension
  2537. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma Aldosterone-renin ratio
  2538. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study
  2539. Confirmatory tests in the diagnosis of primary aldosteronism
  2540. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism
  2541. Inappropriate left ventricular mass in patients with primary aldosteronism
  2542. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism
  2543. Intrarenal hemodynamics in primary aldosteronism before and after treatment
  2544. Hyperparathyroidism and the calcium paradox of aldosteronism
  2545. Use of plasma Aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature.
  2546. Cautions over the current epidemic of primary aldosteronism.
  2547. Role of radiology in the management of primary aldosteronism
  2548. Captopril suppression versus salt loading in confirming primary aldosteronism
  2549. Loss of bone minerals and strength in rats with aldosteronism
  2550. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism
  2551. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study
  2552. Adiponectin and insulin sensitivity in primary aldosteronism
  2553. A possible association between primary aldosteronism and a lower β-cell function
  2554. Relationships of plasma renin levels with renal function in patients with primary aldosteronism
  2555. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study
  2556. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience
  2557. Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication?
  2558. hypertension of Kcnmb1−/− is linked to deficient K secretion and aldosteronism
  2559. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma Aldosterone concentration to plasma renin activity
  2560. Primary hyperparathyroidism with concurrent primary aldosteronism
  2561. Verification and evaluation of aldosteronism demographics in the Taiwan Primary Aldosteronism Investigation Group (TAIPAI Group)
  2562. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication
  2563. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension
  2564. Treatment of primary aldosteronism
  2565. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients
  2566. Progress in primary aldosteronism: present challenges and perspectives
  2567. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings …
  2568. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism
  2569. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects
  2570. Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism
  2571. Surgically correctable hypertension caused by primary aldosteronism
  2572. Increased intima–media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension
  2573. Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism
  2574. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism
  2575. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes
  2576. The metabolic syndrome in primary aldosteronism
  2577. The challenge of more robust and reproducible methodology in screening for primary aldosteronism
  2578. Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men?
  2579. Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism
  2580. … -blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism
  2581. Primary aldosteronism in normokalemic patients with adrenal incidentalomas
  2582. The role of aldosteronism in causing obesity-related cardiovascular risk
  2583. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism
  2584. Primary aldosteronism: diagnosis and treatment
  2585. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism
  2586. Adrenalectomy improves arterial stiffness in primary aldosteronism
  2587. Screening for membrane hormone receptor expression in primary aldosteronism
  2588. High prevalence of primary aldosteronism using postcaptopril plasma Aldosterone to renin ratio as a screening test among Italian hypertensives
  2589. Oxidative stress in aldosteronism
  2590. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism
  2591. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism
  2592. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to Aldosterone-producing adenoma
  2593. Diagnostic value of the post-captopril test in primary aldosteronism
  2594. Differential diagnosis of primary aldosteronism subtypes
  2595. Resistant hypertension and aldosteronism
  2596. Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism
  2597. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an Aldosterone/renin ratio above 25 as a …
  2598. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study
  2599. Variability in the renin/Aldosterone profile under random and standardized sampling conditions in primary aldosteronism
  2600. Captopril test can give misleading results in patients with suspect primary aldosteronism
  2601. Aldosteronism and resistant hypertension
  2602. Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling
  2603. Diagnosis and treatment of primary aldosteronism
  2604. Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface
  2605. Clinicopathological features of primary aldosteronism associated with subclinical Cushing’s syndrome
  2606. Validity of the Aldosterone-renin ratio used to screen for primary aldosteronism
  2607. Primary aldosteronism: revival of a syndrome
  2608. Primary aldosteronism: who should be screened?
  2609. Rapid cortisol assays improve the success rate of adrenal vein sampling for primary aldosteronism
  2610. Renin-angiotensin-Aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism
  2611. Primary aldosteronism: diagnostic accuracy of the losartan and captopril tests
  2612. Predictors of successful outcome after adrenalectomy for primary aldosteronism
  2613. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases
  2614. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype
  2615. The genetic basis of primary aldosteronism
  2616. Diagnosis and management of primary aldosteronism
  2617. Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism
  2618. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients
  2619. Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism
  2620. Within-patient reproducibility of the Aldosterone: renin ratio in primary aldosteronism
  2621. The genetics of primary aldosteronism
  2622. Primary aldosteronism–treatment options
  2623. Primary aldosteronism
  2624. Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism
  2625. Calcium paradox of aldosteronism and the role of the parathyroid glands
  2626. What we still do not know about adrenal vein sampling for primary aldosteronism
  2627. Genetics of primary aldosteronism
  2628. Evaluation of primary aldosteronism
  2629. A diagnostic algorithm—the holy grail of primary aldosteronism
  2630. Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of Aldosterone oversecretion in primary aldosteronism patients
  2631. Screening for primary aldosteronism
  2632. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy
  2633. Diagnosis and management of primary aldosteronism in pregnancy: case report and review of the literature
  2634. Detecting and treating primary aldosteronism
  2635. Aldosterone to renin ratio–a reliable screening tool for primary aldosteronism?
  2636. Primary aldosteronism: from genesis to genetics
  2637. Urinary tetrahydroAldosterone as a screening method for primary aldosteronism: a comparative study
  2638. Primary aldosteronism: part II: subtype differentiation and treatment
  2639. Diuretics and bone loss in rats with aldosteronism
  2640. The Aldosterone-to-renin ratio as a screening test for primary aldosteronism.
  2641. Active renin versus plasma renin activity to define Aldosterone-to-renin ratio for primary aldosteronism
  2642. Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different …
  2643. Aldosterone-and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism
  2644. Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism
  2645. Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates
  2646. Trends in the prevalence of primary aldosteronism, Aldosterone-producing adenomas, and surgically correctable Aldosterone-dependent hypertension
  2647. Hyperparathyroidism can be useful in the identification of primary aldosteronism due to Aldosterone-producing adenoma
  2648. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood
  2649. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment
  2650. 18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes
  2651. The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience
  2652. Primary aldosteronism-part I: prevalence, screening, and selection of cases for adrenal vein sampling
  2653. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of Aldosterone excess baseline and after adrenocorticotropic …
  2654. Peripheral arterial stiffness in primary aldosteronism.
  2655. Subclinical primary aldosteronism
  2656. Relative kidney hyperfiltration in primary aldosteronism: a meta-analysis
  2657. Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment
  2658. Response to Is There an Unrecognized Epidemic of Primary Aldosteronism?(Con)
  2659. Primary aldosteronism
  2660. Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism
  2661. Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study
  2662. The phosphorylated sodium chloride cotransporter in urinary exosomes is superior to prostasin as a marker for aldosteronism
  2663. Primary aldosteronism: the case for screening
  2664. Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary Aldosterone metabolites
  2665. Aldosteronism and a Proinflammatory Vascular Phenotype: Role of Mg2+, Ca2+, and H2O2 in Peripheral Blood Mononuclear Cells
  2666. Aldosterone-to-renin ratio as a screening test for primary aldosteronism–the Dutch ARRAT Study
  2667. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism
  2668. The ovarian cycle as a factor of variability in the laboratory screening for primary aldosteronism in women
  2669. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our …
  2670. Diagnosis and management of primary aldosteronism
  2671. Adrenal vein sampling may not be a gold-standard diagnostic test in primary aldosteronism: final diagnosis depends upon which interpretation rule is used
  2672. Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation italian pedigree
  2673. Concurrent primary aldosteronism and subclinical cortisol hypersecretion: a prospective study
  2674. A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III
  2675. Diagnosis and management of primary aldosteronism
  2676. Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for Aldosterone vasculopathy and prognosis
  2677. Predictive factors of left ventricular mass changes after treatment of primary aldosteronism
  2678. Impact of accessory hepatic veins on adrenal vein sampling for identification of surgically curable primary aldosteronism
  2679. Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area
  2680. From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation
  2681. Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study
  2682. A screening procedure for primary aldosteronism based on the Diasorin Liaison® automated chemiluminescent immunoassay for direct renin
  2683. Primary aldosteronism in pregnancy
  2684. Screening for primary aldosteronism: implications of an increased plasma Aldosterone/renin ratio
  2685. Screening for primary aldosteronism-normal ranges for Aldosterone and renin in three South African population groups
  2686. Eplerenone use in primary aldosteronism during pregnancy
  2687. Primary aldosteronism: evidence against a second epidemic
  2688. Atrial fibrillation in primary aldosteronism
  2689. Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and Aldosterone
  2690. Vascular disturbances in primary aldosteronism: clinical evidence
  2691. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism
  2692. Blood pressure and medication changes following adrenalectomy for unilateral primary aldosteronism: a follow-up study
  2693. Primary aldosteronism: results of adrenalectomy for nonsingle adenoma
  2694. Aldosteronism revisited: perspectives on less well-recognized actions of Aldosterone
  2695. Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue?
  2696. Cardiovascular complications of patients with aldosteronism associated with autonomous cortisol secretion
  2697. Bone loss in rats with aldosteronism
  2698. Cardiac remodeling in patients with primary aldosteronism
  2699. Primary aldosteronism: are we missing the wood for the trees?
  2700. Primary aldosteronism, diagnosis and treatment in Japan
  2701. Integrating genetics and genomics in primary aldosteronism
  2702. Captopril suppression: limitations for confirmation of primary aldosteronism
  2703. Management of primary aldosteronism: its complications and their outcomes after treatment
  2704. Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets
  2705. Renal cysts and hypokalemia in primary aldosteronism: results of long-term follow-up after treatment
  2706. Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism
  2707. Confirmatory testing in primary aldosteronism: extensive medication switching is not needed in all patients
  2708. Primary aldosteronism.
  2709. Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants
  2710. A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating Aldosterone secretion?
  2711. Unilateral adrenal hyperplasia causing primary aldosteronism: limitations of I-131 norcholesterol scanning
  2712. Myocardial and aortic stiffening in the early course of primary aldosteronism
  2713. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism
  2714. Screening tests and diagnostic examinations of hypertensives for primary aldosteronism
  2715. The Aldosterone–renin ratio in screening for primary aldosteronism
  2716. Diurnal blood pressure variationin pheochromocytoma, primary aldosteronism and Cushing’s syndrome
  2717. Progress in primary aldosteronism
  2718. The association of serum potassium level with left ventricular mass in patients with primary aldosteronism
  2719. Case Report: Laparoscopic Adrenalectomy on a Patient with Primary Aldosteronism during Pregnancy
  2720. Diagnostic accuracy of adrenal venous sampling in comparison with other parameters in primary aldosteronism
  2721. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension
  2722. Primary aldosteronism, a common entity? The myth persists
  2723. Intraprocedural cortisol measurement increases adrenal vein sampling success rate in primary aldosteronism
  2724. Would wider screening for primary aldosteronism give any health benefits?
  2725. Cause of residual hypertension after adrenalectomy in patients with primary aldosteronism
  2726. Aberrant hormone receptors in primary aldosteronism
  2727. Familial varieties of primary aldosteronism
  2728. Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene …
  2729. Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population?
  2730. The role of adrenal venous sampling in the surgical management of primary aldosteronism
  2731. A prospective evaluation of postural stimulation testing, computed tomography and adrenal vein sampling in the differential diagnosis of primary aldosteronism
  2732. The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism?
  2733. Primary aldosteronism: the role of confirmatory tests
  2734. Primary aldosteronism associated with severe rhabdomyolysis due to profound hypokalemia
  2735. Primary aldosteronism, a major form of low renin hypertension: from screening to diagnosis
  2736. Single-center outcome of laparoscopic unilateral adrenalectomy for patients with primary aldosteronism: lateralizing disease using results of adrenal venous sampling
  2737. Primary aldosteronism: a common and important problem A practical guide to the diagnosis and treatment
  2738. Evidence for a Role of Vasopressin in the Control of Aldosterone Secretion in Primary Aldosteronism: in Vitro and in Vivo Studies
  2739. Plasma and urine Aldosterone to plasma renin activity ratio in the diagnosis of primary aldosteronism
  2740. Serum 18-hydroxycortisol in primary aldosteronism, hypertension, and normotensives
  2741. A German family with glucocorticoid-remediable aldosteronism
  2742. Pseudo‐aldosteronism’induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients
  2743. New concepts in adrenal vein sampling for Aldosterone in the diagnosis of primary aldosteronism
  2744. Adrenal venous sampling in primary aldosteronism: a low dilution of adrenal venous blood is crucial for a correct interpretation of the results
  2745. Non-invasive adrenal imaging in primary aldosteronism. Sensitivity and positive predictive value of radiocholesterol scintigraphy, CT scan and MRI
  2746. Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy
  2747. Primary aldosteronism: rare bird or common cause of secondary hypertension?
  2748. Treatment of primary aldosteronism: Where are we now?
  2749. The role of adrenal scintigraphy in the preoperative management of primary aldosteronism
  2750. QT interval in patients with primary aldosteronism and low-renin essential hypertension
  2751. Diagnosis of primary aldosteronism: comparison of post-captopril active renin concentration and plasma renin activity
  2752. New aspects on primary aldosteronism
  2753. Primary aldosteronism: from bench to bedside
  2754. Left ventricular changes in primary aldosteronism
  2755. Primary aldosteronism can alter peripheral levels of transforming growth factor β and tumor necrosis factor α
  2756. Primary aldosteronism in 2011: towards a better understanding of causation and consequences
  2757. Is it possible to extirpate cardiovascular events in primary aldosteronism after surgical treatment
  2758. Familial or genetic primary aldosteronism and Gordon syndrome
  2759. Discriminating factors for recurrent hypertension in patients with primary aldosteronism after adrenalectomy
  2760. Does primary aldosteronism exist in normotensive and mildly hypertensive patients, and should we look for it?
  2761. Long-term effects of surgical correction of adrenal hyperplasia and adenoma causing primary aldosteronism
  2762. Primary aldosteronism: what consensus for the diagnosis
  2763. Prediction of successful outcome in patients with primary aldosteronism
  2764. Idiopathic intracranial hypertension with primary aldosteronism: report of 2 cases
  2765. Recent advances in diagnosis and treatment of primary aldosteronism.
  2766. A case of primary aldosteronism due to unilateral adrenal hyperplasia
  2767. Genetic alterations in patients with primary aldosteronism
  2768. Active renin mass concentration to determine Aldosterone-to-renin ratio in screening for primary aldosteronism
  2769. Primary aldosteronism: actual epidemics or false alarm?
  2770. Dietary sodium restriction restores nocturnal reduction of blood pressure in patients with primary aldosteronism
  2771. Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism
  2772. Uncoupling the coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria seen in aldosteronism
  2773. Mitochondria-targeted cardioprotection in aldosteronism
  2774. Is primary aldosteronism underdiagnosed in clinical practice?
  2775. Primary aldosteronism with Aldosterone-producing adenoma consisting of pure zona glomerulosa-type cells in a pregnant woman
  2776. Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene
  2777. Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate
  2778. Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone
  2779. Primary Aldosteronism—One Picture Is Not Worth a Thousand Words
  2780. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy
  2781. Prolongation of the QT interval in primary aldosteronism
  2782. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting
  2783. … /renin ratio (ARR) and comparison of screening accuracy of ARR plus elevated serum Aldosterone concentration for primary aldosteronism screening in different age …
  2784. Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients
  2785. Primary aldosteronism
  2786. Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension
  2787. Somatic Mutations in the KCNJ5 Gene Raise the Lateralization Index: Implications for the Diagnosis of Primary Aldosteronism by Adrenal Vein Sampling
  2788. The pharmacological treatment of primary aldosteronism
  2789. Left heart morphology and function in primary aldosteronism
  2790. Diurnal blood pressure pattern in patients with primary aldosteronism
  2791. Spontaneous remission of idiopathic aldosteronism after long‐term treatment with spironolactone: results from the German Conn’s Registry
  2792. Laboratory diagnosis of primary aldosteronism, and drospirenone-ethinylestradiol therapy
  2793. … Endocrine Causes of hypertension (GECOH) study: a diagnostic accuracy study of Aldosterone to active renin ratio in screening for primary aldosteronism
  2794. Blood pressure, thyroid-stimulating hormone, and thyroid disease prevalence in primary aldosteronism and essential hypertension
  2795. Combined primary aldosteronism and preclinical Cushing’s syndrome: an unusual case presentation of adrenal adenoma
  2796. Recurrent calcium nephrolithiasis associated with primary aldosteronism
  2797. Authors’ Response: Prevalence of Primary Aldosteronism in Unselected Hypertensive Populations—Screening and Definitive Diagnosis
  2798. Is primary aldosteronism rare or common among hypertensive patients?
  2799. Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements
  2800. Primary aldosteronism: A contrarian view
  2801. Functional tests for primary aldosteronism: value of captopril suppression
  2802. Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism
  2803. Coexistence of normotensive primary aldosteronism in two patients with Gitelman’s syndrome and novel thiazide-sensitive Na-Cl cotransporter mutations.
  2804. Establishment of reference values for endocrine tests. III: primary aldosteronism
  2805. Problems in diagnostics of primary aldosteronism-analysis of the own data
  2806. Primary aldosteronism: clinical lateralization and costs
  2807. Value of adrenal venous sampling for lesion localization in primary aldosteronism
  2808. Life-threatening arrhythmia caused by primary aldosteronism
  2809. Chromogranin a measurement for assessing the selectivity of adrenal venous sampling in primary aldosteronism
  2810. Treatment of primary aldosteronism
  2811. Is there an epidemic of primary aldosteronism?
  2812. 131I-6β-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results
  2813. Clinical characteristics of Aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism
  2814. Diagnostics of primary aldosteronism: is obligatory use of confirmatory tests justified?
  2815. Blood Pressure in Patients with Primary Aldosteronism Is Influenced by Bradykinin B2 Receptor and α-Adducin Gene Polymorphisms
  2816. A case with primary aldosteronism due to unilateral multiple adrenocortical micronodules
  2817. The cutoff value of Aldosterone-to-renin ratio for the diagnosis of primary aldosteronism in patients taking antihypertensive medicine
  2818. Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism
  2819. A new presentation of the chimeric CYP11B1/CYP11B2 gene with low prevalence of primary aldosteronism and atypical gene segregation pattern
  2820. Prevalence and role of a raised Aldosterone to renin ratio in the diagnosis of primary aldosteronism: a debate on the scientific logic of the use of the ratio in practice
  2821. Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism
  2822. Reverse remodeling and recovery from cachexia in rats with aldosteronism
  2823. Primary aldosteronism: a practical approach to diagnosis and treatment
  2824. Sporadic solitary Aldosterone-and cortisol-co-secreting adenomas: endocrine, histological and genetic findings in a subtype of primary aldosteronism
  2825. Primary aldosteronism: a pictorial essay
  2826. Indicators of mineralocorticoid excess in the evaluation of primary aldosteronism
  2827. Primary aldosteronism
  2828. A case of primary aldosteronism revealed after renal transplantation
  2829. The genetics of primary aldosteronism: chapter two
  2830. Screening and diagnosis of primary aldosteronism
  2831. High prevalence of thyroid ultrasonographic abnormalities in primary aldosteronism
  2832. Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol
  2833. Contrast‐enhanced MRI index of diffuse myocardial fibrosis is increased in primary aldosteronism
  2834. Coexistence of primary aldosteronism and Hashimoto’s thyroiditis
  2835. Adrenal Venous Sampling for Primary Aldosteronism and Clinical Outcomes After Unilateral Adrenalectomy: A Single‐Center Experience
  2836. Primary aldosteronism
  2837. 18-oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism
  2838. Selection of patients for surgery for primary aldosteronism.
  2839. … with heme arginate alleviates adipose tissue inflammation and improves insulin sensitivity and glucose metabolism in a rat model of Human primary aldosteronism
  2840. Evolution of diagnostic criteria for primary aldosteronism: why is it more common in” drug-resistant” hypertension today?
  2841. Current diagnosis and treatment of primary aldosteronism
  2842. Long-term results of laparoscopic adrenalectomy for primary aldosteronism
  2843. Diagnosis of primary aldosteronism: for medical management, not just surgery
  2844. Pathophysiological roles of the adrenal renin-angiotensin system in patients with primary aldosteronism
  2845. The prevalence of primary aldosteronism in diabetic patients
  2846. Tissue 65Zinc translocation in a rat model of chronic aldosteronism
  2847. Diagnosis of primary aldosteronism in a patient with an incidentally found adrenal mass
  2848. Twenty-four hour blood pressure profile in subjects with different subtypes of primary aldosteronism
  2849. Primary aldosteronism combined with preclinical Cushing’s syndrome in an elderly patient
  2850. Paralysis as first manifestation of primary aldosteronism
  2851. Coexistence of three distinct adrenal tumors in the same adrenal gland in a patient with primary aldosteronism and preclinical Cushing’s syndrome
  2852. Progress in primary aldosteronism 2
  2853. Primary aldosteronism associated with severe hypokalemic rhabdomyolysis
  2854. Discrepant results of adrenal venous sampling in seven patients with primary aldosteronism
  2855. Responses in extracellular and intracellular calcium and magnesium in aldosteronism
  2856. Retroperitoneal laparoscopic management of primary aldosteronism with report of 130 cases
  2857. … for detecting precisely functional state of various lesions in unilateral and bilateral adrenal disorders, inducing primary aldosteronism with subclinical Cushing’s …
  2858. A rare case of primary hyperparathyroidism associated with primary aldosteronism, Hürthle cell thyroid cancer and meningioma
  2859. Genetic analyses of the chimeric CYP11B1/CYP11B2 gene in a Korean family with glucocorticoid-remediable aldosteronism
  2860. Primary aldosteronism: diagnostic and therapeutic considerations
  2861. Caution about the overdiagnosis of primary aldosteronism
  2862. Primary aldosteronism and its impact on the generation of arterial hypertension, endothelial injury and oxidative stress
  2863. Primary aldosteronism: the most frequent form of secondary hypertension?
  2864. Combined primary aldosteronism and Gushing’s syndrome due to a single adrenocortical adenoma complicated by Hashimoto’s thyroiditis
  2865. Prevalence of primary aldosteronism in hypertensive patients and its effect on the heart
  2866. Usefulness of adrenal vein sampling in the evaluation of aldosteronism
  2867. Impact of essential hypertension and primary aldosteronism on plasma brain natriuretic peptide concentration
  2868. Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism
  2869. Role of K+ Channels in the Pathophysiology of Primary Aldosteronism
  2870. Analysis of unilateral adrenal hyperplasia with primary aldosteronism from the aspect of messenger ribonucleic acid expression for steroidogenic enzymes: a …
  2871. Primary aldosteronism: comparison between guidelines of the Japanese and the US Endocrine Society
  2872. Diagnosis of glucocorticoid-remediable aldosteronism in hypertensive children
  2873. Japanese family with glucocorticoid-remediable aldosteronism diagnosed by long-polymerase chain reaction
  2874. 11 C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism
  2875. Assessment of serum sodium to urinary sodium divided by (serum potassium) ² to urinary potassium as a screening tool for primary aldosteronism
  2876. QT interval is prolonged but QT dispersion is maintained in patients with primary aldosteronism
  2877. Primary aldosteronism and a Texas two-step
  2878. Aldosterone antisecretagogue and antihypertensive actions of adrenomedullin in patients with primary aldosteronism
  2879. Primary aldosteronism caused by a unilateral adrenal adenoma accompanied by autonomous cortisol secretion
  2880. Primary aldosteronism and hypercortisolism due to bilateral functioning adrenocortical adenomas
  2881. A clinical observation on twelve cases of primary aldosteronism
  2882. Aldosterone/renin ratio in the diagnosis of primary aldosteronism
  2883. Efficacy of screening for primary aldosteronism by adrenocortical scintigraphy without discontinuing antihypertensive medication
  2884. Primary aldosteronism (PA) and endothelial progenitor cell (EPC) bioavailability
  2885. Prorenin cryoactivation as a possible cause of normal renin levels in patients with primary aldosteronism
  2886. Some considerations about evolution of idiopathic primary aldosteronism
  2887. Non-glucocorticoid-remediable aldosteronism in an infant with low-renin hypertension
  2888. Animal models of primary aldosteronism
  2889. Cautions over idiopathic aldosteronism
  2890. Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases
  2891. Aldosterone improves contractile function of adult rat ventricular cardiomyocytes in a non-acute way: potential relationship to the calcium paradox of aldosteronism
  2892. Clinical and gene mutation studies on a Chinese pedigree with glucocorticoid-remediable aldosteronism.
  2893. Genetic forms of primary aldosteronism
  2894. A case of primary aldosteronism with rhabdomyolysis
  2895. Primary aldosteronism: evolving concepts in diagnosis and treatment
  2896. More fuel to the debate on the “epidemics of primary aldosteronism”
  2897. Single-incision laparoscopic adrenalectomy for primary aldosteronism: report of a case
  2898. Ventricular repolarization before and after treatment in patients with secondary hypertension due to renal-artery stenosis and primary aldosteronism
  2899. Primary aldosteronism
  2900. Possibly simultaneous primary aldosteronism and preclinical Cushing’s syndrome in a patient with double adenomas of right adrenal gland
  2901. One-hour upright posture is an ideal position for serum Aldosterone concentration and plasma renin activity measuring on primary aldosteronism screening
  2902. Prevalence of primary aldosteronism among Bulgarian hypertensive patients
  2903. Renal function in primary aldosteronism
  2904. Does infusion of ANG II increase muscle sympathetic nerve activity in patients with primary aldosteronism?
  2905. Have main types of primary aldosteronism different phenotype?
  2906. Primary aldosteronism and pregnancy: report of 2 cases
  2907. A case of primary aldosteronism associated with renal artery stenosis and preclinical Cushing’s syndrome
  2908. Multiple intracerebral microhemorrhages associated with primary aldosteronism: a case report
  2909. Transumbilical laparo-endoscopic single site surgery for adrenal cortical adenoma inducing primary aldosteronism: initial experience
  2910. Type 2 diabetic patients with resistant hypertension should be screened for primary aldosteronism
  2911. Analytical variation in plasma renin activity: implications for the screening of primary aldosteronism
  2912. Misdiagnosis of two cases of primary aldosteronism owing to failure of computed tomography to detect adrenal microadenoma
  2913. The role of biochemical tests and clinical symptoms in differential diagnosis of primary aldosteronism
  2914. Aldosterone-to-renin ratio threshold for screening primary aldosteronism in Chinese hypertensive patients
  2915. Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism
  2916. Diagnosis of surgically-treatable forms of primary aldosteronism
  2917. The Aldosterone-renin ratio and primary aldosteronism/In reply
  2918. Diagnostic procedures for primary aldosteronism/diagnostische methoden für den primären hyperaldosteronismus
  2919. Salivary Aldosterone as a diagnostic aid in primary aldosteronism
  2920. Primary aldosteronism. A risk factor for aortic dissection?
  2921. Recurrence of primary aldosteronism after percutaneous ethanol injection
  2922. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion
  2923. Aldosterone and aldosteronism
  2924. A case of primary aldosteronism with end stage renal disease
  2925. Malignant hypertension and hypertensive encephalopathy in primary aldosteronism caused by adrenal adenoma
  2926. Effects of hypokalemia and left ventricular hypertrophy on QT interval in patients with primary aldosteronism
  2927. About an epidemic of primary aldosteronism
  2928. Primary aldosteronism caused by unilateral adrenal hyperplasia: rethinking the accuracy of imaging studies
  2929. Measurement of 18-hydroxycorticosterone during adrenal vein sampling for primary aldosteronism
  2930. Primary aldosteronism due to unilateral adrenal microadenoma in an elderly patient: efficacy of selective adrenal venous sampling
  2931. Primary aldosteronism with ventricular fibrillation: a case report
  2932. Diagnosis of primary aldosteronism in chronic kidney disease by I-131 NP-59 SPECT/CT imaging.
  2933. Primary aldosteronism takes (KCNJ) five!
  2934. Primary aldosteronism simulating polymyositis
  2935. A case of primary aldosteronism caused by multiple adrenocortical macronodules
  2936. Genetic screening for glucocorticoid-remediable aldosteronism (GRA): experience of three clinical centres in Poland
  2937. The serum sodium to urinary sodium to (serum potassium)2 to urinary potassium (SUSPPUP) ratio in patients with primary aldosteronism
  2938. Surgical management of primary aldosteronism. not everything that shines is gold
  2939. Metabolic dysfunction in primary aldosteronism
  2940. Change in the pattern of adrenal venous sampling over time in patients with primary aldosteronism
  2941. Overt diabetes mellitus in a patient with combined primary aldosteronism and Cushing’s syndrome
  2942. Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient
  2943. Primary aldosteronism: the case against screening
  2944. Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension.
  2945. Myocardial remodeling in low-renin hypertension: molecular pathways to cellular injury in relative aldosteronism
  2946. Case of ruptured multiple cerebral aneurysms associated with primary aldosteronism
  2947. Screening for primary aldosteronism in a cohort of Brazilian patients with resistant hypertension
  2948. Experience of retroperitoneoscopic adrenalectomy in 195 patients with primary aldosteronism
  2949. Primary aldosteronism
  2950. Simultaneous surgery for chronic aortic dissection and adrenal adenoma with primary aldosteronism
  2951. Hypertensive Complications in Patients with Primary Aldosteronism.
  2952. Successful treatment of primary aldosteronism due to computed tomography‐negative microadenoma
  2953. Response to renal function in primary aldosteronism: is glomerular hyperfiltration a hallmark of primary aldosteronism? Further results from the Primary Aldosteronism …
  2954. Morning plasma Aldosterone predicts the subtype of primary aldosteronism independant of sodium intake
  2955. Glucocorticoid-remediable aldosteronism
  2956. Primary aldosteronism with right-dominant heart failure
  2957. Clinical characteristics and surgery outcomes of unilateral nodular adrenal hyperplasia in primary aldosteronism: study of 145 cases
  2958. hypertension due to primary aldosteronism
  2959. Episodic rage associated with primary aldosteronism resolved with adrenalectomy
  2960. Aortic dissection-a rare complication of primary aldosteronism-a case report
  2961. A case of primary aldosteronism accompanied by rhabdomyolysis
  2962. Primary aldosteronism and resistant arterial hypertension
  2963. Comparison of target organ damages between primary aldosteronism and essential hypertension
  2964. The neuroendocrine-immune interface gone awry in aldosteronism
  2965. Plasma Aldosterone to renin ratio predicts treatment response in primary aldosteronism: Is volume loading needed?
  2966. Characteristics of left ventricular structural damage in patients with primary aldosteronism
  2967. A rare case of primary aldosteronism caused by bilateral functioning adrenocortical adenomas with renal cell carcinoma
  2968. A case of primary aldosteronism in childhood
  2969. Acute cerebral hemorrhage normalized plasma renin activity in a patient with primary aldosteronism
  2970. Metabolic syndrome and primary aldosteronism: time for reappraisal?
  2971. Clinical relevance of dietary salt intake on Aldosterone and the Aldosterone-to-renin ratio as screening parameters for primary aldosteronism
  2972. Aortic cell apoptosis in rat primary aldosteronism model
  2973. Cushing’s syndrome by left adrenocortical adenoma synchronously associated with primary aldosteronism by right adrenocortical adenoma: report of a case
  2974. Primary Aldosteronism
  2975. Left ventricular hypertrophy in patients with primary aldosteronism
  2976. Primary aldosteronism
  2977. Should primary aldosteronism be diagnosed among normotensive subjects during general health check-up and/or at general outpatient clinics?
  2978. New diagnostic procedure for primary aldosteronism: adrenal venous sampling under adrenocorticotropic hormone and angiotensin II receptor blocker—application to …
  2979. Value of saline load test in diagnosis of primary aldosteronism [J]
  2980. Screening for primary aldosteronism: progress and frustration
  2981. Diagnosis and management of primary aldosteronism
  2982. TREATMENT OF PRIMARY ALDOSTERONISM: SHORT AND MIDDLE-TERM EFFECTS OF MEDICAL AND SURGICAL THERAPY IN PRIMARY …
  2983. Combining body mass index and serum potassium to urine potassium clearance ratio is an alternative method to predict primary aldosteronism
  2984. Primary aldosteronism due to adrenocortical adenoma with concurrent ileum carcinoid tumor: case report
  2985. Primary aldosteronism presented with intracranial hemorrhage
  2986. Is primary aldosteronism a benign disorder? Old evidence reconfirmed
  2987. … producing adrenal adenoma associated with a latent aldosteronoma: usefulness of the ACTH loading test for the detection of covert aldosteronism in overt Cushing …
  2988. A case of primary aldosteronism with aortic dissection
  2989. Risk factors of decreased glomerular filtration rate in patients with primary aldosteronism
  2990. A possible association between primary aldosteronism and a lower β-cell function
  2991. 100 cases of primary aldosteronism: careful choice of patients for surgery using adrenal venous sampling and CT imaging results in excellent blood pressure and …
  2992. Evolution features of hypertensive patients with primary aldosteronism-Prospective Study
  2993. The Clinical Implication and Problems of Adrenal Vein Sampling in Patients with Primary Aldosteronism.
  2994. Cautions over idiopathic aldosteronism
  2995. The current epidemic of primary aldosteronism: causes and consequences
  2996. Primary aldosteronism in diabetic subjects with resistant hypertension: response to Umpierrez et al.
  2997. Diagnosis of primary aldosteronism-debate continues. Part I
  2998. Primary aldosteronism presenting as bibrachial paralysis
  2999. Adrenal cortex scintigraphy with and without dexamethasone suppression in the study of primary aldosteronism
  3000. Primary Aldosteronism: The Surgical Perspective
  3001. Potassium supplementation improves the natriuretic response to central volume expansion in primary aldosteronism
  3002. Primary Aldosteronism and public health: new definitions, new challenges
  3003. Anesthesia and laparoscopic adrenalectomy for primary aldosteronism.
  3004. Factors influencing outcome of surgical treatment for primary aldosteronism
  3005. Recovery from renal failure in malignant hypertension associated with primary aldosteronism: effect of an ACE inhibitor
  3006. Use of gadolinium contrast adrenal venography for the assessment of primary aldosteronism in a patient with iodine allergy
  3007. PREVALENCE OF PRIMARY ALDOSTERONISM (PA) IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS: RESULTS OF A NATIONWIDE SURVEY IN ITALY: 5B. 3
  3008. A patient with concurrent primary aldosteronism and Page kidney
  3009. Primary aldosteronism importance to the
  3010. Diagnosis and treatment of primary aldosteronism (report of 46 cases)
  3011. Primary aldosteronism complicated with chronic renal failure
  3012. A case of nephrocalcinosis associated with primary aldosteronism
  3013. Anterior ischemic optic neuropathy associated with idiopathic aldosteronism and hypertension
  3014. Animal models of primary aldosteronism
  3015. Medical Management of Primary Aldosteronism
  3016. Laparoscopic management of primary aldosteronism: a report of 227 cases
  3017. Diagnosis of adenomatous primary aldosteronism in a patient with severe hypertension
  3018. Insulin signaling in adipose tissue of patients with primary aldosteronism
  3019. Adrenalectomy for Primary Aldosteronism
  3020. Biomarkers of endothelial dysfunction and risk of early organ damage: a comparison between patients with primary aldosteronism and essential hypertension
  3021. Bilateral aldosteronoma associated with secondary aldosteronism in a chronic hemodialysis subject
  3022. Adrenal venous sampling crucial in primary aldosteronism?
  3023. A case of adrenocortical carcinoma with concurrent Cushing’s syndrome and primary aldosteronism
  3024. Development of pseudo-aldosteronism depends on amount of glycyrrhizae radix in each individual
  3025. Primary aldosteronism with HIV infection: important considerations when using the Aldosterone: renin ratio to screen this unique population
  3026. Long‐term follow‐up of a girl with primary aldosteronism: Effect of potassium supplement
  3027. Primary Aldosteronism Due to Aldosterone Producing Adenama in the Presence of Contralateral Nonfunctioning Adenama.
  3028. Adrenal venous sampling but not computed tomography is essential before undertaking adrenalectomy for primary aldosteronism
  3029. Surgical Operation of Primary Aldosteronism [J]
  3030. Improving adrenal venous sampling in primary aldosteronism
  3031. A case of primary aldosteronism accompanied by hypokalemic rhabdomyolysis
  3032. Diagnosis and management of primary aldosteronism in cats
  3033. … Role for P450 scc in the Overproduction of Aldosterone in Aldosterone-Producing Adenoma and Idiopathic Hyperaldosteronism in Patients with Primary Aldosteronism
  3034. A new method of super-selective acth-stimulated adrenal venous sampling is revolutionarily useful for treatment of primary aldosteronism: PP. 18.179
  3035. Laboratory Test of Primary Aldosteronism
  3036. Primary aldosteronism and diabetes mellitus
  3037. Response to More Fuel to the Debate on the “Epidemic of Primary Aldosteronism”
  3038. Interpretation of clinical practice guidelines of primary aldosteronism.
  3039. The study of screening rates of primary aldosteronism in obstructive sleep apnea syndrome with hypertension as the blood pressure classification
  3040. Gender difference in QT interval in patients with primary aldosteronism
  3041. Diagnostic value of I-131 NP-59 SPECT/CT scintigraphy in patients with subclinical or atypical features of primary aldosteronism
  3042. Prevalence of metabolic syndrome in patients with primary aldosteronism
  3043. Primary aldosteronism in type 1 diabetes mellitus
  3044. Primary aldosteronism in a patient after surgical treatment of primary hyperparathyroidism
  3045. Observation on the prevalence of primary aldosteronism in the in-patients in Xinjiang [J]
  3046. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism
  3047. Response to the Article:“Primary Aldosteronism: Are We Missing the Wood for the Trees?”
  3048. HIGH EXPRESSION OF THE PRO-RENIN RECEPTOR IN Aldosterone PRODUCING ADENOMA CAUSING HUMAN PRIMARY ALDOSTERONISM: 4D. 02
  3049. Time to normalization of blood pressure after an adrenalectomy for patients with primary aldosteronism
  3050. Prevalence of glucose metabolism disturbance in primary aldosteronism
  3051. … PRESSURE AND POTASSIUM EFFECTS OF THE NEW DIRECT Aldosterone SYNTHASE INHIBITOR, LCI699, IN PATIENTS WITH PRIMARY ALDOSTERONISM …
  3052. Adrenal venous sampling revisited-Crucial role in the management of primary aldosteronism patients
  3053. … adrenal incidentalomas from normotensive and hypertensive patients: Distinguishing subclinical or atypical primary aldosteronism from adrenal incidentaloma
  3054. Diagnosis and treatment of primary aldosteronism
  3055. Kidney in primary aldosteronism: A key determinant of treatment outcome
  3056. Primary Aldosteronism
  3057. Association of renovascular hypertension and primary aldosteronism
  3058. Myasthenia gravis complicated with primary aldosteronism and hypokalemic myopathy
  3059. A possible association between primary aldosteronism and a lower β-cell function
  3060. Anesthetic management for electroconvulsive therapy (ECT) in a patient with primary aldosteronism
  3061. OR-39: Prevalence of unrecognized primary aldosteronism in essential hypertension
  3062. Treatment of primary aldosteronism-debate continues. Part II
  3063. Clinical significance of Aldosterone to renin ratio in screening primary aldosteronism
  3064. Primary Aldosteronism
  3065. A Case Study of Primary Aldosteronism
  3066. Adrenalectomy for primary aldosteronism
  3067. Role of adrenal venous sampling in the treatment strategy for primary aldosteronism
  3068. Clinical Analysis of Primary Aldosteronism
  3069. Primary aldosteronism
  3070. K001 Is primary aldosteronism a channelopathy?
  3071. Primary Aldosteronism
  3072. Misleading diagnosis of renal artery stenosis by magnetic resonance angiography in a patient with primary aldosteronism
  3073. Primary Aldosteronism Complicated by Severe Hypokalemic Myopathy
  3074. HORMONAL EFFECTS OF THE NEW DIRECT Aldosterone SYNTHASE INHIBITOR, LCI699, IN PATIENTS WITH PRIMARY ALDOSTERONISM: 5C. 06
  3075. Will the lessons from primary aldosteronism change the treatment of hypertension and left ventricular hypertrophy?
  3076. Factors Influencing Outcome of Surgical Treatment for Primary Aldosteronism
  3077. Primary aldosteronism
  3078. Nonprimary Aldosteronism
  3079. Surgical treatment of primary aldosteronism [J]
  3080. Diagnosis and surgical Treatment of primary Aldosteronism
  3081. aldosteronism. Some, possibly many, normokalemic
  3082. Analysis of diagnosis and treatment of primary aldosteronism:(Report of 63 cases)
  3083. Primary aldosteronism: analysis of a series of 54 patients
  3084. The evolution of primary aldosteronism
  3085. Long-term consequences of primary aldosteronism
  3086. Primary aldosteronism: an update
  3087. Hypokalemic paralysis in a young woman with thyrotoxicosis and primary aldosteronism
  3088. Diagnosis and treatment of primary aldosteronism
  3089. Evaluation of High-Dose Spironolactone in the Preoperative Preparation of Primary Aldosteronism
  3090. Glucolipid metabolism characteristics analysis of primary aldosteronism
  3091. A brief history of diagnosis and treatment of primary aldosteronism.
  3092. Diagnosis and Treatment of Primary Aldosteronism
  3093. Surgical treatment of primary aldosteronism.
  3094. Is confirmation of an adrenal adenoma in patients with primary aldosteronism sufficient for indication of adrenalectomy?
  3095. Estimation of the efficacy of the measurement of plasma renin activity and direct renin in diagnostics of primary aldosteronism
  3096. The diagnosis and treatment of primary aldosteronism (report of 507 cases)
  3097. Primary aldosteronism presenting with hypertension and quadriparesis
  3098. Controversies on the Diagnosis of Primary Aldosteronism
  3099. Clinical Features of Patients with Primary Aldosteronism
  3100. Studies of diagnosis and differential diagnosis in primary aldosteronism
  3101. Seeing is Believing—Just not in Primary Aldosteronism
  3102. Primary Aldosteronism and Pregnancy: A Case Report
  3103. Current opinion on primary aldosteronism
  3104. Characteristics of glucolipid metabolism and analysis of related factors in patients with primary aldosteronism [J]
  3105. Supracentrimetric nodule on computed tomography does not exclude adrenal venous sampling before surgery for primary aldosteronism
  3106. The Aldosterone-Renin Ratio and Primary Aldosteronism: In Response
  3107. Diagnosis and treatment of primary aldosteronism. An analysis of 18 cases
  3108. Diagnosis and Treatment of Primary Aldosteronism (Report of 14 Cases)[J]
  3109. Normokalaemic primary aldosteronism due to an Aldosterone-producing adrenal adenoma–Case 06/2009
  3110. Genomic profile in primary aldosteronism
  3111. Differential diagnosis of subtypes in primary aldosteronism
  3112. How to screen for pheochromocytoma, primary aldosteronism and Cushing’s syndrome
  3113. Primary aldosteronism-why is the diagnosis difficult?
  3114. Response to About an Epidemic of Primary Aldosteronism
  3115. Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism
  3116. CLINICAL AND BIOLOGICAL ASPECTS OF PRIMARY ALDOSTERONISM: 18 CASES: P3. 115
  3117. New index of using serum sodium and potassium and urine sodium and potassium jointly in screening primary aldosteronism in hypertensive patients
  3118. Primary aldosteronism: from genesis to genetics q
  3119. Progress in medications of primary aldosteronism.
  3120. Response to Metabolic Dysfunction in Primary Aldosteronism
  3121. Evaluation of Aldosterone to renin concentration ratio as a reliable screening parameter for primary aldosteronism applying currently available assays
  3122. Altered heart rate variability but preserved temporal relationship with sleep stages in a patient with primary aldosteronism
  3123. Primary Aldosteronism: An Update on Screening, Diagnosis and Treatment
  3124. Patient Guide to Detection, Diagnosis and Treatment of Primary Aldosteronism
  3125. Recent progress of diagnosis and treatment of primary aldosteronism
  3126. Cardiovascular complications in patients with primary aldosteronism
  3127. Endocrine—Primary Aldosteronism
  3128. Endocrine—Primary Aldosteronism
  3129. Clinical significance of determination of SAC/PRA value in patients with primary aldosteronism
  3130. … ON LEFT VENTRICULAR MASS INDEX AND BLOOD PRESSURE IN PATIENTS WITH PRIMARY ALDOSTERONISM–RETROSPECTIVE ANALYSIS: 5B. 4
  3131. Delayed Arterial Switch Operation for D-Transposition of the Great Arteries and Glucocorticoid Remediable Aldosteronism
  3132. Non-surgical therapy of primary aldosteronism
  3133. Ratio of plasma Aldosterone concentration to renin activity in screening for primary aldosteronism: the current situation and influencing factors.
  3134. 6.15 Roles of Clinical Criteria, CT Scan and Adrenal Vein Sampling in Differential Diagnosis of Primary Aldosteronism Subtypes
  3135. Application of captopril test in the diagnosis of primary aldosteronism
  3136. The value of CT in the etiological classification of primary aldosteronism
  3137. METABOLIC DIFFERENCES BETWEEN MAIN TYPES OF PRIMARY ALDOSTERONISM: PP. 18.188
  3138. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism
  3139. Primary aldosteronism during 2007-2011 in Iceland
  3140. Aberrant receptor expression in primary aldosteronism
  3141. To stimulate or not to stimulate: the differential diagnosis of aldosteronism revisited
  3142. Primary aldosteronism in newly diagnosed hypertensive patients
  3143. Comparison of strategies for biochemical diagnosis of primary aldosteronism in German academic centres
  3144. Screening and diagnosis of primary aldosteronism
  3145. The laparoscopic surgical treatment of primary aldosteronism
  3146. Screening for primary aldosteronism in a secondary care diabetes population
  3147. Atypical clinical manifestations of primary aldosteronism.
  3148. Adrenal venous sampling (AVS) is essential for detecting unilateral or bilateral adrenal lesions in primary aldosteronism
  3149. … OF BLOOD PRESSURE AND LEFT VENTRICULAR (LV) GEOMETRY AFTER ADRENALECTOMY OR MEDICAL TREATMENT FOR PRIMARY ALDOSTERONISM …
  3150. Demonstration of Blood Pressure-Independent Non Infarct Myocardial Fibrosis in Primary Aldosteronism: A Cardiac MRI Study
  3151. PREVALENCE OF PRIMARY ALDOSTERONISM AMONG HYPERTENSIVE PATIENTS: P 774
  3152. Imaging diagnosis of primary aldosteronism.
  3153. The confirmatory Tests of primary aldosteronism should be selected in each countries-the analysis of 83 patients in our hospital
  3154. OR-46: High prevalence of primary aldosteronism among black and white subjects with resistant hypertension
  3155. Role of imaging diagnosis in surgical treatment of primary aldosteronism
  3156. Recent progress in the treatment of idiopathic aldosteronism
  3157. Partial Adrenalectomy in Patients with Primary Aldosteronism
  3158. AN EXPERIENCE OF SURGICAL TREATMENT FOR PRIMARY ALDOSTERONISM ASSOCIATED WITH CHRONIC RENAL FAILURE
  3159. Treatment of primary aldosteronism with retroperitoneal laparoscopic surgery [J]
  3160. Primary Aldosteronism And Inappropriateness Of Left Ventricular Mass
  3161. Retroperitoneal laparoscopic surgery for primary aldosteronism (report of 90 cases)
  3162. Female patients with primary aldosteronism are diagnosed earlier and have a better outcome
  3163. Endocrine hypertension due to primary aldosteronism
  3164. Vitamin D deficiency in primary aldosteronism
  3165. Pseudo-hypo aldosteronism: Type II
  3166. ANALYSING THE RELATIVE FACTORS THAT INFLUENCE GLOMERULAR FILTRATION RATE IN PRIMARY ALDOSTERONISM.
  3167. A Case of Primary Aldosteronism after Renal Transplantation
  3168. A case of nephrocalcinosis with primary aldosteronism
  3169. PSYCHOLOGICAL ASSESSMENT OF PRIMARY ALDOSTERONISM. A CONTROLLED STUDY: PP. 39.279
  3170. Prevalence of primary aldosteronism among hypertensive patients (preliminary results)
  3171. Michał Lityński, MD-the author of the first description in the world literature of primary aldosteronism-after 50 years
  3172. Investigating children of glucocorticoid remediable aldosteronism patients
  3173. Glucocorticoid-remediable aldosteronism: Report of a family and literature review
  3174. Clinical Significance of Strengthening Screening and Diagnosis of Primary Aldosteronism
  3175. Periodic paralysis: an uncommon complication of primary aldosteronism
  3176. Prevalence of primary aldosteronism in hypertensive subjects with hyperglycaemia
  3177. Renal function in patients with primary aldosteronism: comparison with essential hypertension
  3178. Guidelines for diagnosis and treatment of primary aldosteronism
  3179. PREVALENCE OF PRIMARY ALDOSTERONISM AMONG UNSELECTED HYPERTENSIVE PATIENTS: P2. 104
  3180. Potassium channels in primary aldosteronism
  3181. Investigation and Management of Primary Aldosteronism-A Review of Cases and Audit of Outcomes in a Tertiary Referral Centre
  3182. Left ventricular mass in patients with primary aldosteronism after etiologic treatment
  3183. Severe hypokalemia-associated rhabdomyolise and unusual poliuria in patient with primary aldosteronism: A case presentation
  3184. Combined primary aldosteronism and preclinical Cushing
  3185. Primary Aldosteronism: Current Concepts of Epidemic, Diagnosis, and Treatment.
  3186. The influence of the ovarian cycle on the first-step laboratory screening for primary aldosteronism
  3187. PERIPHERAL ARTERIAL STIFFNESS IN PRIMARY ALDOSTERONISM: 8D. 03
  3188. Osteopontin in patients with primary aldosteronism
  3189. Treating Primary Aldosteronism with New Aldosterone Receptor Antagonists
  3190. Moleculan Genetics of Glucocorticoid Remediable Aldosteronism.
  3191. Primary aldosteronism and sleep apnea syndrome.
  3192. Primary Aldosteronism Screening and Diagnosis in Primary Health Care
  3193. DIFFERENCES IN PULSE WAVE VELOCITY BETWEEN MAIN TYPES OF PRIMARY ALDOSTERONISM: 8D. 04
  3194. TRANSCRIPTIONAL AND PATHOLOGICAL ANALYSIS OF PRIMARY ALDOSTERONISM: 4D. 01
  3195. Evaluation of renal function of primary aldosteronism between pre-and post-treatment
  3196. THE COMPARISON OF CLINICAL FEATURES BETWEEN HYPOKALEMIC AND NORMOKALEMIC PRIMARY ALDOSTERONISM PATIENTS: 8D. 05
  3197. Retrospective analysis of diagnostic and treatment outcomes of primary aldosteronism
  3198. Clinical analysis of 330 patients with primry aldosteronism
  3199. Factors Associated with Amelioration of Blood Pressure after Surgery for Primary Aldosteronism
  3200. Metabolic syndrome among patients with primary aldosteronism: a common feature?
  3201. Evaluation of cardiac structure and function changes with tissue Doppler echocardiography in primary aldosteronism patients
  3202. Predicting factors of the post-surgical decline in renal function in patients with primary aldosteronism
  3203. Aortic Intramural Hematoma Associated with Primary Aldosteronism.
  3204. Screening for peptide hormone receptor expression in primary aldosteronism
  3205. Factors Associated with Normal Blood Pressure after Surgery To Treat Primary Aldosteronism
  3206. Glucocorticoid remediable aldosteronism. A Northern Ireland experience
  3207. Anxiety and depressive symptoms in patients with primary aldosteronism in a longitudinal study
  3208. Primary Aldosteronism: Rare or Common Condition in Hypertensive Patients and Normotensive Individuals?
  3209. RELATIVE HYPERFILTRATION IN PRIMARY ALDOSTERONISM: OP 146
  3210. Comparing the Prevalence of Primary Aldosteronism in Hypertensive Diabetic and Non-diabetic Patients.
  3211. P-628: Primary Aldosteronism (PA) Prevalence in Italy (PAPY) study: Results of a nationwide survey
  3212. Primary aldosteronism due to right adrenal adenoma case report.
  3213. Primary aldosteronism: renal effects compared with primary hypertension
  3214. Study on significance of serum level of high-sensitivity C-reactive protein in patients with primary aldosteronism
  3215. Prevalence of primary aldosteronism in Chinese patients with resistant hypertension
  3216. Screening for aberrant peptide hormone responsiveness in primary aldosteronism
  3217. Gene polymorphisms related to metabolic and cardiac complications in patients with primary aldosteronism
  3218. Plasma and urine Aldosterone to PRA ratio in the diagnosis of Primary Aldosteronism
  3219. Adrenal venous sampling in the differential diagnosis of primary aldosteronism
  3220. THE KIDNEY AS TARGET ORGAN IN PRIMARY ALDOSTERONISM: 4B. 7
  3221. Analysis of left ventricular hypertrophy in patients with unilateral and bilateral primary aldosteronism
  3222. Primary aldosteronism screening: What is the Aldosterone: renin test?
  3223. Simultaneous presentation of Brugada syndrome and primary aldosteronism
  3224. INCREASED DIAGNOSIS OF PRIMARY ALDOSTERONISM, INCLUDING SURGICALLY CORRECTABLE FORMS, IN CENTERS FROM FIVE CONTINENTS: P2. 102
  3225. Predictors for cure and normotension after adrenalectomy for primary aldosteronism
  3226. Metabolic disturbance and cardiovascular events in primary aldosteronism: recent advance.
  3227. IS RELYING ON CT-SCAN FOR SUBTYPING OF PRIMARY ALDOSTERONISM REALLY THAT BAD? A FOLLOW-UP BASED APPROACH: PP. 18.180
  3228. Primary aldosteronism associated with subclinical Cushing syndrome
  3229. Daily profiles of Aldosterone secretion in primary aldosteronism
  3230. Incidence of metabolic disorders in patients with essential hypertension and patients with primary aldosteronism
  3231. Primary aldosteronism due to unilateral adrenal hyperplasia: report of a case and review of the literature
  3232. Audit of adrenal vein sampling for primary aldosteronism
  3233. Adrenal venous sampling in the differential diagnosis of primary aldosteronism
  3234. Cornell product left ventricular hypertrophy in electrocardiogram in patients with primary aldosteronism
  3235. The difficulties in differential diagnosis of primary aldosteronism subtypes in women with strokes at a young age
  3236. Retroperitoneal laparoscopic surgery vs open adrenalectomy for primary aldosteronism [J]
  3237. Usefulness of FDG-PET for detecting primary aldosteronism in patient who have bilateral adrenal incidentaloma
  3238. Aldosterone/plasma renin activity ratio is a sensitive parameter for screening patients with primary aldosteronism
  3239. Retroperitoneal laparoscopic surgery for primary aldosteronism as compared with open adrenalectomy
  3240. A case of The Primary Aldosteronism with Hypokalemic Periodic Paralysis
  3241. Primary Aldosteronism in Diabetic Subjects With Resistant hypertension: Response to Ng et al.
  3242. Human primary aldosteronism; investigation of the mechanism leading to autonomous Aldosterone excess
  3243. Postoperative Outcomes in Patients Undergoing Adrenalectomy for Primary Aldosteronism
  3244. The Diagnosis Value of Plasma Aldosterone/renin Activity Ratio in Primary Aldosteronism [J]
  3245. HUMORAL AND CELL-MEDIATED AUTOIMMUNITY MECHANISMS IN THE PATHOGENESIS OF PRIMARY ALDOSTERONISM: PP. 39.286
  3246. Incidental primary aldosteronism and incidental Cushing’s syndrome
  3247. Comparison of Three Different Doses of ACTH Stimulation During AVS For Primary Aldosteronism
  3248. PREVALENCE OF PRIMARY ALDOSTERONISM IN RESISTANT hypertension AND ITS ASSOCIATION WITH EARLY VASCULAR DAMAGE: PP. 18.197
  3249. Use of the 250mcg short synacthen test to differentiate between patients with primary aldosteronism and essential hypertension
  3250. Pathophysiological significance of CYP11B2 immunohistochemical staining in primary aldosteronism
  3251. PRIMARY ALDOSTERONISM AND ESSENTIAL hypertension: ASSESSMENT OF THE GLOBAL CARDIOVASCULAR RISK AT DIAGNOSIS AND FOLLOW-UP …
  3252. Primary aldosteronism and secondary hyperparathyroidism of the vitamin D deficiency
  3253. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal imaging findings
  3254. Metabolic parameters in patients with primary aldosteronism: relation to snps of the adiponectin gene
  3255. CONCURRENT PRIMARY ALDOSTERONISM AND SUBCLINICAL CORTISOL HYPERSECRETION. A PERSPECTIVE STUDY: PP. 39.278
  3256. Intrathoracic blood volume during laparoscopic adrenectomy for primary aldosteronism under general anesthesia
  3257. Arterial stiffness, intima-media thickness and fibrosis of carotid arteries in patients with primari aldosteronism
  3258. Regulation of Aldosterone synthase expression in normal adrenal and primary aldosteronism
  3259. Adrenal Vein Sampling for Identification of the Subtypes of Primary Aldosteronism: Results on 2635 Cases of the Avis Study
  3260. Significance of Aldosterone/plasma renin activity ratio in diagnosis of primary aldosteronism with ROC curve
  3261. Expressions and significance of two kinds of vascular endothelial growth factors of different origin in adrenocortical lesions of primary aldosteronism
  3262. Sympathetic Overactivity in Hypertensive Patients With Primary Aldosteronism
  3263. Usefulness of the Aldosterone-to-Renin Ratio for Screening Primary Aldosteronism
  3264. Diagnostic evaluation of plasma Aldosterone concentration to plasma renin activity ratio in primary aldosteronism
  3265. Secondary hypertension Caused by Endocrine Disorders Except Primary Aldosteronism and Pheochromocytoma
  3266. A-006 PRIMARY ALDOSTERONISM: CYSTATIN C AND ENDOTHELIAL DYSFUNCTION
  3267. Long-Term Regression of Left Ventricular Hypertrophy Through Inward Remodeling with Specific Treatment of Primary Aldosteronism
  3268. ABNORMALITIES OF THE HYPOTHALAMIC-PITUITARY-ADRENAL (HPA) AXIS IN PRIMARY ALDOSTERONISM: P2. 129
  3269. ADRENALECTOMY IMPROVES COMMON CAROTID INTIMA-MEDIA THICKNESS IN PRIMARY ALDOSTERONISM: PP. 39.290
  3270. BLOOD PRESSURE REDUCTION FOLLOWING ADRENALECTOMY IN PRIMARY ALDOSTERONISM: A RETROSPECTIVE FOLLOW-UP STUDY: PP. 18.174
  3271. Two Case of Primary Aldosteronism Induced by Aldosterone Producing Adrenal Adenoma in a Family.
  3272. Adiponectin gene polymorphisms in primary aldosteronism and their relation to the metabolic syndrome
  3273. Control study of clinical effect in retroperitoneal laparoscopic adrenalectomy and open surgery for primary aldosteronism
  3274. Low detection Rate of Primary Aldosteronism when Screening Among Hypertensive Patients with Ongoing Medication
  3275. Adrenal venous sampling should be performed before adrenalectomy in primary aldosteronism?
  3276. Using plasma renin concentration to screen primary aldosteronism in hypertensive patients and to observe the effect of posture
  3277. Lipoprotein (a) is Elevated in Patients with Renovascular hypertension, but not in Patients with Primary Aldosteronism
  3278. A unique case of recurrent malignant hypertension after removal of an adrenal tumor for primary aldosteronism
  3279. Demonstration of blood pressure-independent diffuse cardiac fibrosis in Primary Aldosteronism-a cardiac MRI study
  3280. … APNEA SYNDROME IN HYPERTENSIVE PATIENTS REFERRED TO A SPECIALIZED OUTPATIENT CLINIC AND ASSOCIATION WITH PRIMARY ALDOSTERONISM …
  3281. New quick cortisol assay during adrenal vein sampling in patients with primary aldosteronism
  3282. Percutaneous Transluminal Adrenal Ablation for Aldosteronism: Report of Initial Three Cases
  3283. ACUTE AORTIC DISSECTION COMPLICATING CLINICAL COURSE OF PRIMARY ALDOSTERONISM DUE TO Aldosterone PRODUCING ADENOMA: P1. 300
  3284. Plasma Aldosterone/renin ratio——a sensitive screening test and parameter for primary aldosteronism
  3285. Primary aldosteronism is very frequent in resistant hypertension and is associated to early renal vascular damage
  3286. The effectiveness on screening for primary aldosteronism in patients with hypertension by using the urinary potassium to (serum potassium)~ 2 ratio
  3287. Salivary Aldosterone to cortisol ratio: Potential screening tool for primary aldosteronism
  3288. A Case of Primary Aldosteronism due to Remnant Adenoma after Adrenalectomy in Pregnant Woman
  3289. Successful treatment of a mycotic aortic pseudoaneurysm in a patient with type 2 diabetes mellitus while treating primary aldosteronism with spironolactone
  3290. Influential factors on the ratio of plasma Aldosterone concentration to plasma renin activity in screening primary aldosteronism
  3291. Renal complications of aldosteronism and diabetes: role of oxidative stress and protective effects of polyphenol extract
  3292. … -TERM CHANGES OF LEFT VENTRICULAR DIASTOLIC FUNCTION AFTER ADRENALECTOMY OR MEDICAL TREATMENT FOR PRIMARY ALDOSTERONISM: PP …
  3293. Pseudo-aldosteronism induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients
  3294. Inhibitory effect of carbamazepine on hypotensive action of spironolactone in primary aldosteronism
  3295. primary aldosteronism and (2) the probable hyper-secretion of renin secondary to hypertrophy of the
  3296. Research advance of plasma Aldosterone concentration to plasma renin activity ratio-the screening index of primary aldosteronism
  3297. P-559: Prevalence of primary aldosteronism among unselected hypertensive patients
  3298. Adrenal Adenoma Removal Improves Glucose Control in A Diabetic Patient with Primary Aldosteronism: A Case Report and Literature Review
  3299. Differential diagnosis of primary aldosteronism by peripheral plasma levels of 18-oxo-cortisol: a noninvasive method with a high specificity
  3300. The sodium to urinary sodium to potassium to urinary potassium (SUSPUP) ratio in primary aldosteronism
  3301. Long-term changes of left ventricular (LV) structure and function after adrenalectomy or medical treatment for primary aldosteronism
  3302. EFFECTS OF FEMALE SEX HORMONES AND CONTRACEPTIVE PILL ON THE DIAGNOSTIC WORK-UP FOR PRIMARY ALDOSTERONISM: PP. 18.181
  3303. SUBTLE HYPERPARATHYROIDISM: A NOVEL FEATURE OF PRIMARY ALDOSTERONISM THAT IS CORRECTED BY ADRENALECTOMY: PP. 39.272
  3304. Hyper Transcardiac Extraction of Aldosterone Promote Ventricular Remodeling and Cardiac Mass in Patients with Primary Aldosteronism
  3305. SENSITIVITY, SPECIFICITY AND REPRODUCIBILITY OF THE Aldosterone-TO-RENIN-RATIO AS A SCREENING TEST FOR PRIMARY ALDOSTERONISM: PP …
  3306. Assessing the quality of studies on screening primary aldosteronism by using plasma Aldosterone to renin activity ratio
  3307. DIFFERENTIAL DIAGNOSIS OF PRIMARY ALDOSTERONISM SUBTYPES USING ADRENAL VEIN SAMPLING: EVALUATION OF THE GERMANS CONN’S …
  3308. The accuracy of combining Aldosterone to renin ratio and low renin level in diagnosing primary aldosteronism
  3309. INTRA-OPERATIVE CORTISOL ASSAY IMPROVES THE SUCCESS RATE OF ADRENAL VENOUS SAMPLING FOR PRIMARY ALDOSTERONISM: PP. 18.198
  3310. The effectiveness on screening for primary aldosteronism in patients with hypertension by using the urinary potassium to (serum potassium) ratio.
  3311. Long-term modifications in left ventricular structure and function after adrenalectomy or medical treatment in patients with primary aldosteronism
  3312. Aldosterone elevation during the luteal phase of the menstrual cycle may suggest primary aldosteronism in hypertensive women
  3313. P-534: Predictive value of the Aldosterone-renin ratio in screening for primary aldosteronism
  3314. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism following adrenalectomy
  3315. Sporadic solitary Aldosterone-and cortisol-cosecreting adenomas: a subtype of primary aldosteronism
  3316. 49 HYPOZINCEMIA AND OXIDATIVE STRESS IN RATS WITH CHRONIC ALDOSTERONISM.
  3317. Cardiovascular effects of unilateral adrenalectomy are superior to those of Aldosterone antagonist treatment in primary aldosteronism
  3318. GENETIC PROFILING OF OMENTAL ADIPOSE TISSUE IN PATIENTS WITH PRIMARY ALDOSTERONISM AND CANDIDATE GENES FOR CARDIOMETABOLIC …
  3319. Simultaneous occurrence of hypokalemic periodic paralysis and rhabdomyolysis as complications of hypokalemia with primary aldosteronism
  3320. Aldosterone REDUCTION BY UNILATERAL ADRENALECTOMY REDUCES SALT APPETITE IN PATIENTS CURED OF PRIMARY ALDOSTERONISM: LB2. 4
  3321. Aldosterone-PRODUCING ADENOMA CAUSING HUMAN PRIMARY ALDOSTERONISM ARE CHARACTERISED BY UNDER-EXPRESSION OF THE TWIK …
  3322. 18-Hydroxycorticosterone, 18-hydroxycortisol and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes
  3323. … Adrenal Vein Sampling International Study (Avis) on Use and Interpretation of Adrenal Vein Sampling for Differentiating the Major Subtypes of Primary Aldosteronism …
  3324. In primary aldosteronism, plasma Aldosterone concentration is an independent risk factor for albuminuria, and the higher baseline urinary albumin excretion predicts …
  3325. Mutations in the KCNJ5 Gene Imply a Higher Lateralization Index at Adrenal Vein Sampling for Primary Aldosteronism
  3326. Oxidative Stress, Mitochondrial Permeability Pore Opening and Cardiac Hypertrophy With Fibrosis in Aldosteronism: Response to Supplemental Zinc
  3327. SHOULD MANAGEMENT OF PRIMARY ALDOSTERONISM BE BASED ON ADRENAL VEIN SAMPLING OR ADRENAL CT-SCAN? A RETROSPECTIVE STUDY OF …
  3328. Anger and anxiety in patients with primary aldosteronism treated with amiloride hydrochloride or spironolactone or adrenalectomy
  3329. … DOES NOT AFFECT ADRENAL CORTISOL AND CHROMOGRANIN A RELEASE: IMPLICATIONS FOR THE DIAGNOSIS OF PRIMARY ALDOSTERONISM: PP …
  3330. … Aldosterone EFFECTS OF Aldosterone SYNTHASE INHIBITION VS. MINERALOCORTICOID BLOCKADE IN PATIENTS WITH PRIMARY ALDOSTERONISM …
  3331. 201 CYTOSOLIC CALCIUM AND ZINC IN CARDIOMYOCYTES OF RATS WITH ALDOSTERONISM: RESPONSE TO SPIRONOLACTONE AND AMLODIPINE …
  3332. P-567: Prevalence of primary aldosteronism (PA) nationwide in Italy in newly diagnosed hypertensive patients
  3333. 636 PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3334. P-592: Active renin concentration and the Aldosterone/renin ratio in screening primary aldosteronism
  3335. 7.20 Adiponectin Gene Variants in the Metabolic Syndrome of Patients with Primary Aldosteronism and Essential hypertension
  3336. Aldosterone regulation for 18 years in a case of primary aldosteronism
  3337. OR-12: No association between primary aldosteronism and two CYP11B2 polymorphisms in a well-characterized Australian sample
  3338. P-640: Prevalence of primary aldosteronism among hypertensive patients
  3339. P-598: Prevalence of primary aldosteronism among hypertensive patients
  3340. 73 BONE LOSS IN ALDOSTERONISM. RESCUE WITH HYDROCHLOROTHIAZIDE AND SPIRONOLACTONE.
  3341. 53 CYTOSOLIC AND MITOCHONDRIAL CALCIUM IN RAT CARDIOMYOCYTES: RESPONSE TO ALDOSTERONISM AND COTREATMENT WITH …
  3342. 642 INFLUENCE OF AGING ON THE SCREENING TEST OF PRIMARY ALDOSTERONISM DIAGNOSIS
  3343. 657 RE-EVALUATION OF THE SALINE INFUSION TEST FOR PRIMARY ALDOSTERONISM: DURATION, THE SUBTYPE CLASSIFICATION AND CUT-OFF LIMITS …
  3344. AS-248: Primary Aldosteronism: Treated by Superselecive Adrenal Arterial Embolization
  3345. 84 Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure 88 Primary aldosteronism: cardiovascular, renal and metabolic implications
  3346. 46 URINARY ZINC LOSSES IN RATS WITH ALDOSTERONISM: PREVENTION BY ACETAZOLAMIDE.
  3347. 21 PRIMARY ALDOSTERONISM IN A PATIENT WITH IDIOPATHIC INTRACRANIAL hypertension
  3348. P-568: Apparent prevalence of primary aldosteronism in a referral practice: a retrospective study
  3349. 7. Young W, Stanson A, Thompson G, et al. Role for adrenal ve-nous sampling in primary aldosteronism. Surgery 2004; 136: 1227–1235. 8. Kahn S, Angle J. Adrenal …
  3350. U-004 PRIMARY ALDOSTERONISM: CHANGES IN CYSTATIN C-BASED KIDNEY FILTRATION, PROTEINURIA, AND RENAL DUPLEX INDICES WITH TREATMENT
  3351. 9.13 Metabolic Alterations in Patients with Primary Aldosteronism (PA): Role of Adipokines
  3352. 641 EFFECT OF AGING ON VARIOUS CONFIRMATORY TESTS AND ADRENAL VEIN SAMPLING FOR PRIMARY ALDOSTERONISM DIAGNOSIS
  3353. 5.1 Adiponectin and Insulin Sensitivity in Primary Aldosteronism
  3354. 57 OBSTRUCTIVE SLEEP APNEA IS PREVALENT IN PRIMARY ALDOSTERONISM: 3D MAGNETIC RESONANCE IMAGING TO STUDY IMPROVEMENT WITH …
  3355. 166 ZINC DYSHOMEOSTASIS IN RATS WITH ALDOSTERONISM: RESPONSE TO SPIRONOLACTONE.
  3356. P-667: Circadian rythm of blood pressure in patients with primary aldosteronism compared with essential hypertension patients
  3357. 178 ZINC DYSHOMEOSTASIS IN RATS WITH ALDOSTERONISM: RESPONSE TO SPIRONOLACTONE.
  3358. CLINICAL CHARACTERISES OF 224 CASES WITH NORMOKALEMIC AND HYPERTENSIVE PRIMARY ALDOSTERONISM
  3359. P-611: The application of the Aldosterone/PRA ratio (ARR) in the diagnosis of primary aldosteronism
  3360. 71 CALCIUM AND MAGNESIUM HOMEOSTASIS IN ALDOSTERONISM: RESPONSE TO DIURETICS
  3361. 44 ONGOING KIDNEY IMPAIRMENT IN JAPANESE PATIENTS WITH PRIMARY ALDOSTERONISM: PREDICTORS OF NEW-ONSET CHRONIC KIDNEY DISEASE …
  3362. 51 STRUCTURAL REMODELING OF THE HEART IN RATS WITH ALDOSTERONISM: RESPONSE TO SPIRONOLACTONE OR DIETARY ZINC SUPPLEMENT.
  3363. … (NP-59) uptake per unit volume of adrenal adenoma for differentiation between patients with Cushing’s syndrome, primary aldosteronism, and non-hypersecreting …
  3364. 6.4 Cardiac Modifications in Patients with Primary Aldosteronism Before and After Specific Treatment
  3365. P-593: Drug effects on Aldosterone/plasma renin activity ratio in primary aldosteronism
  3366. 2.30 Diagnostic workup of primary aldosteronism
  3367. P-627: Does the availability of Adrenal Vein Sampling (AVS) affect the diagnosis of the adrenocortical pathology underlying Primary Aldosteronism (PA)? Results of …
  3368. A-004 ENDOTHELIAL PROGENITOR CELLS IN PRIMARY ALDOSTERONISM: A BIOMARKER OF SEVERITY FOR Aldosterone VASCULOPATHY AND …
  3369. P-601: Long-term management of hypertensive patients with primary aldosteronism
  3370. Insulin sensitivity in 32 patients with primary aldosteronism
  3371. … ACID-SENSITIVE K+ CHANNEL 2 (TASK-2) GENE IS A HALLMARK OF Aldosterone PRODUCING ADENOMA CAUSING HUMAN PRIMARY ALDOSTERONISM …
  3372. … EVALUATION OF STRUCTURAL AND FUNCTIONAL CHANGES IN THE HEART AND LARGE ARTERIES IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3373. Serum 18 hydroxycortisol identifies aldosteronoma in the differential diagnosis of primary aldosteronism
  3374. 6.12 Long-Term Effects of Pharmacological and Surgical Treatment on Cardiovascular Parameters in Patients with Primary Aldosteronism
  3375. P-560: Low prevelence of primary aldosteronism in hypertensive diabetics
  3376. 4.26 Left Ventricular Mass Appropriateness in Patients with Primary Aldosteronism
  3377. U-002 DISSECTED AORTIC ANEURYSM: UNCOMMON INITIAL PRESENTATION OF PRIMARY ALDOSTERONISM
  3378. 5.4 Vascular Remodelling in Carotid Arteries of Patients with Primary Aldosteronism by Backscatter Signal and Peripheral Vascular Stiffness Analysis
  3379. P-674: Adrenal catecholamines venous sampling in primary aldosteronism
  3380. OR-13: Serum inflammatory cytokines in patients with primary aldosteronism
  3381. P-532: Identification of hypertensive patients with normokaliemic primary aldosteronism
  3382. 44 SKELETAL MUSCLE ATROPHY, BONE LOSS, AND OXIDATIVE STRESS IN RATS WITH ALDOSTERONISM.
  3383. A-005 MYOCARDIAL ULTRASOUND TISSUE CHARACTERIZATION IN PATIENTSWITH PRIMARY ALDOSTERONISM
  3384. P. 097 ADRENALECTOMY IS MORE EFFECTIVE THAN SPIRONOLACTONE IN REDUCING ARTERIAL STIFFNESS IN PRIMARY ALDOSTERONISM☆
  3385. 637 PREVALENCE OF PRIMARY ALDOSTERONISM IN HYPERTENSIVE SUBJECTS WITH HYPERGLYCEMIA
  3386. 47 SPIRONOLACTONE IN THE TREATMENT OF HYPOZINCEMIA FOUND IN RATS WITH ALDOSTERONISM.
  3387. Characteristics of 330 cases with primary aldosteronism
  3388. 45 SPIRONOLACTONE IN THE PREVENTION OF SKELETAL MUSCLE ATROPHY AND BONE LOSS IN RATS WITH ALDOSTERONISM.
  3389. 18-Oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism
  3390. 5.6 Assessment of the Selectivity and Lateralisation Index for Adrenal Vein Sampling in Primary Aldosteronism
  3391. 12.16 Primary Aldosteronism and Endothelial Progenitor Cell Bioavailability
  3392. 6.16 Rapid Cortisol Assay during Adrenal Vein Sampling in Patients with Primary Aldosteronism
  3393. Use of the 250 mcg short synacthen test in the diagnosis of primary aldosteronism
  3394. 6.2 Comparison of Three Different Doses of ACTH Stimulation During Adrenal Vein Sampling (AVS) in the Work-Up of Primary Aldosteronism
  3395. P-600: Primary aldosteronism with and without hypertensive urgency: Clinical and biochemical features
  3396. 367 ALDOSTERONISM: A PROINFLAMMATORY PHENOTYPE SECONDARY TO CALCIUM OVERLOAD
  3397. … HYPERPARATHYROIDISM AND THE RECOVERY OF FALLEN EXTRACELLULAR CALCIUM AND MAGNESIUM IN RATS WITH CHRONIC ALDOSTERONISM.
  3398. THE COMPLEMENT C1Q TUMOUR NECROSIS FACTOR-RELATED PROTEIN 1 LEVEL IN PATIENTS WITH SLEEP APNOEA AND PRIMARY ALDOSTERONISM
  3399. P-358: Cardiovascular and non-cardiovascular events in patients with primary aldosteronism
  3400. 4 PARATHYROIDECTOMY PREVENTS CALCIUM LOADING AND OXIDATIVE STRESS IN RATS WITH ALDOSTERONISM.
  3401. 624 A NEED TO RE-FOCUS ON PRECISION OF SCREENING AND DIAGNOSTIC TESTS IN PRIMARY ALDOSTERONISM
  3402. 4.6 QT Interval in Patients with Primary Aldosteronism and Low-Renin Essential hypertension
  3403. Clinical nursing experience of 8 patients with primary aldosteronism
  3404. Report of 27 cases of primary aldosteronism
  3405. 1.7 Carotid Intima-Media Thickness and Prevalence of Plaques in Patients with Primary Aldosteronism and With Essential hypertension
  3406. 131 PARATHYROIDECTOMY PREVENTS CALCIUM LOADING AND OXIDATIVE STRESS IN RATS WITH ALDOSTERONISM.
  3407. 70 HYPERPARATHYROIDISM AND THE CALCIUM PARADOX OF ALDOSTERONISM
  3408. Adrenal vein sampling in 22 patients with primary aldosteronism
  3409. 279 SECONDARY HYPERPARATHYROIDISM, INTRACELLULAR CALCIUM OVERLOADING, AND OXIDATIVE STRESS IN RATS WITH ALDOSTERONISM.
  3410. P-562: Atrial and brain natriuretic peptides as markers for afterload and volume retention in primary aldosteronism
  3411. 54 CARDIOMYOCYTE EXPRESSION OF METALLOTHIONEIN AND ZINC TRANSPORTER 1 IN RATS WITH ALDOSTERONISM: RESPONSE TO SPIRONOLACTONE …
  3412. … including saliva-type amylase-secreting secondary parathyroid hyperplasia (SPTH) and insulinoma with adrenal adenoma (AA) showing primary aldosteronism
  3413. O-19: Primary aldosteronism in a referral hypertension center
  3414. P-164: Primary aldosteronism may be associated with albuminuria and hyperfiltration
  3415. Q-008 THE METABOLIC SYNDROME DOES DIFFERENCES IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3416. 643 COSYNTROPIN STIMULATION TEST IS USEFUL IN DISTINGUISHING UNILATERAL FROM BILATERAL PRIMARY ALDOSTERONISM
  3417. A-008 THE ASSOCIATION OF HYPERFILTRATION AND LEFT VENTRICULAR MASS IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3418. 652 LONG-TERM TREATEMENT WITH Aldosterone BLOCKER CAN CAUSE SPONTANEOUSLY REMISSION IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3419. 1090 INTEGRATING GENETICS AND GENOMICS IN PRIMARY ALDOSTERONISM
  3420. … Aldosterone EXCESS BETWEEN BASELINE AND ACTH STIMULATION IN THE ADRENAL VEIN SAMPLING OF PATIENTS WITH PRIMARY ALDOSTERONISM
  3421. 632 SENSITIVITY, SPECIFICITY AND REPRODUCIBILITY OF THE Aldosterone-TO-RENIN-RATIO AS A SCREENING TEST FOR PRIMARY ALDOSTERONISM
  3422. P-664: The captopril test for the screening of primary aldosteronism
  3423. P-497: Biochemical profile of severe obstructive sleep apnea can mimic primary aldosteronism
  3424. … SODIUM DIVIDED BY (SERUM POTASSIUM) 2 TO URINARY POTASSIUM (SUSPPUP RATIO) AS A SCREENING TOOL FOR PRIMARY ALDOSTERONISM: PP …
  3425. U-007 THE INFLUENCE OF HYPOKALEMIA ON VASCULAR STIFFNESS IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3426. 648 ANALYSIS OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3427. 656 COMPARISON OF VARIOUS CONFIRMATORY TESTS FOR FINAL DIAGNOSIS OF PRIMARY ALDOSTERONISM
  3428. 646 GUIDELINES MAY IMPROVE CLINICAL PRACTICE FOR DIAGNOSIS OF PRIMARY ALDOSTERONISM IN JAPAN
  3429. 42 COST-EFFECTIVE AND FEASIBLE SCREENING OF PRIMARY ALDOSTERONISM WITH POTASSIUM EXCRETION CAPACITY/BODY MASS INDEX RATIO
  3430. … EFFECT AFTER TRANSUMBILICAL LAPAROSCOPIC SINGLE-SITE ADRENALECTOMY IN PATIENTS WITH PRIMARY ALDOSTERONISM: A MATCHED CASE …
  3431. P-344: Unusual phenotype in a family affected by glucocorticoid remediable aldosteronism
  3432. … ASSOCIATED WITH PHYSIOLOGICAL INTERMEDIATE PHENOTYPES IN PATIENTS WITH ESSENTIAL hypertension, BUT NOT PRIMARY ALDOSTERONISM
  3433. P-333: Primary aldosteronism and cushing’s syndrome treated by CT-guided radiofrequency thermal ablation in SR-Adenomas
  3434. … OF Aldosterone AND CORTISOL BY HPLC-TANDEM MASS SPECTROMETRY: COULD THIS IMPROVE DECISION MAKING IN PRIMARY ALDOSTERONISM?
  3435. 992 Proceedings ofthe Royal Society ofMedicine mation on everything from aldosteronism to Cushing’s disease, and from the minutia of the history of chemistry of the …
  3436. 659 USEFULNESS OF NEW QUICK CORTISOL ASSAY DURING ADRENAL VEIN SAMPLING IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3437. 647 DIURNAL VARIATION OF ADRENAL VENOUS Aldosterone CONCENTRATION IN PATIENTS WITH PRIMARY ALDOSTERONISM
  3438. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study
  3439. Primary aldosteronism: practical approach to diagnosis and management
  3440. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice
  3441. Diagnosis and management of primary aldosteronism: an updated review
  3442. Primary Aldosteronism and ARMC5 Variants
  3443. Diagnosis and management of primary aldosteronism
  3444. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline
  3445. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment
  3446. An update on novel mechanisms of primary aldosteronism
  3447. Long-term cardio-and cerebrovascular events in patients with primary aldosteronism
  3448. Long term outcome of aldosteronism after target treatments
  3449. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study
  3450. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe
  3451. Update in primary aldosteronism
  3452. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis
  3453. CACNA1H mutations are associated with different forms of primary aldosteronism
  3454. Age-related autonomous aldosteronism
  3455. Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension
  3456. Systematic review of surgery and outcomes in patients with primary aldosteronism
  3457. Primary aldosteronism: the next five years
  3458. Continuum of renin-independent aldosteronism in normotension
  3459. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis
  3460. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism
  3461. Old and new concepts in the molecular pathogenesis of primary aldosteronism
  3462. Management of hypertension in primary aldosteronism
  3463. Laboratory challenges in primary aldosteronism screening and diagnosis
  3464. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan
  3465. Confirmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study
  3466. The prevalence of CTNNB1 mutations in primary aldosteronism and consequences for clinical outcomes
  3467. Nuclear imaging in the diagnosis of primary aldosteronism
  3468. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy
  3469. Primary aldosteronism: emerging trends
  3470. Risk of fracture in primary aldosteronism: a population‐based cohort study
  3471. Pregnancy, Primary Aldosteronism, and Adrenal CTNNB1 Mutations
  3472. Case detection and diagnosis of primary aldosteronism–the consensus of Taiwan Society of Aldosteronism
  3473. Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study
  3474. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism
  3475. Progress in the management of primary aldosteronism
  3476. Outcome of surgical treatment of primary aldosteronism
  3477. SFE/SFHTA/AFCE primary aldosteronism consensus: introduction and handbook
  3478. Is primary aldosteronism still largely unrecognized?
  3479. Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney
  3480. Primary aldosteronism: challenges in diagnosis and management
  3481. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 2: first diagnostic steps
  3482. Update in diagnosis and management of primary aldosteronism
  3483. Bone and mineral metabolism in patients with primary aldosteronism
  3484. Genetics in endocrinology: the expanding genetic horizon of primary aldosteronism
  3485. Subtyping of patients with primary aldosteronism: an update
  3486. Adrenal vein sampling in primary aldosteronism: towards a standardised protocol
  3487. Renal outcomes in medically and surgically treated primary aldosteronism
  3488. Treatment of primary aldosteronism and organ protection
  3489. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an …
  3490. Clinical characteristics and postoperative outcomes of primary aldosteronism in the elderly
  3491. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism
  3492. Primary aldosteronism and salt
  3493. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study
  3494. Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms
  3495. Oxidative stress in patients affected by primary aldosteronism
  3496. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years
  3497. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism
  3498. Role of KCNJ5 in familial and sporadic primary aldosteronism
  3499. Primary aldosteronism: diagnosis and management
  3500. Management of endocrine disease: diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited
  3501. Primary aldosteronism and pregnancy
  3502. Refining the definitions of biochemical and clinical cure for primary aldosteronism using the primary aldosteronism surgical outcome (PASO) classification system
  3503. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: Confirmatory testing
  3504. Primary aldosteronism as a cause of secondary osteoporosis
  3505. Understanding primary aldosteronism: impact of next generation sequencing and expression profiling
  3506. Somatic and germline CACNA1D calcium channel mutations in Aldosterone-producing adenomas and primary aldosteronism
  3507. Recent developments in primary aldosteronism
  3508. Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism
  3509. Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism
  3510. Potential effects of age on screening for primary aldosteronism
  3511. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term
  3512. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial
  3513. Prevalence of primary aldosteronism in primary care: a cross-sectional study
  3514. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism
  3515. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study
  3516. Adrenal histopathology in primary aldosteronism: is it time for a change?
  3517. Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment
  3518. The time has come for systematic screening for primary aldosteronism in all hypertensives
  3519. Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism
  3520. Primary aldosteronism: a common cause of resistant hypertension
  3521. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry
  3522. Can screening and confirmatory testing in the management of patients with primary aldosteronism be improved?
  3523. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism
  3524. Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea
  3525. Somatic and inherited mutations in primary aldosteronism
  3526. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn’s Registry
  3527. Glucocorticoid-remediable aldosteronism
  3528. Primary aldosteronism and obstructive sleep apnea: is this a bidirectional relationship?
  3529. Genetic and histopathologic intertumor heterogeneity in primary aldosteronism
  3530. Glucose metabolism in primary aldosteronism
  3531. Development and validation of subtype prediction scores for the workup of primary aldosteronism
  3532. Mouse models of primary aldosteronism: from physiology to pathophysiology
  3533. The influence of aging on the diagnosis of primary aldosteronism
  3534. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China
  3535. Significance of computed tomography and serum potassium in predicting subtype diagnosis of primary aldosteronism
  3536. Role of ACTH and other hormones in the regulation of Aldosterone production in primary aldosteronism
  3537. Primary aldosteronism as a risk factor for vertebral fracture
  3538. Update in adrenal venous sampling for primary aldosteronism
  3539. … Efficacy of Adrenal Vein Sampling and Imaging Findings in Predicting Clinical Outcomes Following Unilateral Adrenalectomy for Primary Aldosteronism
  3540. Immunohistopathology and steroid profiles associated with biochemical outcomes after adrenalectomy for unilateral primary aldosteronism
  3541. Health-related quality of life and mental health in primary aldosteronism: a systematic review
  3542. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases
  3543. Mass spectrometry–based adrenal and peripheral venous steroid profiling for subtyping primary aldosteronism
  3544. Approach to the surgical management of primary aldosteronism
  3545. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism
  3546. Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes
  3547. Diagnostic rate of primary aldosteronism in Emilia-Romagna, Northern Italy, during 16 years (2000–2015)
  3548. Adrenal nodularity and somatic mutations in primary aldosteronism: one node is the culprit?
  3549. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism
  3550. Disordered CYP11B2 expression in primary aldosteronism
  3551. Cortisol excess in patients with primary aldosteronism impacts left ventricular hypertrophy
  3552. An LC–MS/MS method for steroid profiling during adrenal venous sampling for investigation of primary aldosteronism
  3553. Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism
  3554. Subtype diagnosis of primary aldosteronism: is adrenal vein sampling always necessary?
  3555. Unanswered questions in the genetic basis of primary aldosteronism
  3556. Immunohistochemistry of Aldosterone synthase leads the way to the pathogenesis of primary aldosteronism
  3557. The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism
  3558. ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions
  3559. New advances in the diagnostic workup of primary aldosteronism
  3560. An individualized approach to the evaluation and management of primary aldosteronism
  3561. Test characteristics of the Aldosterone-to-renin ratio as a screening test for primary aldosteronism
  3562. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism
  3563. Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism
  3564. Anxiety, depression, and impaired quality of life in primary aldosteronism: why we shouldn’t ignore it!
  3565. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension
  3566. Diagnostic value of ACTH stimulation test in determining the subtypes of primary aldosteronism
  3567. Cost-effectiveness of screening for primary aldosteronism and subtype diagnosis in the resistant hypertensive patients
  3568. Evaluation of the saline infusion test and the captopril challenge test in Chinese patients with primary aldosteronism
  3569. Primary aldosteronism and pregnancy
  3570. Voltage-gated calcium channels in the human adrenal and primary aldosteronism
  3571. Cardiac remodeling in patients with primary and secondary aldosteronism: a tissue Doppler study
  3572. Primary aldosteronism and impaired natriuresis in mice underexpressing TGFβ1
  3573. Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment
  3574. Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis
  3575. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: subtype diagnosis
  3576. Effects of treating primary aldosteronism on renal function
  3577. Diagnostic accuracy of Aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism
  3578. Local control of Aldosterone production and primary aldosteronism
  3579. Long-term effect of specific treatment of primary aldosteronism on carotid intima–media thickness
  3580. hypertension outcomes of adrenalectomy in patients with primary aldosteronism: a systematic review and meta-analysis
  3581. A subtype prediction score for primary aldosteronism
  3582. Risk of sepsis in patients with primary aldosteronism
  3583. Primary aldosteronism in the primary care setting
  3584. Comparative genomics and transcriptome profiling in primary aldosteronism
  3585. Basal and post-ACTH Aldosterone and its ratios are useful during adrenal vein sampling in primary aldosteronism
  3586. Autoimmune mechanisms activating the angiotensin AT1 receptor in’primary’aldosteronism
  3587. Optimum position of left adrenal vein sampling for subtype diagnosis in primary aldosteronism
  3588. Changes in the clinical manifestations of primary aldosteronism
  3589. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies
  3590. Clinical management of primary aldosteronism
  3591. Clinical management and outcomes of adrenal hemorrhage following adrenal vein sampling in primary aldosteronism
  3592. Aldosterone LC-MS/MS assay-specific threshold values in screening and confirmatory testing for primary aldosteronism
  3593. … of adrenal computed tomography in predicting the unilateral subtype in young patients with hypokalaemia and elevation of Aldosterone in primary aldosteronism
  3594. Does contralateral suppression at adrenal venous sampling predict outcome following unilateral adrenalectomy for primary aldosteronism? A retrospective study
  3595. Overview of the genetic determinants of primary aldosteronism
  3596. Dissecting the molecular pathways of primary aldosteronism
  3597. Primary aldosteronism: functional histopathology and long‐term follow‐up after unilateral adrenalectomy
  3598. Is there a role for segmental adrenal venous sampling and adrenal sparing surgery in patients with primary aldosteronism?
  3599. Outcomes of drug-based and surgical treatments for primary aldosteronism
  3600. The molecular basis of primary aldosteronism: from chimeric gene to channelopathy
  3601. … mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism
  3602. Primary aldosteronism as a public health issue
  3603. Development of a novel nomogram to predict hypertension cure after laparoscopic adrenalectomy in patients with primary aldosteronism
  3604. Does ACTH improve the diagnostic performance of adrenal vein sampling for subtyping primary aldosteronism?
  3605. In primary aldosteronism, mineralocorticoids influence exosomal sodium-chloride cotransporter abundance
  3606. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone
  3607. Adrenal vein sampling is the preferred method to select patients with primary aldosteronism for adrenalectomy: pro side of the argument
  3608. Administrative data on diagnosis and mineralocorticoid receptor antagonist prescription identified patients with primary aldosteronism in Taiwan
  3609. Epicardial fat thickness and primary aldosteronism
  3610. A novel CYP11B2-specific imaging agent for detection of unilateral subtypes of primary aldosteronism
  3611. Idiopathic intracranial hypertension associated with either primary or secondary aldosteronism
  3612. A novel phenotype of familial hyperaldosteronism type III: concurrence of aldosteronism and Cushing’s syndrome
  3613. Genetic characterization of GnRH/LH-responsive primary aldosteronism
  3614. Proportion of patients with hypertension resolution following adrenalectomy for primary aldosteronism: a systematic review and meta‐analysis
  3615. Defining contralateral adrenal suppression in primary aldosteronism: implications for diagnosis and outcome
  3616. KCNJ5 Mutations Are the Most Frequent Genetic Alteration in Primary Aldosteronism
  3617. Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism
  3618. Pregnancy, Primary Aldosteronism, and Somatic CTNNB1 Mutations.
  3619. Diagnosing unilateral primary aldosteronism–comparison of a clinical prediction score, computed tomography and adrenal venous sampling
  3620. Adrenal vein sampling is the preferred method to select patients with primary aldosteronism for adrenalectomy: con side of the argument
  3621. Quantitative value of Aldosterone‐renin ratio for detection of Aldosterone‐producing adenoma: the Aldosterone‐Renin Ratio for Primary Aldosteronism (AQUARR) …
  3622. Immunohistochemistry improves histopathologic diagnosis in primary aldosteronism
  3623. Clinical characteristics of Aldosterone-and cortisol-coproducing adrenal adenoma in primary aldosteronism
  3624. Adrenal venous sampling versus computed tomographic scan to determine treatment in primary aldosteronism (The SPARTACUS Trial) a critique
  3625. Impact of new quick gold nanoparticle-based cortisol assay during adrenal vein sampling for primary aldosteronism
  3626. Correlation between lateralization index of adrenal venous sampling and standardized outcome in primary aldosteronism
  3627. Primary aldosteronism associated with subclinical Cushing syndrome
  3628. Saline suppression test parameters may predict bilateral subtypes of primary aldosteronism
  3629. Rapid screening of primary aldosteronism by a novel chemiluminescent immunoassay
  3630. Primary aldosteronism: Seismic shifts
  3631. Adrenal venous sampling for primary aldosteronism: laboratory medicine best practice
  3632. Primary aldosteronism in hypertensive patients: clinical implications and target therapy
  3633. Potassium channels related to primary aldosteronism: Expression similarities and differences between human and rat adrenals
  3634. Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism
  3635. Importance of contralateral Aldosterone suppression during adrenal vein sampling in the subtype evaluation of primary aldosteronism
  3636. Is it time to screen all patients with hypertension for primary aldosteronism?
  3637. Inflammatory markers in primary aldosteronism
  3638. Cardiac dysfunction in association with increased inflammatory markers in primary aldosteronism
  3639. … -specific monoclonal antibodies against 3β-hydroxysteroid dehydrogenase/isomerase family provide markers for subclassification of human primary aldosteronism
  3640. Age-related cutoffs of plasma Aldosterone/renin concentration for primary aldosteronism screening
  3641. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery
  3642. Primary aldosteronism and thyroid disorders in atrial fibrillation: A Swedish nationwide case–control study
  3643. The impact of Connshing’s syndrome-mild cortisol excess in primary aldosteronism drives diabetes risk
  3644. Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?
  3645. Medical versus surgical treatment of primary aldosteronism
  3646. Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale …
  3647. Genetics of primary aldosteronism
  3648. The latest developments of functional molecular imaging in the diagnosis of primary aldosteronism
  3649. High‐probability features of primary aldosteronism may obviate the need for confirmatory testing without increasing false‐positive diagnoses
  3650. Prevelence of primary aldosteronism in an urban hypertensive population
  3651. Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity
  3652. Cardiovascular risk markers in patients with primary aldosteronism: a systematic review and meta-analysis of literature studies
  3653. A clinical prediction score for diagnosing unilateral primary aldosteronism may not be generalizable
  3654. Plasma Aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism
  3655. Contralateral suppression of Aldosterone at adrenal venous sampling predicts hyperkalemia following adrenalectomy for primary aldosteronism
  3656. Clinicopathologic correlates of primary aldosteronism
  3657. Primary aldosteronism and cardiovascular risk, before and after treatment
  3658. Sequential comparison of Aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism
  3659. Role of adrenal vein sampling in primary aldosteronism: impact of imaging, localization, and age
  3660. Sodium infusion test for diagnosis of primary aldosteronism in chinese population
  3661. … somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism
  3662. Comparisons of microvascular and macrovascular changes in aldosteronism-related hypertension and essential hypertension
  3663. Lower trabecular bone score in patients with primary aldosteronism: human skeletal deterioration by Aldosterone excess
  3664. Primary aldosteronism: New answers, new questions
  3665. Genetic disorders in primary aldosteronism—familial and somatic
  3666. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA?
  3667. Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension
  3668. Adrenal CYP11B1/2 expression in primary aldosteronism: immunohistochemical analysis using novel monoclonal antibodies
  3669. The occurrence of apparent bilateral Aldosterone suppression in adrenal vein sampling for primary aldosteronism
  3670. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism
  3671. A new highly sensitive and specific overnight combined screening and diagnostic test for primary aldosteronism
  3672. Subtyping of primary aldosteronism with adrenal vein sampling: hormone-and side-specific effects of cosyntropin and metoclopramide
  3673. Diagnosis of primary aldosteronism in the hypertension specialist centers in Italy: a national survey
  3674. The renaissance of primary aldosteronism: what has it taught us?
  3675. Aldosterone-producing adenoma in primary aldosteronism: CT-guided radiofrequency ablation—long-term results and recurrence rate
  3676. Comparison between adrenal venous sampling and computed tomography in the diagnosis of primary aldosteronism and in the guidance of adrenalectomy
  3677. Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography–tandem mass spectrometry determinations of plasma Aldosterone concentration
  3678. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism
  3679. A Renin-ssance in Primary Aldosteronism Testing: Obstacles and Opportunities for Screening, Diagnosis, and Management
  3680. Current pattern of primary aldosteronism diagnosis: Delayed and complicated
  3681. Assay characteristics influence the Aldosterone to renin ratio as a screening tool for primary aldosteronism: results of the German Conn’s registry
  3682. New insights into Aldosterone-producing adenomas and hereditary aldosteronism: mutations in the K+ channel KCNJ5
  3683. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism
  3684. Human red blood cells alterations in primary aldosteronism
  3685. Adrenal vein sampling in primary aldosteronism: concordance of simultaneous vs sequential sampling
  3686. Adrenal venous sampling in patients with positive screening but negative confirmatory testing for primary aldosteronism
  3687. Primary aldosteronism and low-renin hypertension: a continuum?
  3688. Suppression of Aldosterone secretion after recumbent saline infusion does not exclude lateralized primary aldosteronism
  3689. Primary aldosteronism: making sense of partial data sets from failed adrenal venous sampling-suppression of adrenal Aldosterone production can be used in clinical …
  3690. Comparison of left ventricular structure and function in primary aldosteronism and essential hypertension by echocardiography
  3691. Aldosterone to active renin ratio as screening test for primary aldosteronism: reproducibility and influence of orthostasis and salt loading
  3692. Dietary salt intake is a determinant of cardiac changes after treatment of primary aldosteronism: a prospective study
  3693. Macrolides for KCNJ5–mutated Aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism
  3694. obesity and the diagnostic accuracy for primary aldosteronism
  3695. Unadjusted plasma renin activity as a “first‐look” test to decide upon further investigations for primary aldosteronism
  3696. Preoperative masked renal damage in J apanese patients with primary aldosteronism: Identification of predictors for chronic kidney disease manifested after …
  3697. Somatic KCNJ5 mutation occurring early in adrenal development may cause a novel form of juvenile primary aldosteronism
  3698. Primary aldosteronism in patients with acute stroke: prevalence and diagnosis during initial hospitalization
  3699. Prevalence of primary aldosteronism in hypertensive subjects with hyperglycemia
  3700. Diagnosis and treatment of unilateral forms of primary aldosteronism
  3701. Mineralocorticoid receptor antagonists in primary aldosteronism
  3702. Post-saline infusion test Aldosterone levels indicate severity and outcome in primary aldosteronism
  3703. Effect of Aldosterone-producing adenoma on endothelial function and Rho-associated kinase activity in patients with primary aldosteronism
  3704. Mineralocorticoid receptor antagonists and clinical outcomes in primary aldosteronism: as good as surgery?
  3705. A new clinical prediction criterion accurately determines a subset of patients with bilateral primary aldosteronism before adrenal venous sampling
  3706. Diagnostic utility of data from adrenal venous sampling for primary aldosteronism despite failed cannulation of the right adrenal vein
  3707. Minireview: potassium channels and Aldosterone dysregulation: is primary aldosteronism a potassium channelopathy?
  3708. Endothelial dysfunction in patients with primary aldosteronism: a biomarker of target organ damage
  3709. Combination of LC–MS/MS Aldosterone and automated direct renin in screening for primary aldosteronism
  3710. Reversible heart rhythm complexity impairment in patients with primary aldosteronism
  3711. Primary aldosteronism and cerebrovascular diseases
  3712. The cardiovascular markers copeptin and high-sensitive C-reactive protein decrease following specific therapy for primary aldosteronism
  3713. Subclinical primary aldosteronism
  3714. Scoring system for the diagnosis of bilateral primary aldosteronism in the outpatient setting before adrenal venous sampling
  3715. Impact of Aldosterone-producing cell clusters on diagnostic discrepancies in primary aldosteronism
  3716. … of strict criteria in adrenal venous sampling increases the proportion of missed patients with unilateral disease who benefit from surgery for primary aldosteronism
  3717. Hyperkalemia in both surgically and medically treated patients with primary aldosteronism
  3718. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism
  3719. Risk of ischemic stroke in primary aldosteronism patients
  3720. Does concomitant autonomous adrenal cortisol overproduction have the potential to confound the interpretation of adrenal venous sampling in primary aldosteronism …
  3721. Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and cardiac structure in patients with resistant …
  3722. Regulation of Aldosterone production by ion channels: from basal secretion to primary aldosteronism
  3723. Catheterization during adrenal vein sampling for primary aldosteronism: failure to use (1–24) ACTH may increase apparent failure rate
  3724. Cost-effectiveness analysis of the diagnosis and treatment of primary aldosteronism in Japan
  3725. Aldosterone excess may inhibit insulin secretion: a comparative study on glucose metabolism pre-and post-adrenalectomy in patients with primary aldosteronism
  3726. An adverse pregnancy-associated outcome due to overlooked primary aldosteronism
  3727. Myocardial ultrasound tissue characterization of patients with primary aldosteronism
  3728. Change in kidney function after unilateral adrenalectomy in patients with primary aldosteronism: identification of risk factors for decreased kidney function
  3729. Parathyroid gland function in primary aldosteronism
  3730. Renal resistive index predicts postoperative blood pressure outcome in primary aldosteronism
  3731. Genetics of primary aldosteronism
  3732. Primary aldosteronism patients show skin alterations and abnormal activation of glucocorticoid receptor in keratinocytes
  3733. Chronic kidney disease score for predicting postoperative masked renal insufficiency in patients with primary aldosteronism
  3734. Factors affecting parathyroid hormone levels in different types of primary aldosteronism
  3735. A short review of primary aldosteronism in a question and answer fashion
  3736. Is there a role for Nuclear Medicine in diagnosis and management of patients with primary aldosteronism?
  3737. Immunohistochemistry of the adrenal in primary aldosteronism
  3738. The subtyping of primary aldosteronism by adrenal vein sampling: sequential blood sampling causes factitious lateralization
  3739. Prevalence of primary aldosteronism without hypertension in the general population: results in Shika study
  3740. How to escape from primary aldosteronism? News and views on an adrenal disorder of salt retention
  3741. Metoclopramide unmasks potentially misleading contralateral suppression in patients undergoing adrenal vein sampling for primary aldosteronism
  3742. Genetic variations in the KCNJ5 gene in primary aldosteronism patients from Xinjiang, China
  3743. Novel approach to establishing an Aldosterone: renin ratio cutoff for primary aldosteronism
  3744. Prevalence of malignancies in patients with primary aldosteronism
  3745. Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era
  3746. Screening for primary aldosteronism using the newly developed IDS-iSYS® automated assay system
  3747. Genetic and potential autoimmune triggers of primary aldosteronism
  3748. … of peripheral blood mononuclear cells reveal transcriptional signatures as novel biomarkers of cardiac remodeling in rats with aldosteronism and hypertensive heart …
  3749. Clinical Practice Guideline for Management of Primary Aldosteronism: What is New in the 2016 Update?
  3750. Dual adrenal venous phase contrast-enhanced MDCT for visualization of right adrenal veins in patients with primary aldosteronism
  3751. The potential of ACTH in the genesis of primary aldosteronism
  3752. Characteristics predicting clinical improvement and cure following laparoscopic adrenalectomy for primary aldosteronism in a large cohort
  3753. Primary aldosteronism and potassium channel mutations
  3754. Role of endogenous ACTH on circadian Aldosterone rhythm in patients with primary aldosteronism
  3755. Liddle syndrome misdiagnosed as primary aldosteronism resulting from a novel frameshift mutation of SCNN1B
  3756. Subtype diagnosis of primary aldosteronism: Approach to different clinical scenarios
  3757. Circadian hemodynamic characteristics in hypertensive patients with primary aldosteronism
  3758. Sleep quality in patients with primary aldosteronism
  3759. Primary aldosteronism and its various clinical scenarios
  3760. Prevalence of primary aldosteronism among patients with type 2 diabetes
  3761. Optimization of left adrenal vein sampling in primary aldosteronism: coping with asymmetrical cortisol secretion
  3762. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: genetic diagnosis of primary aldosteronism
  3763. Identifying unilateral disease in Chinese patients with primary aldosteronism by using a modified prediction score
  3764. Adrenal vein sampling in primary aldosteronism: sensitivity and specificity of basal adrenal vein to peripheral vein cortisol and Aldosterone ratios to confirm …
  3765. Medication adherence during laboratory workup for primary aldosteronism: pilot study
  3766. Saline Infusion Test highly associated with the incidence of cardio-and cerebrovascular events in primary aldosteronism
  3767. Role of adrenal vein sampling in primary aldosteronism: the M onash H ealth experience
  3768. Psychological symptoms and well-being after treatment for primary aldosteronism
  3769. Shortened saline infusion test for subtype prediction in primary aldosteronism
  3770. Right adrenal venography findings correlated with C-arm CT for selection during C-arm CT-assisted adrenal vein sampling in primary aldosteronism
  3771. Diagnosis of primary aldosteronism
  3772. Eplerenone use in primary aldosteronism during pregnancy
  3773. Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implications
  3774. Association of primary aldosteronism with chronic thyroiditis
  3775. Association of the variations in the HSD3β gene with primary aldosteronism
  3776. Screening for primary aldosteronism in a primary care unit
  3777. Novel genes in primary aldosteronism
  3778. Cost‐Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant hypertension
  3779. Primary aldosteronism with concurrent primary hyperparathyroidism: clinical case load in a single centre
  3780. Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism
  3781. Primary aldosteronism with concurrent primary hyperparathyroidism in a patient with arrhythmic disorders
  3782. Worsening of lipid metabolism after successful treatment of primary aldosteronism
  3783. Case detection in primary aldosteronism: high-diagnostic value of the Aldosterone-to-renin ratio when performed under standardized conditions
  3784. A case of primary aldosteronism combined with acquired nephrogenic diabetes insipidus
  3785. Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism
  3786. Hypokalemic rhabdomyolysis: a rare manifestation of primary aldosteronism
  3787. Evaluation of insulin sensitivity and secretion in primary aldosteronism
  3788. Risk factors for renal impairment revealed after unilateral adrenalectomy in patients with primary aldosteronism
  3789. Progress in primary aldosteronism: translation on the move
  3790. Deciphering the role of vasopressin in primary aldosteronism
  3791. Clinical utility of the adrenocorticotropin stimulation test with/without dexamethasone suppression for definitive and subtype diagnosis of primary aldosteronism
  3792. Despite limited specificity, computed tomography predicts lateralization and clinical outcome in primary aldosteronism
  3793. Volumetric and densitometric evaluation of the adrenal glands in patients with primary aldosteronism
  3794. Non-stimulated adrenal venous sampling using Dyna computed tomography in patients with primary aldosteronism
  3795. Evaluation of right adrenal vein anatomy by Dyna computed tomography in patients with primary aldosteronism
  3796. Bilateral Aldosterone suppression and its resolution in adrenal vein sampling of patients with primary aldosteronism: analysis of data from the WAVES‐J study
  3797. Alterations in vascular function in primary aldosteronism: a cardiovascular magnetic resonance imaging study
  3798. The many faces of primary aldosteronism and cushing syndrome: a reflection of adrenocortical tumor heterogeneity
  3799. Adrenal vein sampling versus CT scanning in primary aldosteronism
  3800. Development of novel nomograms to predict renal functional outcomes after laparoscopic adrenalectomy in patients with primary aldosteronism
  3801. A useful tool to improve the case detection rate of primary aldosteronism: the Aldosterone–renin ratio (ARR)-App
  3802. Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: a meta-analysis
  3803. Primary aldosteronism: a channelopathy?
  3804. Hypokalemia may mask primary aldosteronism: a case series
  3805. NT-proBNP, a useful tool in hypertensive patients undergoing a diagnostic evaluation for primary aldosteronism
  3806. Risk of new-onset dyslipidemia after laparoscopic adrenalectomy in patients with primary aldosteronism
  3807. Subtype prediction in primary aldosteronism: measurement of circadian variation of adrenocortical hormones and 24‐h urinary Aldosterone
  3808. The relationship among cardiac structure, dietary salt and Aldosterone in patients with primary aldosteronism
  3809. Factors associated with resolution of hypertension after adrenalectomy in patients with primary aldosteronism
  3810. Transcriptome analysis of primary aldosteronism in adrenal glands and controls
  3811. Analysis of postoperative biochemical values and clinical outcomes after adrenalectomy for primary aldosteronism
  3812. Aldosterone to renin ratio as a screening instrument for primary aldosteronism in a middle-aged population with atrial fibrillation
  3813. Twenty-four-hour urinary Aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism
  3814. Significance of adrenal computed tomography in predicting laterality and indicating adrenal vein sampling in primary aldosteronism
  3815. A late diagnosis of primary aldosteronism
  3816. Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of Aldosterone-producing adenoma
  3817. Relationship of ocular microcirculation, measured by laser speckle flowgraphy, and silent brain infarction in primary aldosteronism
  3818. The role of urinary Aldosterone for the diagnosis of primary aldosteronism
  3819. … of the TWIK-Related Acid-Sensitive K+ Channel 2 (TASK-2) Gene Is a Hallmark of Aldosterone-Producing Adenoma Causing Human Primary Aldosteronism
  3820. Body mass index and contralateral ratio predict outcome following unilateral adrenalectomy in primary aldosteronism
  3821. The third case report a patient with primary aldosteronism, seizures, and neurologic abnormalities (PASNA) syndrome de novo variant mutations in the CACNA1D …
  3822. A case of primary aldosteronism caused by unilateral multiple adrenocortical micronodules presenting as muscle cramps at rest: the importance of functional …
  3823. Visualizing adrenal steroids in primary aldosteronism: the expected and the unexplained
  3824. … rise in IVC Aldosterone following cosyntropin administration during AVS is a signal to the presence of adrenal hyperplasia in primary aldosteronism
  3825. A case of monozygotic twins with primary aldosteronism: a case report
  3826. Primary aldosteronism: a field on the move
  3827. Improvement of bone turnover markers and bone mineral density following treatment of primary aldosteronism.
  3828. Fully automated chemiluminescence vs RIA Aldosterone assay in primary aldosteronism work-up
  3829. Decreased plasma prorenin levels in primary aldosteronism: potential diagnostic implications
  3830. Expression and functional role of the prorenin receptor in the human adrenocortical zona glomerulosa and in primary aldosteronism
  3831. Primary aldosteronism: a new insight into pathogenesis, diagnosis, and treatment in hypertensive patients
  3832. Electrical and myocardial remodeling in primary aldosteronism
  3833. Hypokalemic myopathy in primary aldosteronism: A case report
  3834. Rational Approach to a Patient with Suspected Primary Aldosteronism.
  3835. Screening for primary aldosteronism in an argentinian population: a multicenter prospective study
  3836. Ambulatory blood pressure monitoring–derived short‐term blood pressure variability in primary aldosteronism
  3837. Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism
  3838. Aldosteronism with mild hypokalemia presenting as life-threatening ventricular arrhythmias: A case report
  3839. Primary aldosteronism with type 2 diabetes mellitus requires more antihypertensive drugs for blood pressure control: a retrospective observational study
  3840. The clinical value of salivary Aldosterone in diagnosis and follow-up of primary aldosteronism
  3841. Adrenal reserve function after unilateral adrenalectomy in patients with primary aldosteronism
  3842. PROGRESS IN PRIMARY ALDOSTERONISM: Mineralocorticoid antagonist treatment for Aldosterone-producing adenoma
  3843. ACTH stimulation test and computed tomography are useful for differentiating the subtype of primary aldosteronism
  3844. Adrenal vein sampling in the diagnosis of aldosteronism
  3845. Genetic characterization of a mouse line with primary aldosteronism
  3846. Enhanced soluble serum CD40L and serum P-selectin levels in primary aldosteronism
  3847. Implication of aortic calcification on persistent hypertension after laparoscopic adrenalectomy in patients with primary aldosteronism
  3848. Prevalence of angiotensin II type 1 receptor (AT1R)–activating autoantibodies in primary aldosteronism
  3849. Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion.
  3850. Heterogeneous machine learning system for improving the diagnosis of primary aldosteronism
  3851. Primary aldosteronism: from case detection to histopathology with up to 6 years of follow‐up
  3852. Reversing the established order: Should adrenal venous sampling precede cross‐sectional imaging in the evaluation of primary aldosteronism?
  3853. Reassessment of the cosyntropin stimulation test in the confirmatory diagnosis and subtype classification of primary aldosteronism
  3854. Effect of eplerenone on the glomerular filtration rate (GFR) in primary aldosteronism: sequential changes in the GFR during preoperative eplerenone treatment to …
  3855. Primary Aldosteronism or Not Primary Aldosteronism: Is This Now the Question in Normotension?
  3856. Simultaneous occurrence of primary aldosteronism due to aldosteronoma and ectopic meningioma in the adrenal gland: a case report
  3857. Comparison of 24-h urinary Aldosterone level and random urinary Aldosterone-to-creatinine ratio in the diagnosis of primary aldosteronism
  3858. Prognostic value of semiquantification NP-59 SPECT/CT in primary aldosteronism patients after adrenalectomy
  3859. Response to effectiveness of adrenalectomy and Aldosterone antagonists for long-term treatment of primary aldosteronism
  3860. A normotensive patient with primary aldosteronism
  3861. Association of serum parathyrine and calcium levels with primary aldosteronism: a meta-analysis
  3862. Persistent primary aldosteronism despite iatrogenic adrenal hemorrhage after adrenal vein sampling
  3863. A case of Adrenocoricotrophic hormone-independent bilateral adrenocortical macronodular hyperplasia concomitant with primary aldosteronism
  3864. Association of CYP11B2 polymorphisms with susceptibility to primary aldosteronism: a meta-analysis
  3865. Delayed diagnosis of primary aldosteronism in patients with autosomal dominant polycystic kidney diseases
  3866. Biological diagnosis of primary aldosteronism: summary of new French and international guidelines
  3867. Clinical characteristics and long-term outcome of primary aldosteronism in a Norwegian population
  3868. The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old
  3869. Hypokalemia correlated with arterial stiffness but not microvascular endothelial function in patients with primary aldosteronism
  3870. Assessment of postoperative changes in antihypertensive drug consumption in patients with primary aldosteronism using the defined daily dose
  3871. Splitting atoms: the Endocrine Society guideline for the management of primary aldosteronism
  3872. Are catecholamine-derived indexes in adrenal venous sampling useful for judging selectivity and laterality in patients with primary aldosteronism?
  3873. Aldosterone-renin ratio in the assessment of primary aldosteronism
  3874. Diagnosing and managing primary aldosteronism in hypertensive patients: a case-based approach
  3875. Lateralization index but not contralateral suppression at adrenal vein sampling predicts improvement in blood pressure after adrenalectomy for primary aldosteronism
  3876. Aldosterone-induced oxidative stress: a potential mechanism of Aldosterone autonomy in primary aldosteronism
  3877. Adrenal androgen measurement for assessing the selectivity of adrenal venous sampling in primary aldosteronism
  3878. Investigation of primary aldosteronism in patients with resistant hypertension–Authors’ reply
  3879. Confirmatory testing for primary aldosteronism
  3880. Primary aldosteronism as a public health issue–Authors’ reply
  3881. Subtype prediction of primary aldosteronism by combining Aldosterone concentrations in the left adrenal vein and inferior vena cava: a multicenter collaborative study …
  3882. Rapid diagnosis of primary Aldosteronism: oxymoron or one small step?
  3883. Downregulated serum 14, 15-epoxyeicosatrienoic acid is associated with abdominal aortic calcification in patients with primary aldosteronism
  3884. The spectrum of subclinical primary aldosteronism and incident hypertension
  3885. The application of captopril challenge test in the diagnosis of primary aldosteronism
  3886. Cardiac magnetic resonance imaging of myocardial mass and fibrosis in primary aldosteronism
  3887. Issues in the diagnosis and treatment of primary aldosteronism
  3888. A multi-institutional comparison of adrenal venous sampling in patients with primary Aldosteronism: caution advised if successful bilateral adrenal vein sampling is not …
  3889. An app for the diagnosis of primary aldosteronism
  3890. A prediction model for primary aldosteronism when the salt loading test is inconclusive